Radiolabeled	O
m	B
-	I
iodobenzylguanidine	I
(	O
MIBG	B
)	O
is	O
a	O
tumor	O
-	O
seeking	O
radioactive	O
drug	O
used	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
pheochromocytomas	O
and	O
neuroblastomas	O
.	O

It	O
is	O
transported	O
into	O
the	O
tumor	O
cells	O
by	O
the	O
neuronal	O
norepinephrine	B
(	O
NE	B
)	O
transporter	O
(	O
NET	O
)	O
which	O
is	O
expressed	O
in	O
almost	O
all	O
neuroblastoma	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
synthesis	O
and	O
some	O
pharmacological	O
properties	O
of	O
a	O
series	O
of	O
fluorescent	O
compounds	O
structurally	O
related	O
to	O
the	O
NET	O
substrate	O
,	O
MIBG	B
,	O
or	O
to	O
the	O
NET	O
inhibitors	O
,	O
(	B
-	I
)	I
-	I
(	I
2R	I
,	I
3S	I
)	I
-	I
cocaine	I
and	O
nisoxetine	B
.	O

Three	O
of	O
synthesized	O
fluorescent	O
compounds	O
,	O
1	B
-	I
(	I
1	I
-	I
naphthylmethyl	I
)	I
guanidinium	I
sulfate	I
(	O
1	O
)	O
,	O
1	B
-	I
[	I
2	I
-	I
(	I
dibenz	I
[	I
b	I
,	I
f	I
]	I
azepin	I
-	I
5	I
-	I
yl	I
)	I
ethyl	I
]	I
guanidinium	I
sulfate	I
(	O
2	O
)	O
,	O
and	O
(	B
2R	I
,	I
3S	I
)	I
-	I
2beta	I
-	I
ethoxycarbonyl	I
-	I
3beta	I
-	I
tropanyl	I
5	I
-	I
(	I
dimethylamino	I
)	I
naphthalene	I
-	I
1	I
-	I
sulfonate	I
(	O
6	O
)	O
,	O
exhibited	O
high	O
affinity	O
(	O
IC	O
(	O
)	O
about	O
nM	O
)	O
for	O
the	O
NET	O
.	O

The	O
nisoxetine	B
derivatives	B
8	O
(	O
rac	B
-	I
N	I
-	I
[	I
(	I
3	I
-	I
methylamino	I
-	I
1	I
-	I
phenyl	I
)	I
propyl	I
]	I
-	I
5	I
-	I
(	I
dimethylamino	I
)	I
-	I
1	I
-	I
naphthale	I
nesulfonamide	I
)	O
and	O
9	O
(	O
rac	B
-	I
4	I
-	I
[	I
(	I
3	I
-	I
methylamino	I
-	I
1	I
-	I
phenyl	I
)	I
propyl	I
]	I
amino	I
-	I
7	I
-	I
nitro	I
-	I
2,1	I
,	I
3	I
-	I
benzoxadiazole	I
)	O
and	O
especially	O
the	O
guanidine	B
derivative	B
4	O
(	O
1	B
-	I
[	I
4	I
-	I
(	I
4	I
-	I
phenyl	I
-	I
1,3	I
-	I
butadienyl	I
)	I
benzyl	I
]	I
guanidinium	I
sulfate	I
)	O
which	O
are	O
characterized	O
by	O
intermediate	O
affinity	O
for	O
the	O
NET	O
(	O
IC	O
(	O
)	O
nM	O
)	O
caused	O
significant	O
and	O
nisoxetine	B
-	O
sensitive	O
cell	O
fluorescence	O
.	O

At	O
least	O
the	O
guanidine	B
derivative	B
4	O
might	O
represent	O
a	O
potentially	O
useful	O
agent	O
for	O
imaging	O
of	O
neuroblastoma	O
cells	O
.	O

A	O
series	O
of	O
2	B
-	I
(	I
diethylamino	I
)	I
thieno1	I
,	I
3	I
?	I
xazin	I
-	I
4	I
-	I
ones	I
was	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
for	O
inhibitory	O
activity	O
toward	O
human	O
leukocyte	O
elastase	O
(	O
HLE	O
)	O
.	O

The	O
Gewald	O
thiophene	B
synthesis	O
was	O
utilized	O
to	O
obtain	O
several	O
ethyl	B
2	I
-	I
aminothiophene	I
-	I
3	I
-	I
carboxylates	I
.	O

These	O
precursors	O
were	O
subjected	O
to	O
a	O
five	O
-	O
step	O
route	O
to	O
obtain	O
thieno2	B
,	I
3	I
-	I
d1	I
,	I
3	I
?	I
xazin	I
-	I
4	I
-	I
ones	I
bearing	O
various	O
substituents	O
at	O
positions	O
5	O
and	O
6	O
.	O

Both	O
thieno2	B
,	I
3	I
-	I
d	I
and	O
thieno3	B
,	I
2	I
-	I
d	I
fused	O
oxazin	B
-	I
4	I
-	I
ones	I
possess	O
extraordinary	O
chemical	O
stability	O
,	O
which	O
was	O
expressed	O
as	O
rate	O
constants	O
of	O
the	O
alkaline	O
hydrolysis	O
.	O

The	O
kinetic	O
parameters	O
of	O
the	O
HLE	O
inhibition	O
were	O
determined	O
.	O

The	O
most	O
potent	O
compound	O
,	O
2	B
-	I
(	I
diethylamino	I
)	I
-	I
4H	I
-	I
1benzothieno2	I
,	I
3	I
-	I
d1	I
,	I
3	I
?	I
xazin	I
-	I
4	I
-	I
one	I
,	O
exhibited	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
5.8	O
nM	O
.	O

2	B
-	I
(	I
Diethylamino	I
)	I
thieno1	I
,	I
3	I
?	I
xazin	I
-	I
4	I
-	I
ones	I
act	O
as	O
acyl	O
-	O
enzyme	O
inhibitors	O
of	O
HLE	O
,	O
similar	O
to	O
the	O
inhibition	O
of	O
serine	O
proteases	O
by	O
4H	B
-	I
3,1	I
-	I
benzoxazin	I
-	I
4	I
-	I
ones	I
.	O

The	O
isosteric	O
benzene	B
-	I
thiophene	I
replacement	O
accounts	O
for	O
an	O
enhanced	O
stability	O
of	O
the	O
acyl	O
-	O
enzyme	O
intermediates	O
.	O

Enalapril	B
in	O
subantihypertensive	O
dosage	O
attenuates	O
kidney	O
proliferation	O
and	O
functional	O
recovery	O
in	O
normotensive	O
ablation	O
nephropathy	O
of	O
the	O
rat	O
.	O

Most	O
studies	O
on	O
the	O
antiproliferative	O
action	O
of	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
)	O
were	O
performed	O
in	O
a	O
rat	O
hypertensive	O
remnant	O
kidney	O
model	O
with	O
5	O
/	O
6	O
kidney	O
ablation	O
which	O
raised	O
objections	O
about	O
the	O
antihypertensive	O
effect	O
of	O
ACEI	O
and	O
the	O
influence	O
of	O
other	O
antihypertensive	O
drugs	O
administered	O
to	O
remnant	O
kidney	O
control	O
rats	O
.	O

To	O
prevent	O
these	O
objections	O
,	O
a	O
normotensive	O
4	O
/	O
6	O
remnant	O
kidney	O
model	O
was	O
elaborated	O
and	O
a	O
subantihypertensive	O
dosage	O
of	O
enalapril	B
was	O
used	O
to	O
evaluate	O
its	O
antiproliferative	O
action	O
.	O

Subtotally	O
nephrectomized	O
rats	O
(	O
Nx	O
)	O
markedly	O
increased	O
the	O
remnant	O
kidney	O
weight	O
during	O
a	O
4	O
-	O
week	O
period	O
and	O
this	O
rise	O
was	O
prevented	O
by	O
the	O
treatment	O
with	O
enalapril	B
(	O
NxE	O
)	O
(	O
Nx	O
+	O
297	O
+	O
/	O
-	O
35	O
mg	O
vs.	O
sham	O
-	O
operated	O
+	O
145	O
+	O
/	O
-	O
32	O
mg	O
,	O
p	O
<	O
0.001	O
;	O
NxE	O
+	O
154	O
+	O
/	O
-	O
35	O
mg	O
vs.	O
Nx	O
p	O
<	O
0.001	O
)	O
.	O

While	O
collagen	O
concentration	O
in	O
the	O
kidney	O
cortex	O
was	O
not	O
increased	O
in	O
sham	O
-	O
operated	O
rats	O
(	O
Sham	O
)	O
in	O
comparison	O
with	O
the	O
control	O
group	O
(	O
Ctrl	O
)	O
at	O
the	O
beginning	O
of	O
the	O
study	O
,	O
the	O
subsequent	O
increase	O
was	O
significant	O
in	O
the	O
Nx	O
group	O
and	O
enalapril	B
did	O
not	O
attenuate	O
this	O
increase	O
(	O
Sham	O
148	O
+	O
/	O
-	O
5	O
mg	O
/	O
g	O
w	O
.	O

w	O
.	O
vs.	O
Nx	O
164	O
+	O
/	O
-	O
2	O
mg	O
/	O
g	O
w	O
.	O

w	O
.	O
,	O
p	O
<	O
0.01	O
;	O
NxE	O
161	O
+	O
/	O
-	O
4	O
mg	O
/	O
g	O
w	O
.	O

w	O
.	O
vs.	O
Sham	O
p	O
<	O
0.05	O
)	O
.	O

The	O
tubular	O
protein	O
/	O
DNA	O
ratio	O
increase	O
,	O
which	O
was	O
significant	O
in	O
the	O
Nx	O
group	O
,	O
was	O
inhibited	O
by	O
enalapril	B
(	O
Nx	O
26.2	O
+	O
/	O
-	O
vs.	O
NxE	O
15.3	O
+	O
/	O
-	O
2.6	O
,	O
p	O
<	O
0.05	O
)	O
.	O

The	O
protein	O
/	O
DNA	O
ratio	O
was	O
much	O
lower	O
in	O
glomeruli	O
,	O
with	O
no	O
significant	O
changes	O
in	O
either	O
the	O
Nx	O
or	O
NxE	O
groups	O
.	O

Serum	O
urea	B
concentrations	O
were	O
slightly	O
higher	O
in	O
the	O
Nx	O
group	O
than	O
in	O
the	O
sham	O
-	O
operated	O
group	O
,	O
but	O
markedly	O
elevated	O
in	O
the	O
NxE	O
group	O
(	O
Nx	O
+	O
/	O
-	O
0.76	O
mmol	O
/	O
l	O
vs.	O
Sham	O
6.10	O
+	O
/	O
-	O
0.33	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
;	O
NxE	O
28.9	O
+	O
/	O
-	O
2.6	O
mmol	O
/	O
l	O
vs.	O
Sham	O
p	O
<	O
0.001	O
)	O
.	O

Creatinine	B
concentrations	O
in	O
the	O
Nx	O
group	O
were	O
increased	O
in	O
comparison	O
with	O
the	O
sham	O
-	O
operated	O
group	O
and	O
markedly	O
increased	O
in	O
the	O
NxE	O
group	O
(	O
Nx	O
63.7	O
+	O
/	O
-	O
3.56	O
micromol	O
/	O
l	O
vs.	O
Sham	O
37.2	O
+	O
/	O
-	O
2.84	O
micromol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
;	O
NxE	O
+	O
/	O
-	O
5.2	O
micromol	O
/	O
l	O
vs.	O
Sham	O
p	O
<	O
0.001	O
)	O
.	O

The	O
clearance	O
of	O
creatinine	B
was	O
lower	O
in	O
the	O
Nx	O
group	O
than	O
in	O
the	O
sham	O
-	O
operated	O
group	O
and	O
was	O
markedly	O
reduced	O
in	O
the	O
NxE	O
group	O
(	O
Nx	O
0.89	O
+	O
/	O
-	O
0.06	O
ml	O
/	O
min	O
.	O

g	O
kidney	O
wt	O
.	O
vs.	O
Sham	O
1.05	O
+	O
/	O
-	O
0.16	O
ml	O
/	O
min	O
x	O
g	O
kidney	O
wt	O
.	O
,	O
p	O
<	O
0.01	O
;	O
NxE	O
0.58	O
+	O
/	O
-	O
0.029	O
ml	O
/	O
min	O
x	O
g	O
kidney	O
wt	O
.	O
vs.	O
Sham	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Enalapril	B
improved	O
proteinuria	O
in	O
comparison	O
with	O
the	O
Nx	O
group	O
(	O
NxE	O
5.6	O
+	O
/	O
-	O
0.6	O
mg	O
/	O
24	O
h	O
vs.	O
Nx	O
16.1	O
+	O
/	O
-	O
3.4	O
mg	O
/	O
24	O
h	O
,	O
p	O
<	O
0.05	O
)	O
.	O

Thus	O
remnant	O
kidney	O
proliferation	O
is	O
substantial	O
even	O
in	O
normotensive	O
rats	O
.	O

It	O
includes	O
both	O
proliferation	O
and	O
collagen	O
accumulation	O
with	O
partial	O
recovery	O
of	O
kidney	O
weight	O
and	O
function	O
,	O
but	O
is	O
accompanied	O
by	O
enhanced	O
proteinuria	O
.	O

Enalapril	B
attenuates	O
the	O
proliferation	O
and	O
decreases	O
proteinuria	O
but	O
prolongs	O
kidney	O
function	O
recovery	O
.	O

Antiestrogens	O
reduce	O
plasma	O
levels	O
of	O
endothelin	O
-	O
1	O
without	O
affecting	O
nitrate	B
levels	O
in	O
breast	O
cancer	O
patients	O
.	O

Tamoxifen	B
protects	O
against	O
myocardial	O
infarction	O
through	O
mechanisms	O
that	O
are	O
poorly	O
understood	O
.	O

We	O
studied	O
the	O
effects	O
of	O
tamoxifen	B
and	O
another	O
antiestrogen	O
,	O
toremifene	B
,	O
on	O
the	O
production	O
of	O
vasoconstrictive	O
endothelin	O
-	O
1	O
and	O
of	O
vasodilatory	O
nitric	B
oxide	I
in	O
44	O
postmenopausal	O
patients	O
with	O
breast	O
cancer	O
.	O

These	O
started	O
treatment	O
,	O
in	O
randomized	O
order	O
,	O
with	O
either	O
tamoxifen	B
(	O
mg	O
/	O
day	O
;	O
n	O
=	O
25	O
)	O
or	O
toremifene	O
(	O
mg	O
/	O
day	O
;	O
n	O
=	O
19	O
)	O
.	O

Plasma	O
samples	O
collected	O
before	O
treatment	O
and	O
after	O
6	O
and	O
12	O
months	O
of	O
both	O
regimens	O
were	O
assayed	O
for	O
endothelin	O
-	O
1	O
with	O
a	O
specific	O
radioimmunoassay	O
and	O
for	O
nitrite	B
/	O
nitrate	B
with	O
a	O
method	O
based	O
on	O
the	O
Griess	O
reaction	O
.	O

The	O
antiestrogen	O
group	O
as	O
a	O
whole	O
showed	O
a	O
fall	O
in	O
endothelin	O
-	O
1	O
at	O
6	O
months	O
(	O
5.9	O
+	O
/	O
-	O
3.3	O
%	O
;	O
p	O
=	O
0.06	O
)	O
(	O
mean	O
+	O
/	O
-	O
SE	O
)	O
and	O
at	O
12	O
months	O
(	O
7.1	O
+	O
/	O
-	O
5.5	O
%	O
;	O
p	O
=	O
0.03	O
)	O
.	O

This	O
fall	O
was	O
solely	O
due	O
to	O
toremifene	B
,	O
the	O
use	O
of	O
which	O
was	O
associated	O
with	O
falls	O
in	O
endothelin	O
-	O
1	O
at	O
6	O
months	O
(	O
12.9	O
+	O
/	O
-	O
4.7	O
%	O
;	O
p	O
=	O
0.01	O
)	O
and	O
12	O
months	O
(	O
9.2	O
+	O
/	O
-	O
6.2	O
%	O
;	O
p	O
=	O
0.06	O
)	O
.	O

The	O
antiestrogen	O
regimen	O
failed	O
to	O
affect	O
plasma	O
nitric	B
oxide	I
significantly	O
but	O
nevertheless	O
the	O
ratio	O
between	O
nitric	B
oxide	I
and	O
endothelin	O
-	O
1	O
rose	O
by	O
31.6	O
+	O
/	O
-	O
13.3	O
%	O
at	O
6	O
months	O
and	O
by	O
35.6	O
+	O
/	O
-	O
15.3	O
%	O
at	O
12	O
months	O
in	O
the	O
antiestrogen	O
users	O
,	O
an	O
effect	O
similar	O
in	O
the	O
tamoxifen	B
and	O
toremifene	B
groups	O
.	O

We	O
conclude	O
that	O
antiestrogens	O
may	O
protect	O
against	O
myocardial	O
infarction	O
by	O
preventing	O
the	O
release	O
of	O
endothelin	O
-	O
1	O
and	O
by	O
shifting	O
the	O
balance	O
between	O
nitric	B
oxide	I
and	O
endothelin	O
-	O
1	O
to	O
the	O
dominance	O
of	O
the	O
former	O
.	O

Our	O
data	O
predict	O
that	O
toremifene	B
and	O
tamoxifen	B
at	O
the	O
doses	O
studied	O
here	O
will	O
provide	O
similar	O
cardiovascular	O
protection	O
.	O

Allopurinol	B
induces	O
renal	O
toxicity	O
by	O
impairing	O
pyrimidine	B
metabolism	O
in	O
mice	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
toxic	O
effect	O
of	O
allopurinol	B
and	O
pyrimidine	B
metabolism	O
in	O
mice	O
.	O

Allopurinol	B
-	O
induced	O
increases	O
in	O
plasma	O
transaminase	O
levels	O
in	O
dinitrofluorobenzene	B
(	O
DNFB	B
)	O
-	O
sensitized	O
mice	O
were	O
not	O
affected	O
by	O
uridine	B
.	O

In	O
contrast	O
,	O
plasma	O
creatinine	B
and	O
BUN	O
tended	O
to	O
decrease	O
18	O
hr	O
after	O
the	O
last	O
injection	O
of	O
uridine	B
.	O

Both	O
plasma	O
and	O
urinary	O
orotidine	B
(	O
OD	B
)	O
were	O
detected	O
in	O
DNFB	O
-	O
sensitized	O
mice	O
after	O
administration	O
of	O
a	O
single	O
dose	O
of	O
allopurinol	B
.	O

In	O
contrast	O
,	O
TEI	B
-	I
,	O
a	O
newly	O
synthesized	O
xanthine	O
oxidase	O
/	O
xanthine	O
dehydrogenase	O
inhibitor	O
,	O
caused	O
neither	O
pyrimidine	B
metabolism	O
abnormality	O
nor	O
renal	O
impairment	O
in	O
DNFB	B
-	O
sensitized	O
mice	O
.	O

Also	O
,	O
normal	O
mice	O
administered	O
high	O
doses	O
of	O
allopurinol	B
showed	O
abnormal	O
pyrimidine	B
metabolism	O
together	O
with	O
renal	O
toxicity	O
which	O
could	O
be	O
ameliorated	O
by	O
uridine	B
,	O
indicating	O
that	O
allopurinol	B
essentially	O
causes	O
pyrimidine	B
metabolism	O
abnormality	O
leading	O
to	O
renal	O
impairment	O
.	O

In	O
DNFB	O
-	O
sensitized	O
mice	O
,	O
allopurinol	B
increased	O
urinary	O
OD	B
excretion	O
to	O
an	O
extent	O
similar	O
to	O
that	O
in	O
normal	O
mice	O
administered	O
the	O
same	O
dose	O
of	O
allopurinol	B
.	O

However	O
,	O
renal	O
impairment	O
by	O
allopurinol	B
was	O
more	O
striking	O
in	O
DNFB	O
-	O
sensitized	O
mice	O
than	O
in	O
normal	O
mice	O
.	O

Histopathological	O
observations	O
showed	O
that	O
allopurinol	B
induced	O
calculus	O
formation	O
in	O
the	O
collecting	O
tubules	O
and	O
papillary	O
duct	O
.	O

Calculus	O
formation	O
was	O
increased	O
by	O
DNFB	B
and	O
decreased	O
by	O
uridine	B
.	O

These	O
observations	O
indicate	O
that	O
the	O
enhancement	O
of	O
the	O
renal	O
toxicity	O
of	O
allopurinol	B
by	O
DNFB	O
-	O
sensitization	O
may	O
be	O
due	O
to	O
some	O
biological	O
interactions	O
between	O
DNFB	B
and	O
allopurinol	B
.	O

In	O
humans	O
,	O
it	O
is	O
possible	O
that	O
there	O
are	O
some	O
biological	O
interactions	O
which	O
serve	O
to	O
enhance	O
the	O
toxicity	O
of	O
allopurinol	B
,	O
resulting	O
in	O
the	O
development	O
of	O
allopurinol	B
hypersensitivity	O
syndrome	O
(	O
AHS	O
)	O
.	O

In	O
contrast	O
,	O
TEI	B
-	I
,	O
had	O
no	O
effect	O
on	O
pyrimidine	B
metabolism	O
and	O
showed	O
no	O
toxic	O
effect	O
.	O

11597479	O
Synthesis	O
of	O
pyridino	B
[	I
2,3	I
-	I
f	I
]	I
indole	I
-	I
4,9	I
-	I
dione	I
and	O
6,7	B
-	I
disubstituted	I
quinoline	I
-	I
5,8	I
-	I
dione	I
derivatives	B
and	O
evaluation	O
on	O
their	O
cytotoxic	O
activity	O
.	O

We	O
report	O
upon	O
the	O
synthesis	O
of	O
the	O
following	O
derivatives	O
:	O
N	B
-	I
substituted	I
-	I
pyridino	I
[	I
2,3	I
-	I
f	I
]	I
indole	I
-	I
4,9	I
-	I
dione	I
,	O
and	O
6	B
-	I
(	I
alpha	I
-	I
diethoxycarbonyl	I
-	I
methyl	I
)	I
-	I
7	I
-	I
substituted	I
-	I
amino	I
-	I
quinoline	I
-	I
5,8	I
-	I
dione	I
,	O
which	O
contain	O
the	O
active	O
quinoline	B
-	I
5,8	I
-	I
dione	I
(	O
VII	O
)	O
moiety	B
.	O

The	O
cytotoxic	O
activities	O
of	O
these	O
compounds	O
have	O
been	O
tested	O
in	O
SRB	O
(	O
SulfoRhodamine	O
B	O
)	O
assays	O
against	O
the	O
cancer	O
cell	O
lines	O
of	O
A	O
-	O
549	O
(	O
human	O
lung	O
cancer	O
)	O
,	O
SK	O
-	O
MEL	O
-	O
2	O
(	O
human	O
melanoma	O
cancer	O
)	O
,	O
SK	O
-	O
OV	O
-	O
3	O
(	O
human	O
ovarian	O
cancer	O
)	O
,	O
XF	O
-	O
498	O
(	O
human	O
brain	O
cancer	O
)	O
and	O
HCT	O
15	O
(	O
human	O
colon	O
cancer	O
)	O
.	O

The	O
compound	O
,	O
N	B
-	I
benzyl	I
-	I
3	I
-	I
ethoxycarbonyl	I
-	I
2	I
-	I
hydroxy	I
-	I
pyridino	I
[	I
2,3	I
-	I
f	I
]	I
indole	I
-	I
4,9	I
-	I
dione	I
(	O
A	O
-	O
9	O
)	O
,	O
also	O
showed	O
higher	O
activity	O
than	O
cis	B
-	I
platin	I
.	O

The	O
highest	O
level	O
of	O
cytotoxic	O
activity	O
in	O
these	O
human	O
tumor	O
cell	O
lines	O
was	O
observed	O
in	O
the	O
compound	O
6	B
-	I
(	I
alpha	I
-	I
diethoxycarbonyl	I
-	I
methyl	I
)	I
-	I
7	I
-	I
(	I
2	I
-	I
methyl	I
-	I
phenylamino	I
)	I
-	I
quinoline	I
-	I
5,8	I
-	I
dione	I
(	O
B	O
-	O
3	O
)	O
.	O

Maitotoxin	B
-	O
induced	O
calcium	O
entry	O
in	O
human	O
lymphocytes	O
:	O
modulation	O
by	O
yessotoxin	B
,	O
Ca	B
(	I
2	I
+	I
)	I
channel	O
blockers	O
and	O
kinases	O
.	O

We	O
have	O
studied	O
the	O
effect	O
of	O
the	O
ciguatera	O
-	O
related	O
toxin	O
maitotoxin	B
(	O
MTX	B
)	O
on	O
the	O
cytosolic	O
free	O
calcium	B
concentration	O
(	O
[	O
Ca	B
(	I
2	I
+	I
)	I
]	O
i	O
)	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
loaded	O
with	O
the	O
fluorescent	O
probe	O
Fura2	O
and	O
the	O
regulation	O
of	O
MTX	B
action	O
by	O
different	O
drugs	O
known	O
to	O
interfere	O
in	O
cellular	O
Ca	B
(	I
2	I
+	I
)	I
signalling	O
mechanisms	O
and	O
by	O
the	O
marine	O
phycotoxin	O
yessotoxin	B
(	O
YTX	B
)	O
.	O

MTX	B
produced	O
a	O
concentration	O
-	O
dependent	O
elevation	O
of	O
[	O
Ca	B
(	I
2	I
+	I
)	I
]	O

i	O
in	O
a	O
Ca	B
(	I
2	I
+	I
)	I
-	O
containing	O
medium	O
.	O

This	O
effect	O
was	O
stimulated	O
by	O
pretreatment	O
with	O
YTX	B
1	O
microM	O
and	O
NiCl	B
(	I
2	I
)	I
15	O
microM	O
.	O

The	O
voltage	O
-	O
independent	O
Ca	B
(	I
2	I
+	I
)	I
channel	O
antagonist	O
1	B
-	I
[	I
beta	I
-	I
[	I
3	I
-	I
(	I
4	I
-	I
methoxyphenyl	I
)	I
propoxyl	I
]	I
-	I
4	I
-	I
methoxyphenyl	I
]	I
-	I
1H	I
-	I
imidazole	I
hydrochloride	I
(	O
SKF96365	B
)	O
blocked	O
the	O
MTX	B
-	O
induced	O
[	O
Ca	B
(	I
2	I
+	I
)	I
]	O
i	O
elevation	O
,	O
while	O
the	O
L	O
-	O
type	O
channel	O
blocker	O
nifedipine	B
had	O
no	O
effect	O
.	O

Pretreatment	O
with	O
NiCl	B
(	I
2	I
)	I
or	O
nifedipine	B
did	O
not	O
modify	O
YTX	B
-	O
induced	O
potentiation	O
of	O
MTX	B
effect	O
,	O
and	O
SKF96365	B
-	O
induced	O
inhibition	O
was	O
reduced	O
in	O
the	O
presence	O
of	O
YTX	B
,	O
which	O
suggest	O
different	O
pathways	O
to	O
act	O
on	O
[	O
Ca	B
(	I
2	I
+	I
)	I
]	O
i	O
.	O

Preincubation	O
with	O
N	B
-	I
[	I
2	I
-	I
(	I
p	I
-	I
bromocinnamylamino	I
)	I
ethyl	I
]	I
-	I
5	I
-	I
isoquinolinesulfonamide	I
.	O

2HCl	B
(	O
H	B
-	I
89	I
)	O
or	O
genistein	B
(	O
microM	O
)	O
also	O
had	O
no	O
effect	O
on	O
the	O
MTX	B
-	O
induced	O
[	O
Ca	B
(	I
2	I
+	I
)	I
]	O
i	O
increment	O
.	O

In	O
contrast	O
,	O
the	O
PKC	O
inhibitor	O
bisindolilmaleimide	B
I	I
(	O
GF109203X	B
1	O
microM	O
)	O
potentiated	O
the	O
MTX	B
effect	O
,	O
whereas	O
phosphatidylinositol	O
(	O
PI	O
)	O
3	O
-	O
kinase	O
inhibition	O
with	O
wortmannin	B
(	O
nM	O
)	O
reduced	O
the	O
MTX	B
-	O
elicited	O
Ca	B
(	I
2	I
+	I
)	I
entry	O
.	O

In	O
summary	O
,	O
MTX	B
produced	O
Ca	B
(	I
2	I
+	I
)	I
influx	O
into	O
human	O
lymphocytes	O
through	O
a	O
SKF96365	B
-	O
sensitive	O
,	O
nifedipine	B
-	O
insensitive	O
pathway	O
.	O

The	O
MTX	B
-	O
induced	O
[	O
Ca	B
(	I
2	I
+	I
)	I
]	O
i	O
elevation	O
was	O
stimulated	O
by	O
the	O
marine	O
toxin	O
YTX	B
through	O
a	O
mechanism	O
insensitive	O
to	O
SKF96365	B
,	O
nifedipine	B
or	O
NiCl	B
(	I
2	I
)	I
.	O

It	O
was	O
also	O
stimulated	O
by	O
the	O
divalent	O
cation	O
Ni	B
(	I
2	I
+	I
)	I
and	O
PKC	O
inhibition	O
and	O
was	O
partially	O
inhibited	O
by	O
PI	O
3	O
-	O
kinase	O
inhibition	O
.	O

A	O
number	O
of	O
derivatives	O
structurally	O
related	O
to	O
cirazoline	B
(	O
1	O
)	O
were	O
synthesized	O
and	O
studied	O
with	O
the	O
purpose	O
of	O
modulating	O
alpha2	O
-	O
adrenoreceptors	O
selectivity	O
versus	O
both	O
alpha1	O
-	O
adrenoreceptors	O
and	O
I2	O
imidazoline	B
binding	O
sites	O
.	O

The	O
most	O
potent	O
alpha2	O
-	O
agonist	O
was	O
2	B
-	I
[	I
1	I
-	I
(	I
biphenyl	I
-	I
2	I
-	I
yloxy	I
)	I
ethyl	I
]	I
-	I
4,5	I
-	I
dihydro	I
-	I
1H	I
-	I
imidazole	I
(	O
7	O
)	O
,	O
whose	O
key	O
pharmacophoric	O
features	O
closely	O
matched	O
those	O
found	O
in	O
the	O
alpha2	O
-	O
agonist	O
2	B
-	I
(	I
3	I
-	I
exo	I
-	I
(	I
3	I
-	I
phenylprop	I
-	I
1	I
-	I
yl	I
)	I
-	I
2	I
-	I
exo	I
-	I
norbornyl	I
)	I
amino	I
-	I
2	I
-	I
oxazoline	I
(	O
15	O
)	O
.	O

(	O
S	O
)	O
-	O
(	O
-	O
)	O
-	O
7	O
was	O
the	O
most	O
potent	O
of	O
the	O
two	O
enantiomers	O
,	O
confirming	O
the	O
stereospecificity	O
of	O
the	O
interaction	O
with	O
alpha2	O
-	O
adrenoreceptors	O
.	O

This	O
eutomer	O
was	O
tested	O
on	O
two	O
algesiometric	O
paradigms	O
and	O
,	O
because	O
of	O
the	O
interaction	O
with	O
alpha2	O
-	O
adrenoreceptors	O
,	O
showed	O
a	O
potent	O
and	O
long	O
-	O
lasting	O
antinociceptive	O
activity	O
,	O
since	O
it	O
was	O
abolished	O
by	O
the	O
selective	O
alpha2	O
-	O
antagonist	O
RX821002	B
.	O

In	O
an	O
attempt	O
to	O
increase	O
the	O
combined	O
toxicity	O
of	O
the	O
metabolic	O
end	O
-	O
products	O
[	O
acrolein	B
(	O
4	O
)	O
and	O
phosphoramide	O
mustard	O
(	O
3	O
)	O
]	O
from	O
cyclophosphamide	B
(	O
1	O
)	O
,	O
the	O
analog	B
2	B
-	I
[	I
bis	I
(	I
2	I
-	I
chloroethyl	I
)	I
amino	I
]	I
tetrahydro	I
-	I
6	I
-	I
trifluoromethyl	I
-	I
2H	I
-	I
1,3,2	I
-	I
oxazaphosphorine	I
2	I
-	I
oxide	I
(	O
2	B
,	I
6	I
-	I
trifluoromethylcyclophosphamide	I
)	O
was	O
synthesized	O
and	O
its	O
metabolism	O
and	O
antitumor	O
activity	O
studied	O
.	O

Following	O
metabolism	O
of	O
2	O
by	O
rat	O
liver	O
microsomes	O
the	O
predicted	O
formation	O
of	O
4,4,4	B
-	I
trifluorocrotonaldehyde	I
(	O
5	O
)	O
was	O
confirmed	O
by	O
isolation	O
and	O
identification	O
,	O
by	O
mass	O
spectrometry	O
,	O
of	O
its	O
dinitrophenylhydrazone	B
.	O

The	O
therapeutic	O
indices	O
(	O
LD50	O
-	O
/	O
ID90	O
)	O
for	O
2	O
against	O
the	O
ADJ	O
/	O
PC6	O
mouse	O
tumor	O
and	O
the	O
Walker	O
256	O
tumor	O
in	O
the	O
rat	O
were	O
28.6	O
and	O
7.7	O
,	O
respectively	O
,	O
and	O
were	O
lower	O
than	O
the	O
corresponding	O
values	O
for	O
1	O
(	O
91.8	O
and	O
33.2	O
,	O
respectively	O
)	O
although	O
the	O
toxicities	O
toward	O
Walker	O
cells	O
in	O
a	O
bioassay	O
system	O
of	O
1	O
and	O
2	O
following	O
microsomal	O
metabolism	O
were	O
similar	O
.	O

In	O
order	O
to	O
study	O
the	O
toxicities	O
of	O
4	O
and	O
5	O
released	O
under	O
drug	O
metabolizing	O
conditions	O
independently	O
of	O
the	O
production	O
of	O
a	O
toxic	O
mustard	B
the	O
analogs	B
18	O
[	O
2	B
-	I
(	I
diethylamino	I
)	I
tetrahydro	I
-	I
2H	I
-	I
1,3,2	I
-	I
oxazaphosphorine	I
2	I
-	I
oxide	I
]	O
and	O
6	O
[	O
2	B
-	I
(	I
diethylamino	I
)	I
tetrahydro	I
-	I
6	I
-	I
trifluoromethyl	I
-	I
2H	I
-	I
1,3,2	I
-	I
oxazaphosphorine	I
2	I
-	I
oxide	I
]	O
were	O
also	O
synthesized	O
.	O

The	O
release	O
of	O
5	O
from	O
6	O
following	O
metabolism	O
was	O
confirmed	O
and	O
shown	O
by	O
use	O
of	O
the	O
bioassay	O
system	O
to	O
be	O
an	O
event	O
of	O
similar	O
toxicity	O
to	O
release	O
of	O
4	O
from	O
18	O
;	O
in	O
vivo	O
,	O
however	O
,	O
6	O
(	O
LD50	O
mg	O
/	O
kg	O
)	O
was	O
more	O
toxic	O
to	O
mice	O
than	O
18	O
(	O
LD50	O
greater	O
than	O
mg	O
/	O
kg	O
)	O
.	O

A	O
novel	O
class	O
of	O
5	B
-	I
substituted	I
acyclic	I
pyrimidine	I
nucleosides	I
,	O
1	B
-	I
[	I
(	I
2	I
-	I
hydroxyethoxy	I
)	I
methyl	I
]	I
-	I
5	I
-	I
(	I
1	I
-	I
azidovinyl	I
)	I
uracil	I
(	O
9a	O
)	O
,	O
1	B
-	I
[	I
(	I
2	I
-	I
hydroxy	I
-	I
1	I
-	I
(	I
hydroxymethyl	I
)	I
ethoxy	I
)	I
methyl	I
]	I
-	I
5	I
-	I
(	I
1	I
-	I
azidovinyl	I
)	I
uracil	I
(	O
9b	O
)	O
,	O
and	O
1	B
-	I
[	I
4	I
-	I
hydroxy	I
-	I
3	I
-	I
(	I
hydroxymethyl	I
)	I
-	I
1	I
-	I
butyl	I
]	I
-	I
5	I
-	I
(	I
1	I
-	I
azidovinyl	I
)	I
uracil	I
(	O
9c	O
)	O
,	O
were	O
synthesized	O
by	O
regiospecific	O
addition	O
of	O
bromine	B
azide	I
to	O
the	O
5	B
-	I
vinyl	I
substituent	B
of	O
the	O
respective	O
5	B
-	I
vinyluracils	I
(	O
2a	O
-	O
c	O
)	O
followed	O
by	O
treatment	O
of	O
the	O
obtained	O
5	B
-	I
(	I
1	I
-	I
azido	I
-	I
2	I
-	I
bromoethyl	I
)	I
compounds	B
(	O
3a	O
-	O
c	O
)	O
with	O
t	B
-	I
BuOK	I
,	O
to	O
affect	O
the	O
base	O
-	O
catalyzed	O
elimination	O
of	O
HBr	B
.	O

Thermal	O
decomposition	O
of	O
9b	O
and	O
9c	O
at	O
degrees	O
C	O
in	O
dioxane	B
yielded	O
corresponding	O
5	B
-	I
[	I
2	I
-	I
(	I
1	I
-	I
azirinyl	I
)	I
]	I
uracil	I
analogues	B
(	O
,	O
c	O
)	O
.	O

The	O
5	B
-	I
(	I
1	I
-	I
azidovinyl	I
)	I
uracil	I
derivatives	B
9a	O
-	O
c	O
were	O
found	O
to	O
exhibit	O
potent	O
and	O
selective	O
in	O
vitro	O
anti	O
-	O
HBV	O
activity	O
against	O
duck	O
hepatitis	O
B	O
virus	O
(	O
DHBV	O
)	O
infected	O
primary	O
duck	O
hepatocytes	O
at	O
low	O
concentrations	O
(	O
EC	O
(	O
)	O
=	O
0.01	O
-	O
0.1	O
microg	O
/	O
mL	O
range	O
)	O
.	O

The	O
most	O
active	O
anti	O
-	O
DHBV	O
agent	O
(	O
9c	O
)	O
,	O
possessing	O
a	O
[	B
4	I
-	I
hydroxy	I
-	I
3	I
-	I
(	I
hydroxymethyl	I
)	I
-	I
1	I
-	I
butyl	I
]	I
substituent	B
at	O
N	O
-	O
1	O
,	O
exhibited	O
an	O
activity	O
(	O
EC	O
(	O
)	O
of	O
0.01	O
-	O
0.05	O
microg	O
/	O
mL	O
)	O
comparable	O
to	O
that	O
of	O
reference	O
compound	O
(	B
-	I
)	I
-	I
beta	I
-	I
L	I
-	I
2	I
'	I
,	I
3	I
'	I
-	I
dideoxy	I
-	I
3	I
'	I
-	I
thiacytidine	I
(	O
3	O
-	O
TC	O
)	O
(	O
EC	O
(	O
)	O
=	O
0.01	O
-	O
0.05	O
microg	O
/	O
mL	O
)	O
.	O

In	O
contrast	O
,	O
related	O
5	B
-	I
[	I
2	I
-	I
(	I
1	I
-	I
azirinyl	I
)	I
]	I
uracil	I
analogues	B
(	O
,	O
c	O
)	O
were	O
devoid	O
of	O
anti	O
-	O
DHBV	O
activity	O
,	O
indicating	O
that	O
an	O
acyclic	O
side	O
chain	O
at	O
C	O
-	O
5	O
position	O
of	O
the	O
pyrimidine	B
ring	O
is	O
essential	O
for	O
anti	O
-	O
HBV	O
activity	O
.	O

The	O
pyrimidine	B
nucleosides	B
(	O
9a	O
-	O
c	O
,	O
,	O
c	O
)	O
exhibited	O
no	O
cytotoxic	O
activity	O
against	O
a	O
panel	O
of	O
human	O
cancer	O
cell	O
lines	O
.	O

All	O
of	O
the	O
compounds	O
investigated	O
did	O
not	O
show	O
any	O
detectable	O
toxicity	O
to	O
several	O
stationary	O
and	O
proliferating	O
host	O
cell	O
lines	O
or	O
to	O
mitogen	O
stimulated	O
proliferating	O
human	O
T	O
lymphocytes	O
,	O
up	O
to	O
the	O
highest	O
concentration	O
tested	O
.	O

We	O
have	O
previously	O
described	O
(	B
RS	I
)	I
-	I
2	I
-	I
amino	I
-	I
3	I
-	I
(	I
3	I
-	I
hydroxy	I
-	I
7,8	I
-	I
dihydro	I
-	I
6H	I
-	I
cyclohepta	I
[	I
d	I
]	I
isoxazol	I
-	I
4	I
-	I
yl	I
)	I
propionic	I
acid	I
(	O
4	B
-	I
AHCP	I
)	O
as	O
a	O
highly	O
effective	O
agonist	O
at	O
non	O
-	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
(	O
non	O
-	O
NMDA	O
)	O
glutamate	O
(	O
Glu	O
)	O
receptors	O
in	O
vivo	O
,	O
which	O
is	O
more	O
potent	O
than	O
(	B
RS	I
)	I
-	I
2	I
-	I
amino	I
-	I
3	I
-	I
(	I
3	I
-	I
hydroxy	I
-	I
5	I
-	I
methylisoxazol	I
-	I
4	I
-	I
yl	I
)	I
propionic	I
acid	I
(	O
AMPA	B
)	O
but	O
inactive	O
at	O
NMDA	O
receptors	O
.	O

However	O
,	O
4	B
-	I
AHCP	I
was	O
found	O
to	O
be	O
much	O
weaker	O
than	O
AMPA	B
as	O
an	O
inhibitor	O
of	O
[	B
(	I
3	I
)	I
H	I
]	I
AMPA	I
binding	O
and	O
to	O
have	O
limited	O
effect	O
in	O
a	O
[	B
(	I
3	I
)	I
H	I
]	I
kainic	I
acid	I
binding	O
assay	O
using	O
rat	O
cortical	O
membranes	O
.	O

To	O
shed	O
light	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
quite	O
enigmatic	O
pharmacological	O
profile	O
of	O
4	B
-	I
AHCP	I
,	O
we	O
have	O
now	O
developed	O
a	O
synthesis	O
of	O
(	B
S	I
)	I
-	I
4	I
-	I
AHCP	I
(	O
6	O
)	O
and	O
(	B
R	I
)	I
-	I
4	I
-	I
AHCP	I
(	O
7	O
)	O
.	O

At	O
cloned	O
metabotropic	O
Glu	O
receptors	O
mGluR1alpha	O
(	O
group	O
I	O
)	O
,	O
mGluR2	O
(	O
group	O
II	O
)	O
,	O
and	O
mGluR4a	O
(	O
group	O
III	O
)	O
,	O
neither	O
6	O
nor	O
7	O
showed	O
significant	O
agonist	O
or	O
antagonist	O
effects	O
.	O

The	O
stereoisomer	O
6	O
,	O
but	O
not	O
7	O
,	O
activated	O
cloned	O
AMPA	O
receptor	O
subunits	O
GluR1o	O
,	O
GluR3o	O
,	O
and	O
GluR4o	O
with	O
EC	O
(	O
)	O
values	O
in	O
the	O
range	O
4.5	O
-	O
15	O
microM	O
and	O
the	O
coexpressed	O
kainate	B
-	O
preferring	O
subunits	O
GluR6	O
+	O
KA2	O
(	O
EC	O
(	O
)	O
=	O
6.4	O
microM	O
)	O
.	O

Compound	O
6	O
,	O
but	O
not	O
7	O
,	O
proved	O
to	O
be	O
a	O
very	O
potent	O
agonist	O
(	O
EC	O
(	O
)	O
=	O
0.13	O
microM	O
)	O
at	O
the	O
kainate	B
-	O
preferring	O
GluR5	O
subunit	O
,	O
equipotent	O
with	O
(	B
S	I
)	I
-	I
2	I
-	I
amino	I
-	I
3	I
-	I
(	I
5	I
-	I
tert	I
-	I
butyl	I
-	I
3	I
-	I
hydroxyisothiazol	I
-	I
4	I
-	I
yl	I
)	I
propionic	I
acid	I
[	O
(	B
S	I
)	I
-	I
Thio	I
-	I
ATPA	I
,	O
4	O
]	O
and	O
almost	O
4	O
times	O
more	O
potent	O
than	O
(	B
S	I
)	I
-	I
2	I
-	I
amino	I
-	I
3	I
-	I
(	I
5	I
-	I
tert	I
-	I
butyl	I
-	I
3	I
-	I
hydroxyisoxazol	I
-	I
4	I
-	I
yl	I
)	I
propionic	I
acid	I
[	O
(	B
S	I
)	I
-	I
ATPA	I
,	O
3	O
]	O
.	O

Compound	O
6	O
thus	O
represents	O
a	O
new	O
structural	O
class	O
of	O
GluR5	O
agonists	O
.	O

Molecular	O
modeling	O
and	O
docking	O
to	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
the	O
AMPA	B
subunit	O
GluR2	O
has	O
enabled	O
identification	O
of	O
the	O
probable	O
active	O
conformation	O
and	O
binding	O
mode	O
of	O
6	O
.	O

We	O
are	O
able	O
to	O
rationalize	O
the	O
observed	O
selectivities	O
by	O
comparing	O
the	O
docking	O
of	O
4	O
and	O
6	O
to	O
subtype	O
constructs	O
,	O
i.e.	O
,	O
a	O
crystal	O
structure	O
of	O
the	O
extracellular	O
binding	O
domain	O
of	O
GluR2	O
and	O
a	O
homology	O
model	O
of	O
GluR5	O
.	O

12742193	O
Attenuation	O
of	O
cerebral	O
vasospasm	O
in	O
rabbits	O
using	O
clonidine	B
hydrochloride	I
,	O
a	O
central	O
adrenergic	O
agonist	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
,	O
firstly	O
,	O
if	O
exclusion	O
of	O
central	O
noradrenergic	O
areas	O
in	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
with	O
the	O
central	O
sympathetic	O
blocker	O
clonidine	B
hydrochloride	I
could	O
prevent	O
the	O
development	O
of	O
chronic	O
vasospasm	O
following	O
experimental	O
subarachnoid	O
haemorrhage	O
in	O
rabbits	O
and	O
,	O
secondly	O
,	O
if	O
,	O
parallel	O
with	O
the	O
effect	O
on	O
cerebral	O
arteries	O
,	O
changes	O
in	O
dopamine	O
beta	O
-	O
hydroxylase	O
concentration	O
in	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
could	O
also	O
be	O
detected	O
.	O

Experimental	O
subarachnoid	O
haemorrhage	O
,	O
in	O
concentrations	O
of	O
1	O
ml	O
of	O
autologous	O
arterial	O
blood	O
/	O
1	O
kg	O
of	O
body	O
weight	O
was	O
carried	O
out	O
on	O
18	O
New	O
Zealand	O
rabbits	O
.	O

Histological	O
specimens	O
were	O
obtained	O
by	O
the	O
method	O
of	O
perfusion	O
fixation	O
after	O
the	O
rabbits	O
were	O
sacrificed	O
on	O
day	O
8	O
after	O
subarachnoid	O
haemorrhage	O
.	O

The	O
spastic	O
effect	O
of	O
experimentally	O
induced	O
subarachnoid	O
haemorrhage	O
was	O
determined	O
by	O
assessing	O
the	O
intensity	O
of	O
corrugation	O
of	O
the	O
intima	O
of	O
the	O
rabbit	O
basilar	O
artery	O
by	O
the	O
previously	O
developed	O
method	O
of	O
corrugation	O
coefficient	O
and	O
computer	O
image	O
analysis	O
.	O

The	O
concentration	O
and	O
localization	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
in	O
noradrenaline	B
-	O
containing	O
neurons	O
was	O
immunohistochemically	O
assessed	O
(	O
semiquantitatively	O
as	O
0	O
,	O
1	O
and	O
2	O
)	O
with	O
anti	O
-	O
dopamine	O
beta	O
-	O
hydroxylase	O
,	O
at	O
precisely	O
defined	O
sites	O
of	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
of	O
the	O
same	O
rabbit	O
.	O

The	O
results	O
revealed	O
less	O
corrugated	O
and	O
smoother	O
intima	O
in	O
the	O
basilar	O
artery	O
and	O
significantly	O
lower	O
dopamine	O
beta	O
-	O
hydroxylase	O
concentration	O
in	O
the	O
control	O
group	O
of	O
rabbits	O
with	O
sham	O
subarachnoid	O
haemorrhage	O
and	O
without	O
any	O
additional	O
interventions	O
(	O
mean	O
corrugation	O
coefficient	O
=	O
1.123	O
+	O
/	O
-	O
0.024	O
,	O
P	O
=	O
0.35	O
x	O
(	O
-	O
3	O
)	O
;	O
mean	O
dopamine	O
beta	O
-	O
hydroxylase	O
=	O
0.350	O
+	O
/	O
-	O
0.071	O
,	O
P	O
=	O
0.22	O
x	O
(	O
-	O
3	O
)	O
)	O
,	O
and	O
smoother	O
intima	O
in	O
the	O
basilar	O
artery	O
with	O
significantly	O
lower	O
concentration	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
in	O
the	O
clonidine	B
group	B
(	O
rabbits	O
with	O
subarachnoid	O
haemorrhage	O
and	O
central	O
alpha	O
(	O
2	O
)	O
-	O
blocker	O
clonidine	B
hydrochloride	I
at	O
a	O
daily	O
dose	O
of	O
0.03	O
mg	O
/	O
kg	O
of	O
body	O
weight	O
for	O
8	O
days	O
;	O
mean	O
corrugation	O
coefficient	O
=	O
1.177	O
+	O
/	O
-	O
0.058	O
,	O
P	O
=	O
1.7	O
x	O
(	O
-	O
3	O
)	O
;	O
mean	O
dopamine	B
beta	O
-	O
hydroxylase	O
=	O
0.583	O
+	O
/	O
-	O
0.175	O
,	O
P	O
=	O
1.1	O
x	O
(	O
-	O
3	O
)	O
)	O
.	O

In	O
comparison	O
,	O
the	O
haemorrhage	O
only	O
group	O
(	O
rabbits	O
with	O
subarachnoid	O
haemorrhage	O
and	O
without	O
medication	O
;	O
mean	O
corrugation	O
coefficient	O
=	O
1.370	O
+	O
/	O
-	O
0.101	O
;	O
mean	O
dopamine	O
beta	O
-	O
hydroxylase	O
=	O
1.214	O
+	O
/	O
-	O
0.313	O
)	O
displayed	O
intensive	O
corrugation	O
of	O
the	O
intima	O
of	O
the	O
basilar	O
artery	O
and	O
a	O
significantly	O
more	O
intensive	O
accumulation	O
of	O
dopamine	O
beta	O
-	O
hydroxylase	O
than	O
did	O
the	O
control	O
group	O
and	O
the	O
clonidine	O
group	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
the	O
central	O
alpha	O
(	O
2	O
)	O
-	O
blocker	O
clonidine	B
hydrochloride	I
effectively	O
prevents	O
vasospasm	O
,	O
and	O
diminishes	O
the	O
concentration	O
of	O
cerebral	O
dopamine	O
beta	O
-	O
hydroxylase	O
in	O
the	O
hypothalamus	O
and	O
brain	O
stem	O
after	O
experimental	O
subarachnoid	O
haemorrhage	O
in	O
rabbits	O
.	O

Involvement	O
of	O
phospholipase	O
D2	O
in	O
lysophosphatidate	B
-	O
induced	O
transactivation	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
-	O
beta	O
in	O
human	O
bronchial	O
epithelial	O
cells	O
.	O

Lysophosphatidate	B
(	O
LPA	B
)	O
mediates	O
multiple	O
cellular	O
responses	O
via	O
heterotrimeric	O
G	O
protein	O
coupled	O
LPA	O
-	O
1	O
,	O
LPA	O
-	O
2	O
,	O
and	O
LPA	O
-	O
3	O
receptors	O
.	O

Many	O
G	O
protein	O
-	O
coupled	O
receptors	O
stimulate	O
ERK	O
following	O
tyrosine	B
phosphorylation	O
of	O
growth	O
factor	O
receptors	O
;	O
however	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
transactivation	O
of	O
receptor	O
tyrosine	O
kinases	O
are	O
not	O
well	O
defined	O
.	O

Here	O
,	O
we	O
provide	O
evidence	O
for	O
the	O
involvement	O
of	O
phospholipase	O
D	O
(	O
PLD	O
)	O
in	O
LPA	B
-	O
mediated	O
transactivation	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptor	O
-	O
beta	O
(	O
PDGF	O
-	O
R	O
beta	O
)	O
.	O

In	O
primary	O
cultures	O
of	O
human	O
bronchial	O
epithelial	O
cells	O
(	O
HBEpCs	O
)	O
,	O
LPA	B
stimulated	O
tyrosine	B
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
and	O
threonine	B
/	O
tyrosine	B
phosphorylation	O
of	O
ERK1	O
/	O
2	O
.	O

The	O
LPA	B
-	O
mediated	O
activation	O
of	O
ERK	O
and	O
tyrosine	B
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
was	O
attenuated	O
by	O
tyrphostin	B
AG	B
1296	I
,	O
an	O
inhibitor	O
of	O
PDGF	O
-	O
R	O
kinase	O
,	O
suggesting	O
transactivation	O
of	O
PDGF	O
-	O
R	O
by	O
LPA	B
.	O

Furthermore	O
,	O
LPA	B
-	O
,	O
but	O
not	O
PDGF	O
beta	O
-	O
chain	O
homodimer	O
-	O
induced	O
tyrosine	O
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
was	O
partially	O
blocked	O
by	O
pertussis	O
toxin	O
,	O
indicating	O
coupling	O
of	O
LPA	B
-	O
R	O
(	O
s	O
)	O
to	O
Gi	O
.	O

Exposure	O
of	O
HBEpCs	O
to	O
LPA	O
activated	O
PLD	O
.	O

Butan	B
-	I
1	I
-	I
ol	I
,	O
which	O
acts	O
as	O
an	O
acceptor	O
of	O
phosphatidate	B
generated	O
by	O
the	O
PLD	O
pathway	O
,	O
blocked	O
LPA	B
-	O
mediated	O
transactivation	O
of	O
PDGF	O
-	O
R	O
beta	O
.	O

This	O
effect	O
was	O
not	O
seen	O
with	O
butan	B
-	I
3	I
-	I
ol	I
,	O
suggesting	O
PLD	O
involvement	O
.	O

The	O
role	O
of	O
PLD1	O
and	O
PLD2	O
in	O
the	O
PDGF	O
-	O
R	O
beta	O
transactivation	O
by	O
LPA	B
was	O
investigated	O
by	O
infection	O
of	O
cells	O
with	O
adenoviral	O
constructs	O
of	O
wild	O
type	O
and	O
catalytically	O
inactive	O
mutants	O
of	O
PLD	O
.	O

LPA	B
activated	O
both	O
PLD1	O
and	O
PLD2	O
in	O
HBEpCs	O
;	O
however	O
,	O
infection	O
of	O
cells	O
with	O
cDNA	O
for	O
wild	O
type	O
PLD2	O
,	O
but	O
not	O
PLD1	O
,	O
increased	O
the	O
tyrosine	O
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
in	O
response	O
to	O
LPA	B
.	O

Also	O
,	O
the	O
LPA	B
-	O
mediated	O
tyrosine	B
phosphorylation	O
of	O
PDGF	O
-	O
R	O
beta	O
was	O
attenuated	O
by	O
the	O
catalytically	O
inactive	O
mutant	O
mPLD2	O
-	O
K758R	O
.	O

Infection	O
of	O
HBEpCs	O
with	O
adenoviral	O
constructs	O
of	O
wild	O
type	O
hPLD1	O
,	O
mPLD2	O
,	O
and	O
the	O
inactive	O
mutants	O
of	O
hPLD1	O
and	O
mPLD2	O
resulted	O
in	O
association	O
of	O
PLD2	O
wild	O
type	O
and	O
inactive	O
mutant	O
proteins	O
with	O
the	O
PDGF	O
-	O
R	O
beta	O
compared	O
with	O
PLD1	O
.	O

These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
transactivation	O
of	O
PDGF	O
-	O
R	O
beta	O
by	O
LPA	B
in	O
HBEpCs	O
is	O
regulated	O
by	O
PLD2	O
.	O

Nucleotide	B
regulation	O
of	O
heat	O
-	O
stable	O
enterotoxin	O
receptor	O
binding	O
and	O
of	O
guanylate	O
cyclase	O
activation	O
.	O

Certain	O
nucleotides	B
were	O
found	O
to	O
regulate	O
the	O
binding	O
of	O
the	O
Escherichia	O
coli	O
heat	O
-	O
stable	O
enterotoxin	O
(	O
STa	O
)	O
to	O
its	O
receptor	O
in	O
pig	O
intestinal	O
brush	O
border	O
membranes	O
.	O

ATP	B
and	O
adenine	B
nucleotide	B
analogues	B
inhibited	O
125I	O
-	O
STa	O
binding	O
,	O
while	O
guanine	B
nucleotide	B
analogues	B
stimulated	O
binding	O
,	O
with	O
maximal	O
effects	O
at	O
0.5	O
-	O
1.0	O
mM	O
.	O

The	O
strongest	O
inhibitors	O
were	O
adenosine	B
5	I
'	I
-	I
[	I
beta	I
gamma	I
-	I
imido	I
]	I
triphosphate	I
(	O
App	B
[	I
NH	I
]	I
p	I
)	O
(	O
36	O
%	O
)	O
and	O
adenosine	B
5	I
'	I
-	I
[	I
beta	I
-	I
thio	I
]	I
diphosphate	I
(	O
ADP	B
[	I
S	I
]	I
)	O
(	O
41	O
%	O
)	O
.	O

Inhibition	O
did	O
not	O
require	O
Mg2	B
+	I
,	O
and	O
was	O
blocked	O
by	O
p	B
-	I
chloromercuribenzenesulphonate	I
(	O
PCMBS	B
)	O
.	O

Stimulation	O
of	O
binding	O
required	O
Mg2	B
+	I
,	O
was	O
not	O
prevented	O
by	O
PCMBS	B
and	O
was	O
maximal	O
with	O
GDP	B
[	I
S	I
]	I
(	O
41	O
%	O
)	O
.	O

While	O
App	B
[	I
NH	I
]	I
p	I
and	O
MgGDP	B
[	I
S	I
]	I
appeared	O
to	O
be	O
acting	O
at	O
different	O
sites	O
,	O
they	O
also	O
interfered	O
with	O
each	O
other	O
.	O

These	O
nucleotides	B
exerted	O
only	O
inhibitory	O
effects	O
on	O
STa	O
-	O
stimulated	O
guanylate	O
cyclase	O
activity	O
,	O
in	O
contrast	O
with	O
the	O
stimulatory	O
effects	O
of	O
adenine	B
nucleotides	O
on	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
-	O
stimulated	O
guanylate	O
cyclase	O
.	O

Inhibition	O
by	O
low	O
concentrations	O
of	O
MgApp	B
[	I
NH	I
]	I
p	I
and	O
MgATP	B
was	O
weaker	O
above	O
0.1	O
mM	O
,	O
while	O
MgGDP	B
[	I
S	I
]	I
and	O
magnesium	B
guanosine	I
5	I
'	I
-	I
[	I
gamma	I
-	I
thio	I
]	I
triphosphate	I
(	O
MgGTP	B
[	I
S	I
]	I
)	O
inhibited	O
in	O
a	O
single	O
phase	O
.	O

Inhibition	O
by	O
MgApp	B
[	I
NH	I
]	I
p	I
,	O
at	O
all	O
concentrations	O
,	O
was	O
competitive	O
with	O
the	O
substrate	O
(	O
MgGTP	B
)	O
,	O
as	O
was	O
that	O
by	O
MgGDP	B
[	I
S	I
]	I
and	O
MgGTP	B
[	I
S	I
]	I
.	O

Whereas	O
membrane	O
guanylate	O
cyclases	O
usually	O
show	O
positively	O
co	O
-	O
operative	O
kinetics	O
with	O
respect	O
to	O
the	O
substrate	O
,	O
STa	O
-	O
stimulated	O
activity	O
exhibited	O
Michaelis	O
-	O
Menten	O
kinetics	O
with	O
respect	O
to	O
MgGTP	B
.	O

This	O
changed	O
to	O
positive	O
co	O
-	O
operativity	O
when	O
Lubrol	B
PX	I
was	O
the	O
activator	O
,	O
or	O
when	O
the	O
substrate	O
was	O
MnGTP	B
.	O

These	O
results	O
suggest	O
the	O
presence	O
of	O
both	O
a	O
regulatory	O
and	O
a	O
catalytic	O
nucleotide	O
-	O
binding	O
site	O
,	O
which	O
do	O
not	O
interact	O
co	O
-	O
operatively	O
with	O
STa	O
activation	O
.	O

14591846	O
Cognitive	O
assessment	O
of	O
geriatric	O
schizophrenic	O
patients	O
with	O
severe	O
impairment	O
.	O

There	O
is	O
evidence	O
that	O
some	O
elderly	O
patients	O
with	O
chronic	O
schizophrenia	O
experience	O
marked	O
impairments	O
in	O
cognitive	O
functioning	O
.	O

Assessment	O
of	O
these	O
patients	O
may	O
be	O
difficult	O
with	O
traditional	O
neuropsychological	O
measures	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
if	O
cognitive	O
functioning	O
could	O
be	O
validly	O
assessed	O
with	O
the	O
Alzheimer	O
's	O
Disease	O
Assessment	O
Scale	O
-	O
Late	O
Version	O
Cognitive	O
factor	O
score	O
(	O
ADAS	O
-	O
L	O
Cog	O
)	O
in	O
patients	O
whose	O
scores	O
on	O
the	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
reflect	O
profound	O
cognitive	O
impairment	O
.	O

Patients	O
with	O
MMSE	O
scores	O
from	O
0	O
to	O
were	O
selected	O
from	O
a	O
larger	O
database	O
.	O

Neuropsychological	O
instruments	O
designed	O
for	O
the	O
assessment	O
of	O
mild	O
to	O
moderate	O
dementia	O
were	O
found	O
to	O
be	O
inadequate	O
in	O
this	O
profoundly	O
impaired	O
population	O
,	O
due	O
to	O
floor	O
effects	O
.	O

In	O
contrast	O
,	O
there	O
was	O
a	O
significant	O
relationship	O
between	O
ADAS	O
-	O
L	O
scores	O
and	O
several	O
criterion	O
measures	O
,	O
including	O
the	O
MMSE	O
(	O
R	O
=	O
-	O
.71	O
,	O
P	O
<	O
.001	O
)	O
,	O
the	O
Social	O
Adaptive	O
Functions	O
Evaluation	O
(	O
SAFE	O
)	O
social	O
functions	O
scale	O
(	O
R	O
=	O
.47	O
,	O
P	O
<	O
.001	O
)	O
,	O
and	O
the	O
negative	O
symptom	O
total	O
score	O
of	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
(	O
PANSS	O
)	O
(	O
R	O
=	O
.412	O
,	O
P	O
<	O
.001	O
)	O
.	O

The	O
MMSE	O
was	O
somewhat	O
less	O
strongly	O
correlated	O
with	O
both	O
social	O
functions	O
(	O
R	O
=	O
-	O
.401	O
,	O
P	O
<	O
.001	O
)	O
and	O
the	O
negative	O
symptom	O
total	O
score	O
of	O
the	O
PANSS	O
(	O
R	O
=	O
-	O
.366	O
,	O
P	O
<	O
.001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
cognition	O
can	O
be	O
reliably	O
and	O
validly	O
assessed	O
with	O
instruments	O
such	O
as	O
the	O
ADAS	O
-	O
L	O
that	O
are	O
designed	O
for	O
the	O
assessment	O
of	O
severely	O
impaired	O
patients	O
.	O

In	O
a	O
continuing	O
effort	O
to	O
design	O
small	O
-	O
molecule	O
inhibitors	O
of	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
that	O
combine	O
the	O
enzyme	O
-	O
binding	O
selectivity	O
of	O
2,4	B
-	I
diamino	I
-	I
5	I
-	I
(	I
3	I
'	I
,	I
4	I
'	I
,	I
5	I
'	I
-	I
trimethoxybenzyl	I
)	I
pyrimidine	I
(	O
trimethoprim	B
,	O
TMP	B
)	O
with	O
the	O
potency	O
of	O
2,4	B
-	I
diamino	I
-	I
5	I
-	I
methyl	I
-	I
6	I
-	I
(	I
2	I
'	I
,	I
5	I
'	I
-	I
dimethoxybenzyl	I
)	I
pyrido	I
[	I
2,3	I
-	I
d	I
]	I
pyrimidine	I
(	O
piritrexim	B
,	O
PTX	B
)	O
,	O
seven	O
previously	O
undescribed	O
2,4	B
-	I
diamino	I
-	I
5	I
-	I
[	I
2	I
'	I
-	I
methoxy	I
-	I
5	I
'	I
-	I
(	I
substituted	I
benzyl	I
)	I
]	I
pyrimidines	I
were	O
synthesized	O
in	O
which	O
the	O
substituent	O
at	O
the	O
5	O
'	O
-	O
position	O
was	O
a	O
carboxyphenyl	B
group	B
linked	O
to	O
the	O
benzyl	B
moiety	B
by	O
a	O
bridge	O
of	O
two	O
or	O
four	O
atoms	O
in	O
length	O
.	O

The	O
new	O
analogues	O
were	O
all	O
obtained	O
from	O
2,4	B
-	I
diamino	I
-	I
5	I
-	I
(	I
5	I
'	I
-	I
iodo	I
-	I
2	I
'	I
-	I
methoxybenzyl	I
)	I
pyrimidine	I
via	O
a	O
Sonogashira	O
reaction	O
,	O
followed	O
,	O
where	O
appropriate	O
,	O
by	O
catalytic	O
hydrogenation	O
.	O

The	O
new	O
analogues	O
were	O
tested	O
as	O
inhibitors	O
of	O
DHFR	O
from	O
Pneumocystis	O
carinii	O
(	O
Pc	O
)	O
,	O
Toxoplasma	O
gondii	O
(	O
Tg	O
)	O
,	O
and	O
Mycobacterium	O
avium	O
(	O
Ma	O
)	O
,	O
three	O
life	O
-	O
threatening	O
pathogens	O
often	O
found	O
in	O
AIDS	O
patients	O
and	O
individuals	O
whose	O
immune	O
system	O
is	O
impaired	O
as	O
a	O
result	O
of	O
treatment	O
with	O
immunosuppressive	O
chemotherapy	O
or	O
radiation	O
.	O

The	O
selectivity	O
index	O
(	O
SI	O
)	O
of	O
each	O
compound	O
was	O
obtained	O
by	O
dividing	O
its	O
inhibitory	O
concentration	O
(	O
IC	O
(	O
)	O
)	O
against	O
Pc	O
,	O
Tg	O
,	O
or	O
Ma	O
DHFR	O
by	O
its	O
IC	O
(	O
)	O
against	O
rat	O
DHFR	O
.	O

2,4	B
-	I
Diamino	I
-	I
[	I
2	I
'	I
-	I
methoxy	I
-	I
5	I
'	I
-	I
(	I
3	I
-	I
carboxyphenyl	I
)	I
ethynylbenzyl	I
]	I
pyrimidine	I
(	O
28	O
)	O
,	O
with	O
an	O
IC	O
(	O
)	O
of	O
23	O
nM	O
and	O
an	O
SI	O
of	O
28	O
in	O
the	O
Pc	O
DHFR	O
assay	O
,	O
had	O
about	O
the	O
same	O
potency	O
as	O
PTX	B
and	O
was	O
times	O
more	O
potent	O
than	O
TMP	B
.	O

As	O
an	O
inhibitor	O
of	O
Tg	O
DHFR	O
,	O
28	O
had	O
an	O
IC	O
(	O
)	O
of	O
5.5	O
nM	O
(	O
-	O
fold	O
lower	O
than	O
that	O
of	O
TMP	B
and	O
similar	O
to	O
that	O
of	O
PTX	B
)	O
and	O
an	O
SI	O
value	O
of	O
(	O
2	O
-	O
fold	O
better	O
than	O
TMP	B
and	O
vastly	O
superior	O
to	O
PTX	B
)	O
.	O

Against	O
Ma	O
DHFR	O
,	O
28	O
had	O
IC	O
(	O
)	O
and	O
SI	O
values	O
of	O
1.5	O
nM	O
and	O
,	O
respectively	O
,	O
compared	O
with	O
nM	O
and	O
for	O
TMP	B
.	O

Although	O
it	O
had	O
2.5	O
-	O
fold	O
lower	O
potency	O
than	O
28	O
against	O
Ma	O
DHFR	O
(	O
IC	O
(	O
)	O
=	O
3.7	O
nM	O
)	O
and	O
was	O
substantially	O
weaker	O
against	O
Pc	O
and	O
Tg	O
DHFR	O
,	O
2,4	B
-	I
diamino	I
-	I
[	I
2	I
'	I
-	I
methoxy	I
-	I
5	I
'	I
-	I
(	I
4	I
-	I
carboxyphenyl	I
)	I
ethynylbenzyl	I
]	I
pyrimidine	I
(	O
29	O
)	O
,	O
with	O
the	O
carboxy	B
group	B
at	O
the	O
para	O
rather	O
than	O
the	O
meta	O
position	O
,	O
displayed	O
-	O
fold	O
selectivity	O
against	O
the	O
Ma	O
enzyme	O
and	O
was	O
the	O
most	O
selective	O
2,4	B
-	I
diamino	I
-	I
5	I
-	I
(	I
5	I
'	I
-	I
substituted	I
benzyl	I
)	I
pyrimidine	I
inhibitor	O
of	O
this	O
enzyme	O
we	O
have	O
encountered	O
to	O
date	O
.	O

Additional	O
bioassay	O
data	O
for	O
these	O
compounds	O
are	O
also	O
reported	O
.	O

The	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
several	O
unsaturated	B
acyclonucleosides	I
related	O
to	O
augustmycin	B
A	I
are	O
described	O
.	O

The	O
(	B
propargyloxy	I
)	I
methyl	I
acyclonucleoside	I
analogues	B
of	O
6	B
-	I
chloropurine	I
,	O
adenine	B
,	O
6	B
-	I
methoxypurine	I
,	O
hypoxanthine	B
,	O
6	B
-	I
mercaptopurine	I
,	O
and	O
azathioprine	B
have	O
been	O
prepared	O
.	O

The	O
9	B
-	I
[	I
(	I
propargyloxy	I
)	I
methyl	I
]	I
adenine	I
(	O
5	O
)	O
and	O
9	B
-	I
[	I
(	I
propargyloxy	I
)	I
methyl	I
]	I
hypoxanthine	I
(	O
12	O
)	O
analogues	B
were	O
converted	O
to	O
the	O
corresponding	O
5	B
'	I
-	I
tributylstannyl	I
intermediates	B
(	O
9	O
and	O
13	O
)	O
,	O
respectively	O
,	O
which	O
gave	O
9	B
-	I
[	I
[	I
[	I
(	I
Z	I
)	I
-	I
5	I
-	I
iodo	I
-	I
5	I
-	I
propenyl	I
]	I
oxy	I
]	I
methyl	I
]	I
adenine	I
(	O
)	O
and	O
9	B
-	I
[	I
[	I
[	I
(	I
Z	I
)	I
-	I
5	I
-	I
iodo	I
-	I
5	I
-	I
propenyl	I
]	I
oxy	I
]	I
methyl	I
]	I
hypoxanthine	I
(	O
14	O
)	O
,	O
respectively	O
,	O
after	O
iododestannylation	O
.	O

The	O
[	O
125I	O
]	O
-	O
radiolabeled	O
congeners	O
of	O
and	O
14	O
were	O
prepared	O
as	O
potential	O
metabolic	O
markers	O
.	O

Among	O
the	O
unsaturated	B
acyclonucleosides	I
tested	O
,	O
9	B
-	I
[	I
(	I
propargyloxy	I
)	I
methyl	I
]	I
-	I
6	I
-	I
chloropurine	I
(	O
3	O
)	O
,	O
9	B
-	I
[	I
(	I
propargyloxy	I
)	I
methyl	I
]	I
-	I
6	I
-	I
mercaptopurine	I
(	O
15	O
)	O
,	O
9	B
-	I
[	I
(	I
propargyloxy	I
)	I
methyl	I
]	I
azathioprine	I
(	O
17	O
)	O
,	O
and	O
angustmycin	B
A	I
analogue	O
showed	O
inhibition	O
of	O
cancer	O
cell	O
growth	O
,	O
but	O
only	O
at	O
a	O
minimal	O
level	O
,	O
and	O
17	O
also	O
showed	O
14	O
%	O
cancer	O
cell	O
death	O
in	O
vitro	O
.	O

Compound	O
provided	O
approximately	O
protection	O
against	O
HIV	O
at	O
(	O
-	O
4	O
)	O
M	O
concentrations	O
.	O

Biodistribution	O
results	O
of	O
[	O
125I	O
]	O
-	O
in	O
mice	O
indicate	O
that	O
compound	O
is	O
readily	O
metabolized	O
via	O
deiodination	O
in	O
vivo	O
,	O
possibly	O
by	O
serving	O
as	O
a	O
substrate	O
for	O
the	O
enzyme	O
S	O
-	O
adenosyl	O
-	O
L	O
-	O
homocysteine	O
hydrolase	O
.	O

Degarelix	O
(	O
FE200486	B
,	O
Ac	O
-	O
d	O
-	O
2Nal	O
(	O
1	O
)	O
-	O
d	O
-	O
4Cpa	O
(	O
2	O
)	O
-	O
d	O
-	O
3Pal	O
(	O
3	O
)	O
-	O
Ser	O
(	O
4	O
)	O
-	O
4Aph	O
(	O
l	O
-	O
Hor	O
)	O
(	O
5	O
)	O
-	O
d	O
-	O
4Aph	O
(	O
Cbm	O
)	O
(	O
6	O
)	O
-	O
Leu	O
(	O
7	O
)	O
-	O
ILys	O
(	O
8	O
)	O
-	O
Pro	O
(	O
9	O
)	O
-	O
d	O
-	O
Ala	O
(	O
)	O
-	O
NH	O
(	O
2	O
)	O
)	O
is	O
a	O
potent	O
and	O
very	O
long	O
acting	O
antagonist	O
of	O
gonadotropin	O
-	O
releasing	O
hormone	O
(	O
GnRH	O
)	O
after	O
subcutaneous	O
administration	O
in	O
mammals	O
including	O
humans	O
.	O

Analogues	O
of	O
degarelix	B
were	O
synthesized	O
,	O
characterized	O
,	O
and	O
screened	O
for	O
the	O
antagonism	O
of	O
GnRH	O
-	O
induced	O
response	O
in	O
a	O
reporter	O
gene	O
assay	O
in	O
HEK	O
-	O
293	O
cells	O
expressing	O
the	O
human	O
GnRH	O
receptor	O
.	O

The	O
duration	O
of	O
action	O
was	O
also	O
determined	O
in	O
the	O
castrated	O
male	O
rat	O
assay	O
to	O
measure	O
the	O
extent	O
(	O
efficacy	O
and	O
duration	O
of	O
action	O
)	O
of	O
inhibition	O
of	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
release	O
.	O

Structurally	O
,	O
this	O
series	O
of	O
analogues	O
has	O
novel	O
substitutions	O
at	O
positions	O
3	O
,	O
7	O
,	O
and	O
8	O
and	O
N	O
(	O
alpha	O
)	O
-	O
methylation	O
at	O
positions	O
6	O
,	O
7	O
,	O
and	O
8	O
in	O
the	O
structure	O
of	O
degarelix	B
.	O

These	O
substitutions	O
were	O
designed	O
to	O
probe	O
the	O
spatial	O
limitations	O
of	O
the	O
receptor	O
's	O
cavity	O
and	O
to	O
map	O
the	O
steric	O
and	O
ionic	O
boundaries	O
.	O

Some	O
functional	O
groups	O
were	O
introduced	O
that	O
were	O
hypothesized	O
to	O
influence	O
the	O
phamacokinetic	O
properties	O
of	O
the	O
analogues	O
such	O
as	O
bioavailability	O
,	O
solubility	O
,	O
intra	O
-	O
or	O
intermolecular	O
hydrogen	O
bond	O
forming	O
capacity	O
,	O
and	O
ability	O
to	O
bind	O
carrier	O
proteins	O
.	O

Substitutions	O
at	O
positions	O
3	O
(	O
[	B
N	I
(	I
beta	I
)	I
-	I
(	I
2	I
-	I
pyridyl	I
-	I
methyl	I
)	I
d	I
-	I
Dap	I
(	I
3	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
2.71	O
nM	O
)	O
(	O
5	O
)	O
,	O
7	O
(	O
[	B
Pra	I
(	I
7	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
2.11	O
nM	O
)	O
(	O
16	O
)	O
,	O
and	O
8	O
(	O
[	B
N	I
(	I
delta	I
)	I
-	I
(	I
IGly	I
)	I
Orn	I
(	I
8	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
1.38	O
nM	O
)	O
(	O
)	O
and	O
N	O
-	O
methylation	O
(	O
[	B
N	I
(	I
alpha	I
)	I
-	I
methyl	I
-	I
Leu	I
(	I
7	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
1.47	O
nM	O
)	O
(	O
32	O
)	O
yielded	O
analogues	O
that	O
were	O
equipotent	O
to	O
degarelix	B
(	O
2	O
)	O
in	O
vitro	O
(	O
IC	O
(	O
)	O
=	O
1.64	O
nM	O
)	O
but	O
shorter	O
acting	O
in	O
vivo	O
.	O

Out	O
of	O
the	O
33	O
novel	O
analogues	O
tested	O
for	O
the	O
duration	O
of	O
action	O
in	O
this	O
series	O
,	O
two	O
analogues	O
(	O
[	B
N	I
(	I
epsilon	I
)	I
-	I
cyclohexyl	I
-	I
Lys	I
(	I
8	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
1.50	O
nM	O
)	O
(	O
23	O
)	O
and	O
(	O
[	B
N	I
(	I
beta	I
)	I
-	I
(	I
IbetaAla	I
)	I
Dap	I
(	I
8	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
1.98	O
nM	O
)	O
(	O
26	O
)	O
had	O
antagonist	O
potencies	O
and	O
duration	O
of	O
action	O
similar	O
to	O
that	O
of	O
azaline	B
B	I
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
)	O
release	O
for	O
&	O
gt	O
;	O
72	O
h	O
after	O
sc	O
injection	O
to	O
castrated	O
male	O
rats	O
at	O
a	O
standard	O
dose	O
of	O
mug	O
/	O
rat	O
in	O
5	O
%	O
mannitol	O
}	O
.	O

Under	O
similar	O
conditions	O
analogues	O
(	O
[	B
N	I
(	I
gamma	I
)	I
-	I
(	I
IGly	I
)	I
Dab	I
(	I
8	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
1.56	O
nM	O
)	O
(	O
21	O
)	O
and	O
(	O
[	B
IOrn	I
(	I
8	I
)	I
]	I
degarelix	I
,	O
IC	O
(	O
)	O
=	O
1.72	O
nM	O
)	O
(	O
18	O
)	O
had	O
a	O
longer	O
duration	O
of	O
action	O
{	O
inhibited	O
LH	O
(	O
&	O
gt	O
;	O
96	O
h	O
)	O
release	O
}	O
than	O
azaline	B
B	I
;	O
however	O
they	O
were	O
shorter	O
acting	O
than	O
degarelix	B
.	O

Hydrophilicity	O
of	O
these	O
analogues	O
,	O
a	O
potential	O
measure	O
of	O
their	O
ability	O
to	O
be	O
formulated	O
for	O
sustained	O
release	O
,	O
was	O
determined	O
using	O
RP	O
-	O
HPLC	O
at	O
neutral	O
pH	O
yielding	O
analogues	O
with	O
shorter	O
as	O
well	O
as	O
longer	O
retention	O
times	O
.	O

No	O
correlation	O
was	O
found	O
between	O
retention	O
times	O
and	O
antagonist	O
potency	O
or	O
duration	O
of	O
action	O
.	O

16946562	O
Novel	O
genetic	O
variations	O
and	O
haplotypes	O
of	O
hepatocyte	O
nuclear	O
factor	O
4alpha	O
(	O
HNF4A	O
)	O
found	O
in	O
Japanese	O
type	O
II	O
diabetic	O
patients	O
.	O

Thirty	O
-	O
nine	O
single	O
nucleotide	O
variations	O
,	O
including	O
16	O
novel	O
ones	O
,	O
were	O
found	O
in	O
the	O
5	O
'	O
promoter	O
region	O
,	O
all	O
of	O
the	O
exons	O
and	O
their	O
surrounding	O
introns	O
of	O
HNF4A	O
in	O
74	O
Japanese	O
type	O
II	O
diabetic	O
patients	O
.	O

The	O
following	O
novel	O
variations	O
were	O
identified	O
(	O
based	O
on	O
the	O
amino	O
acid	O
numbering	O
of	O
splicing	O
variant	O
2	O
)	O
:	O
-	O
>	O
C	O
in	O
the	O
5	O
'	O
promoter	O
region	O
;	O
1154C	O
>	O
T	O
(	O
A385V	O
)	O
and	O
1193	O
T	O
>	O
C	O
(	O
M398	O
T	O
)	O
in	O
the	O
coding	O
exons	O
;	O
>	O
A	O
,	O
1852	O
G	O
>	O
T	O
,	O
>	O
T	O
,	O
>	O
A	O
,	O
and	O
2362	O
_	O
2380	O
delAAGAATGGTGTGGGAGAGG	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
,	O
and	O
IVS1	O
+	O
231	O
G	O
>	O
A	O
,	O
IVS2	O
-	O
83C	O
>	O
T	O
,	O
IVS3	O
+	O
>	O
T	O
,	O
IVS3	O
-	O
54delC	O
,	O
IVS5	O
+	O
173	O
_	O
176	O
delTTAG	O
,	O
IVS5	O
-	O
181	O
_	O
-	O
,	O
IVS8	O
-	O
>	O
G	O
,	O
and	O
IVS9	O
-	O
151A	O
>	O
C	O
in	O
the	O
introns	O
.	O

The	O
allele	O
frequencies	O
were	O
0.311	O
for	O
2362	O
_	O
2380	O
delAAGAATGGTGTGGGAGAGG	O
,	O
0.054	O
for	O
>	O
A	O
,	O
0.047	O
for	O
1852	O
G	O
>	O
T	O
,	O
0.020	O
for	O
IVS1	O
+	O
231	O
G	O
>	O
A	O
,	O
0.014	O
for	O
IVS9	O
-	O
151A	O
>	O
C	O
,	O
and	O
0.007	O
for	O
the	O
other	O
11	O
variations	O
.	O

In	O
addition	O
,	O
one	O
known	O
nonsynonymous	O
single	O
nucleotide	O
polymorphism	O
,	O
416C	O
>	O
T	O
(	O
T139I	O
)	O
,	O
was	O
detected	O
at	O
a	O
0.007	O
frequency	O
.	O

Based	O
on	O
the	O
linkage	O
disequilibrium	O
profiles	O
,	O
the	O
region	O
analyzed	O
was	O
divided	O
into	O
three	O
blocks	O
.	O

Haplotype	O
analysis	O
determined	O
/	O
inferred	O
,	O
16	O
,	O
and	O
12	O
haplotypes	O
for	O
block	O
1	O
,	O
2	O
,	O
and	O
3	O
,	O
respectively	O
.	O

Our	O
results	O
on	O
HNF4A	O
variations	O
and	O
haplotypes	O
would	O
be	O
useful	O
for	O
pharmacogenetic	O
studies	O
in	O
Japanese	O
.	O

A	O
series	O
of	O
8	B
-	I
(	I
trifluoromethyl	I
)	I
-	I
substituted	I
quinolones	I
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
,	O
and	O
phototolerance	O
in	O
a	O
mouse	O
phototolerance	O
assay	O
.	O

These	O
analogues	O
were	O
compared	O
to	O
the	O
corresponding	O
series	O
of	O
6,8	B
-	I
difluoro	I
-	I
and	O
6	B
-	I
fluoro	I
-	I
8H	I
-	I
quinolones	I
(	O
ciprofloxacin	B
type	O
)	O
.	O

Although	O
their	O
in	O
vitro	O
antibacterial	O
activities	O
are	O
less	O
than	O
the	O
6,8	B
-	I
difluoro	I
analogues	B
,	O
the	O
8	B
-	I
(	I
trifluoromethyl	I
)	I
quinolones	I
are	O
generally	O
equivalent	O
to	O
their	O
8H	B
analogues	B
.	O

In	O
vivo	O
,	O
they	O
are	O
comparable	O
to	O
the	O
6,8	B
-	I
difluoro	I
series	B
and	O
show	O
up	O
to	O
-	O
fold	O
improvement	O
in	O
efficacy	O
when	O
compared	O
to	O
their	O
ciprofloxacin	B
counterparts	O
vs	O
Streptococcus	O
pyogenes	O
and	O
Streptococcus	O
pneumonia	O
.	O

In	O
the	O
phototolerance	O
model	O
,	O
the	O
8	B
-	I
(	I
trifluoromethyl	I
)	I
quinolones	I
are	O
comparable	O
to	O
the	O
8H	B
-	I
quinolones	I
.	O

Both	O
of	O
these	O
series	O
display	O
much	O
higher	O
no	O
effect	O
doses	O
(	O
greater	O
tolerance	O
)	O
than	O
the	O
corresponding	O
6,8	B
-	I
difluoroquinolones	I
.	O

17368496	O
Tissue	O
and	O
serum	O
levels	O
of	O
principal	O
androgens	B
in	O
benign	O
prostatic	O
hyperplasia	O
and	O
prostate	O
cancer	O
.	O

Androgens	B
are	O
considered	O
to	O
play	O
a	O
substantial	O
role	O
in	O
pathogenesis	O
of	O
both	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
prostate	O
cancer	O
.	O

The	O
importance	O
of	O
determination	O
of	O
androgen	B
levels	O
in	O
tissue	O
and	O
serum	O
for	O
cancer	O
progression	O
and	O
prognosis	O
has	O
been	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
study	O
was	O
to	O
find	O
out	O
hormonal	O
differences	O
in	O
both	O
diseases	O
,	O
their	O
correlations	O
between	O
intraprostatic	O
and	O
serum	O
levels	O
and	O
predicted	O
value	O
of	O
their	O
investigation	O
.	O

Testosterone	B
,	O
dihydrotestosterone	B
,	O
androstenedione	B
and	O
also	O
epitestosterone	B
were	O
determined	O
in	O
prostate	O
tissue	O
from	O
57	O
patients	O
who	O
underwent	O
transvesical	O
prostatectomy	O
for	O
BPH	O
and	O
121	O
patients	O
after	O
radical	O
prostatectomy	O
for	O
prostate	O
cancer	O
.	O

In	O
75	O
subjects	O
with	O
cancer	O
and	O
51	O
with	O
BPH	O
the	O
serum	O
samples	O
were	O
analyzed	O
for	O
testosterone	B
,	O
dihydrotestosterone	B
and	O
SHBG	O
.	O

Significantly	O
higher	O
intraprostatic	O
androgen	B
concentrations	O
,	O
i.e.	O
8.85	O
+	O
/	O
-	O
6.77	O
versus	O
6.44	O
+	O
/	O
-	O
6.43	O
pmol	O
/	O
g	O
,	O
p	O
<	O
0.01	O
for	O
dihydrotestosterone	B
,	O
and	O
4.61	O
+	O
/	O
-	O
7.02	O
versus	O
3.44	O
+	O
/	O
-	O
4.53	O
pmol	O
/	O
g	O
,	O
p	O
<	O
0.05	O
for	O
testosterone	B
,	O
respectively	O
,	O
were	O
found	O
in	O
patients	O
with	O
prostate	O
cancer	O
than	O
in	O
BPH	O
.	O

Higher	O
levels	O
in	O
cancer	O
tissue	O
were	O
found	O
also	O
for	O
epitestosterone	B
.	O

However	O
,	O
no	O
differences	O
were	O
found	O
in	O
serum	O
levels	O
.	O

Highly	O
significant	O
correlations	O
occurred	O
between	O
all	O
pairs	O
of	O
intraprostatic	O
androgens	B
and	O
also	O
epitestosterone	B
as	O
well	O
as	O
between	O
serum	O
testosterone	B
and	O
dihydrotestosterone	B
(	O
p	O
<	O
0.001	O
)	O
in	O
both	O
BPH	O
and	O
cancer	O
groups	O
.	O

Correlation	O
was	O
not	O
found	O
between	O
corresponding	O
tissue	O
and	O
serum	O
testosterone	B
and	O
dihydrotestosterone	B
,	O
either	O
in	O
benign	O
or	O
cancer	O
samples	O
.	O

The	O
results	O
point	O
to	O
importance	O
of	O
intraprostatic	O
hormone	O
levels	O
for	O
evaluation	O
of	O
androgen	O
status	O
of	O
patients	O
,	O
contrasting	O
to	O
a	O
low	O
value	O
of	O
serum	O
hormone	O
measurement	O
.	O

Structure	O
-	O
activity	O
relationships	O
have	O
been	O
investigated	O
for	O
inhibition	O
of	O
DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
ATM	O
kinase	O
by	O
a	O
series	O
of	O
pyran	B
-	I
2	I
-	I
ones	I
,	O
pyran	B
-	I
4	I
-	I
ones	I
,	O
thiopyran	B
-	I
4	I
-	I
ones	I
,	O
and	O
pyridin	B
-	I
4	I
-	I
ones	I
.	O

A	O
wide	O
range	O
of	O
IC50	O
values	O
were	O
observed	O
for	O
pyranones	B
and	O
thiopyranones	B
substituted	O
at	O
the	O
6	O
-	O
position	O
,	O
with	O
the	O
3	O
-	O
and	O
5	O
-	O
positions	O
proving	O
intolerant	O
to	O
substitution	O
.	O

Related	O
pyran	B
-	I
2	I
-	I
ones	I
,	O
pyran	B
-	I
4	I
-	I
ones	I
,	O
and	O
thiopyran	B
-	I
4	I
-	I
ones	I
showed	O
similar	O
IC50	O
values	O
against	O
DNA	O
-	O
PK	O
,	O
whereas	O
the	O
pyridin	B
-	I
4	I
-	I
one	I
system	O
proved	O
,	O
in	O
general	O
,	O
ineffective	O
at	O
inhibiting	O
DNA	O
-	O
PK	O
.	O

Extended	O
libraries	O
exploring	O
the	O
6	O
-	O
position	O
of	O
2	B
-	I
morpholino	I
-	I
pyran	I
-	I
4	I
-	I
ones	I
and	O
2	B
-	I
morpholino	I
-	I
thiopyrano	I
-	I
4	I
-	I
ones	I
identified	O
the	O
first	O
highly	O
potent	O
and	O
selective	O
ATM	O
inhibitor	O
2	B
-	I
morpholin	I
-	I
4	I
-	I
yl	I
-	I
6	I
-	I
thianthren	I
-	I
1	I
-	I
yl	I
-	I
pyran	I
-	I
4	I
-	I
one	I
(	O
151C	O
;	O
ATM	O
;	O
IC50	O
=	O
13	O
nM	O
)	O
and	O
revealed	O
constrained	O
SARs	O
for	O
ATM	O
inhibition	O
compared	O
with	O
DNA	O
-	O
PK	O
.	O

One	O
of	O
the	O
most	O
potent	O
DNA	O
-	O
PK	O
inhibitors	O
identified	O
,	O
2	B
-	I
(	I
4	I
-	I
methoxyphenyl	I
)	I
-	I
6	I
-	I
(	I
morpholin	I
-	I
4	I
-	I
yl	I
)	I
pyran	I
-	I
4	I
-	I
one	I
(	O
16	O
;	O
DNA	O
-	O
PK	O
;	O
IC50	O
=	O
nM	O
)	O
effectively	O
sensitized	O
HeLa	O
cells	O
to	O
the	O
topoisomerase	O
II	O
inhibitor	O
etoposide	B
in	O
vitro	O
.	O

Selective	O
protection	O
of	O
(	B
9R	I
)	I
-	I
9	I
-	I
amino	I
-	I
9	I
-	I
deoxoerythromycin	I
A	I
allowed	O
for	O
elimination	O
of	O
the	O
12	B
-	I
hydroxyl	I
group	B
to	O
afford	O
a	O
versatile	O
12,21	B
-	I
olefin	I
intermediate	B
.	O

Further	O
modifications	O
of	O
the	O
intermediate	O
led	O
to	O
the	O
syntheses	O
of	O
(	B
9R	I
)	I
-	I
9	I
-	I
deoxo	I
-	I
9	I
-	I
(	I
N	I
,	I
N	I
-	I
dimethylamino	I
)	I
-	I
12,21	I
-	I
epoxyerythromycin	I
B	I
,	O
(	B
9R	I
)	I
-	I
9	I
-	I
deoxo	I
-	I
9	I
-	I
(	I
N	I
,	I
N	I
-	I
dimethylamino	I
)	I
-	I
21	I
-	I
hydroxyerythromycin	I
A	I
,	O
and	O
(	B
9R	I
)	I
-	I
9	I
-	I
deoxo	I
-	I
9	I
-	I
(	I
N	I
,	I
N	I
-	I
dimethylamino	I
)	I
-	I
21	I
-	I
hydroxyerythromycin	I
B	I
.	O

All	O
three	O
compounds	O
retained	O
antibacterial	O
activity	O
against	O
several	O
organisms	O
normally	O
susceptible	O
to	O
(	B
9R	I
)	I
-	I
9	I
-	I
deoxo	I
-	I
9	I
-	I
(	I
N	I
,	I
N	I
-	I
dimethylamino	I
)	I
erythromycin	I
A	I
.	O

However	O
,	O
the	O
21	B
-	I
hydroxylated	I
erythromycin	I
A	I
analogue	B
was	O
weaker	O
in	O
potency	O
than	O
the	O
corresponding	O
erythromycin	B
B	I
congener	I
and	O
much	O
weaker	O
than	O
the	O
epoxy	B
derivative	B
.	O

This	O
suggests	O
that	O
while	O
substitution	O
of	O
a	O
polar	O
functionality	O
at	O
C	O
-	O
21	O
does	O
not	O
abolish	O
antibacterial	O
activity	O
,	O
introduction	O
of	O
vicinal	O
polar	O
groups	O
at	O
both	O
C	O
-	O
12	O
and	O
C	O
-	O
21	O
may	O
lead	O
to	O
reduction	O
in	O
potency	O
.	O

Nevertheless	O
,	O
these	O
21	O
-	O
functionalized	O
derivatives	O
of	O
(	B
9R	I
)	I
-	I
erythromycylamine	I
provide	O
an	O
entry	O
into	O
novel	O
analogues	O
of	O
the	O
important	O
macrolide	O
antibiotic	O
erythromycin	B
.	O

Thalamic	O
atrophy	O
and	O
cognition	O
in	O
unilateral	O
temporal	O
lobe	O
epilepsy	O
.	O

This	O
study	O
examined	O
quantitative	O
magnetic	O
resonance	O
volumes	O
of	O
the	O
thalamus	O
and	O
hippocampus	O
and	O
determined	O
their	O
relationship	O
with	O
cognitive	O
function	O
and	O
clinical	O
seizure	O
characteristics	O
in	O
a	O
sample	O
of	O
46	O
unilateral	O
temporal	O
lobe	O
epilepsy	O
(	O
TLE	O
)	O
subjects	O
(	O
left	O
and	O
26	O
right	O
)	O
and	O
29	O
controls	O
.	O

The	O
hippocampus	O
and	O
thalamus	O
exhibited	O
different	O
patterns	O
of	O
volume	O
abnormality	O
,	O
different	O
associations	O
with	O
clinical	O
seizure	O
characteristics	O
,	O
and	O
different	O
patterns	O
of	O
relationship	O
with	O
cognitive	O
measures	O
.	O

Hippocampal	O
volume	O
reduction	O
was	O
primarily	O
ipsilateral	O
to	O
the	O
seizure	O
focus	O
,	O
and	O
thalamic	O
volume	O
reduction	O
was	O
bilateral	O
.	O

Ipsilateral	O
hippocampal	O
volume	O
was	O
significantly	O
correlated	O
with	O
both	O
early	O
neurodevelopmental	O
features	O
(	O
age	O
of	O
seizure	O
onset	O
)	O
and	O
disease	O
characteristics	O
(	O
duration	O
of	O
epilepsy	O
)	O
,	O
whereas	O
thalamus	O
integrity	O
was	O
related	O
only	O
to	O
disease	O
variables	O
.	O

Hippocampal	O
volume	O
showed	O
a	O
selective	O
association	O
with	O
verbal	O
memory	O
performance	O
.	O

In	O
contrast	O
,	O
both	O
left	O
and	O
right	O
thalamic	O
volumes	O
were	O
significantly	O
correlated	O
with	O
performance	O
on	O
both	O
memory	O
and	O
nonmemory	O
cognitive	O
domains	O
.	O

These	O
findings	O
underscore	O
the	O
importance	O
of	O
thalamic	O
atrophy	O
in	O
chronic	O
TLE	O
and	O
its	O
potential	O
implications	O
for	O
cognition	O
.	O

Quantitative	O
magnetic	O
resonance	O
image	O
analysis	O
of	O
the	O
cerebellum	O
in	O
macrocephalic	O
and	O
normocephalic	O
children	O
and	O
adults	O
with	O
autism	O
.	O

A	O
detailed	O
morphometric	O
analysis	O
of	O
the	O
cerebellum	O
in	O
autism	O
with	O
and	O
without	O
macrocephaly	O
.	O

Four	O
subject	O
groups	O
(	O
N	O
=	O
65	O
;	O
male	O
;	O
IQs	O
>	O
or	O
=	O
65	O
;	O
age	O
7	O
to	O
26	O
years	O
)	O
were	O
studied	O
with	O
quantitative	O
MRI	O
;	O
normocephalic	O
and	O
macrocephalic	O
individuals	O
with	O
autism	O
without	O
mental	O
retardation	O
were	O
compared	O
to	O
normocephalic	O
and	O
benign	O
macrocephalic	O
typically	O
developing	O
individuals	O
.	O

Total	O
cerebellum	O
volumes	O
and	O
surface	O
areas	O
of	O
four	O
lobular	O
midsagittal	O
groups	O
were	O
measured	O
.	O

Independent	O
t	O
-	O
tests	O
between	O
autism	O
and	O
control	O
subjects	O
matched	O
for	O
head	O
size	O
revealed	O
no	O
significant	O
differences	O
.	O

Multivariate	O
analyses	O
of	O
variance	O
were	O
also	O
performed	O
,	O
using	O
the	O
diagnostic	O
group	O
as	O
the	O
fixed	O
factor	O
,	O
cerebellar	O
measures	O
as	O
the	O
dependent	O
variables	O
and	O
total	O
intracranial	O
volume	O
,	O
total	O
brain	O
volume	O
,	O
age	O
,	O
verbal	O
IQ	O
,	O
and	O
performance	O
IQ	O
as	O
covariates	O
.	O

No	O
significant	O
differences	O
were	O
found	O
;	O
however	O
,	O
a	O
trend	O
was	O
noted	O
in	O
which	O
macrocephalic	O
individuals	O
with	O
autism	O
consistently	O
exhibited	O
slightly	O
smaller	O
cerebellar	O
volume	O
or	O
surface	O
area	O
when	O
compared	O
to	O
individuals	O
with	O
benign	O
macrocephaly	O
.	O

In	O
autism	O
,	O
with	O
and	O
without	O
macrocephaly	O
,	O
cerebellar	O
structures	O
were	O
found	O
to	O
be	O
proportional	O
to	O
head	O
size	O
and	O
did	O
not	O
differ	O
from	O
typically	O
developing	O
subjects	O
.	O

Visual	O
perception	O
in	O
prediagnostic	O
and	O
early	O
stage	O
Huntington	O
's	O
disease	O
.	O

Disturbances	O
of	O
visual	O
perception	O
frequently	O
accompany	O
neurodegenerative	O
disorders	O
but	O
have	O
been	O
little	O
studied	O
in	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
gene	O
carriers	O
.	O

We	O
used	O
psychophysical	O
tests	O
to	O
assess	O
visual	O
perception	O
among	O
individuals	O
in	O
the	O
prediagnostic	O
and	O
early	O
stages	O
of	O
HD	O
.	O

The	O
sample	O
comprised	O
four	O
groups	O
,	O
which	O
included	O
nongene	O
carriers	O
(	O
NG	O
)	O
,	O
32	O
prediagnostic	O
gene	O
carriers	O
with	O
minimal	O
neurological	O
abnormalities	O
(	O
PD1	O
)	O
;	O
prediagnostic	O
gene	O
carriers	O
with	O
moderate	O
neurological	O
abnormalities	O
(	O
PD2	O
)	O
,	O
and	O
36	O
gene	O
carriers	O
with	O
diagnosed	O
HD	O
.	O

Contrast	O
sensitivity	O
for	O
stationary	O
and	O
moving	O
sinusoidal	O
gratings	O
,	O
and	O
tests	O
of	O
form	O
and	O
motion	O
discrimination	O
,	O
were	O
used	O
to	O
probe	O
different	O
visual	O
pathways	O
.	O

Patients	O
with	O
HD	O
showed	O
impaired	O
contrast	O
sensitivity	O
for	O
moving	O
gratings	O
.	O

For	O
one	O
of	O
the	O
three	O
contrast	O
sensitivity	O
tests	O
,	O
the	O
prediagnostic	O
gene	O
carriers	O
with	O
greater	O
neurological	O
abnormality	O
(	O
PD2	O
)	O
also	O
had	O
impaired	O
performance	O
as	O
compared	O
with	O
NG	O
.	O

These	O
findings	O
suggest	O
that	O
early	O
stage	O
HD	O
disrupts	O
visual	O
functions	O
associated	O
with	O
the	O
magnocellular	O
pathway	O
.	O

However	O
,	O
these	O
changes	O
are	O
only	O
observed	O
in	O
individuals	O
diagnosed	O
with	O
HD	O
or	O
who	O
are	O
in	O
the	O
more	O
symptomatic	O
stages	O
of	O
prediagnostic	O
HD	O
.	O

Worker	O
size	O
in	O
the	O
formosan	O
subterranean	O
termite	O
in	O
relation	O
to	O
colony	O
breeding	O
structure	O
as	O
inferred	O
from	O
molecular	O
markers	O
.	O

The	O
Formosan	O
subterranean	O
termite	O
,	O
Coptotermes	O
formosanus	O
Shiraki	O
,	O
is	O
an	O
invasive	O
species	O
that	O
originated	O
in	O
China	O
and	O
has	O
been	O
introduced	O
to	O
Hawaii	O
and	O
the	O
U	O
.	O

S	O
.	O
mainland	O
.	O

Colonies	O
are	O
headed	O
either	O
by	O
a	O
pair	O
of	O
reproductives	O
(	O
simple	O
families	O
)	O
or	O
by	O
varying	O
numbers	O
of	O
inbreeding	O
reproductives	O
(	O
extended	O
families	O
)	O
,	O
and	O
therefore	O
have	O
variable	O
degrees	O
of	O
inbreeding	O
.	O

Worker	O
size	O
also	O
varies	O
among	O
colonies	O
of	O
Formosan	O
termites	O
.	O

We	O
tested	O
whether	O
variation	O
in	O
worker	O
size	O
can	O
be	O
explained	O
by	O
the	O
breeding	O
system	O
.	O

Workers	O
were	O
collected	O
from	O
colonies	O
from	O
three	O
geographically	O
separated	O
populations	O
(	O
China	O
,	O
Hawaii	O
,	O
and	O
Louisiana	O
)	O
,	O
and	O
body	O
weight	O
and	O
head	O
size	O
were	O
measured	O
.	O

Microsatellite	O
genotyping	O
was	O
used	O
to	O
establish	O
whether	O
colonies	O
were	O
simple	O
or	O
extended	O
families	O
and	O
to	O
determine	O
the	O
heterozygosity	O
of	O
workers	O
and	O
their	O
degree	O
of	O
inbreeding	O
relative	O
to	O
their	O
colony	O
(	O
F	O
(	O
IC	O
)	O
,	O
sensitive	O
to	O
the	O
number	O
of	O
reproductives	O
)	O
.	O

All	O
Chinese	O
colonies	O
contained	O
multiple	O
inbreeding	O
neotenics	O
.	O

In	O
Hawaii	O
,	O
37	O
%	O
of	O
the	O
colonies	O
were	O
simple	O
families	O
and	O
63	O
%	O
were	O
extended	O
families	O
,	O
both	O
having	O
considerable	O
degrees	O
of	O
inbreeding	O
.	O

In	O
Louisiana	O
,	O
57	O
%	O
of	O
the	O
colonies	O
were	O
simple	O
families	O
,	O
which	O
were	O
mostly	O
headed	O
by	O
unrelated	O
pairs	O
,	O
and	O
43	O
%	O
were	O
extended	O
families	O
.	O

In	O
simple	O
families	O
,	O
size	O
and	O
body	O
weight	O
of	O
workers	O
were	O
not	O
associated	O
with	O
F	O
(	O
IC	O
)	O
or	O
heterozygosity	O
.	O

In	O
extended	O
families	O
of	O
two	O
populations	O
,	O
both	O
size	O
parameters	O
were	O
negatively	O
correlated	O
with	O
F	O
(	O
IC	O
)	O
;	O
however	O
,	O
heterozygosity	O
was	O
not	O
associated	O
with	O
worker	O
size	O
in	O
any	O
of	O
the	O
populations	O
.	O

This	O
suggests	O
that	O
the	O
number	O
of	O
reproductives	O
within	O
colonies	O
has	O
a	O
stronger	O
influence	O
on	O
worker	O
size	O
than	O
the	O
individuals	O
'	O
genetic	O
diversity	O
in	O
Formosan	O
subterranean	O
termite	O
colonies	O
.	O

Photodynamic	O
diagnostics	O
of	O
bladder	O
tumors	O
.	O

Approximately	O
18,000	O
new	O
cases	O
of	O
urothelial	O
cancer	O
of	O
the	O
bladder	O
occur	O
annually	O
,	O
making	O
it	O
the	O
most	O
frequent	O
urogenital	O
neoplasia	O
representing	O
nearly	O
4	O
%	O
of	O
all	O
malignomas	O
.	O

Tumor	O
stage	O
defines	O
two	O
subgroups	O
requiring	O
specific	O
therapeutic	O
approaches	O
and	O
implying	O
distinct	O
prognoses	O
.	O

Non	O
-	O
muscle	O
-	O
invasive	O
urothelial	O
cancer	O
recurs	O
frequently	O
and	O
occasionally	O
progresses	O
to	O
muscle	O
-	O
invasive	O
stages	O
.	O

Remnant	O
tumor	O
after	O
initial	O
resection	O
is	O
seen	O
as	O
one	O
major	O
factor	O
in	O
high	O
recurrence	O
rates	O
.	O

Although	O
photodynamic	O
diagnostics	O
improving	O
detection	O
and	O
increasing	O
recurrence	O
-	O
free	O
survival	O
has	O
been	O
introduced	O
to	O
broad	O
application	O
,	O
it	O
has	O
yet	O
not	O
been	O
established	O
as	O
standard	O
procedure	O
.	O

This	O
article	O
reviews	O
the	O
current	O
literature	O
and	O
discusses	O
controversial	O
aspects	O
.	O

X	O
-	O
ray	O
beam	O
stabilization	O
at	O
BL	O
-	O
17A	O
,	O
the	O
protein	O
microcrystallography	O
beamline	O
of	O
the	O
Photon	O
Factory	O
.	O

BL	O
-	O
17A	O
is	O
a	O
new	O
structural	O
biology	O
beamline	O
at	O
the	O
Photon	O
Factory	O
,	O
Japan	O
.	O

The	O
high	O
-	O
brilliance	O
beam	O
,	O
derived	O
from	O
the	O
new	O
short	O
-	O
gap	O
undulator	O
(	O
SGU	O
#	O
17	O
)	O
,	O
allows	O
for	O
unique	O
protein	O
crystallographic	O
experiments	O
such	O
as	O
data	O
collection	O
from	O
microcrystals	O
and	O
structural	O
determination	O
using	O
softer	O
X	O
-	O
rays	O
.	O

However	O
,	O
microcrystal	O
experiments	O
require	O
robust	O
beam	O
stability	O
during	O
data	O
collection	O
and	O
minor	O
fluctuations	O
could	O
not	O
be	O
ignored	O
.	O

Initially	O
,	O
significant	O
beam	O
instability	O
was	O
observed	O
at	O
BL	O
-	O
17A	O
.	O

The	O
causes	O
of	O
the	O
beam	O
instability	O
were	O
investigated	O
and	O
its	O
various	O
sources	O
identified	O
.	O

Subsequently	O
,	O
several	O
effective	O
countermeasures	O
have	O
been	O
implemented	O
,	O
and	O
the	O
fluctuation	O
of	O
the	O
beam	O
intensity	O
successfully	O
suppressed	O
to	O
within	O
1	O
%	O
.	O

Here	O
the	O
instability	O
reduction	O
techniques	O
used	O
at	O
BL	O
-	O
17A	O
are	O
presented	O
.	O

Implementation	O
of	O
remote	O
monitoring	O
and	O
diffraction	O
evaluation	O
systems	O
at	O
the	O
Photon	O
Factory	O
macromolecular	O
crystallography	O
beamlines	O
.	O

Owing	O
to	O
recent	O
advances	O
in	O
high	O
-	O
throughput	O
technology	O
in	O
macromolecular	O
crystallography	O
beamlines	O
,	O
such	O
as	O
high	O
-	O
brilliant	O
X	O
-	O
ray	O
sources	O
,	O
high	O
-	O
speed	O
readout	O
detectors	O
and	O
robotics	O
,	O
the	O
number	O
of	O
samples	O
that	O
can	O
be	O
examined	O
in	O
a	O
single	O
visit	O
to	O
the	O
beamline	O
has	O
increased	O
dramatically	O
.	O

In	O
order	O
to	O
make	O
these	O
experiments	O
more	O
efficient	O
,	O
two	O
functions	O
,	O
remote	O
monitoring	O
and	O
diffraction	O
image	O
evaluation	O
,	O
have	O
been	O
implemented	O
in	O
the	O
macromolecular	O
crystallography	O
beamlines	O
at	O
the	O
Photon	O
Factory	O
(	O
PF	O
)	O
.	O

Remote	O
monitoring	O
allows	O
scientists	O
to	O
participate	O
in	O
the	O
experiment	O
by	O
watching	O
from	O
their	O
laboratories	O
,	O
without	O
having	O
to	O
come	O
to	O
the	O
beamline	O
.	O

Diffraction	O
image	O
evaluation	O
makes	O
experiments	O
easier	O
,	O
especially	O
when	O
using	O
the	O
sample	O
exchange	O
robot	O
.	O

To	O
implement	O
these	O
two	O
functions	O
,	O
two	O
independent	O
clients	O
have	O
been	O
developed	O
that	O
work	O
specifically	O
for	O
remote	O
monitoring	O
and	O
diffraction	O
image	O
evaluation	O
.	O

In	O
the	O
macromolecular	O
crystallography	O
beamlines	O
at	O
PF	O
,	O
beamline	O
control	O
is	O
performed	O
using	O
STARS	O
(	O
simple	O
transmission	O
and	O
retrieval	O
system	O
)	O
.	O

The	O
system	O
adopts	O
a	O
client	O
-	O
server	O
style	O
in	O
which	O
client	O
programs	O
communicate	O
with	O
each	O
other	O
through	O
a	O
server	O
process	O
using	O
the	O
STARS	O
protocol	O
.	O

This	O
is	O
an	O
advantage	O
of	O
the	O
extension	O
of	O
the	O
system	O
;	O
implementation	O
of	O
these	O
new	O
functions	O
required	O
few	O
modifications	O
of	O
the	O
existing	O
system	O
.	O

Inhomogeneity	O
of	O
Fecal	O
Flora	O
in	O
Separately	O
Reared	O
Laboratory	O
Mice	O
,	O
as	O
Detected	O
by	O
Denaturing	O
Gradient	O
Gel	O
Electrophoresis	O
(	O
DGGE	O
)	O
.	O

Laboratory	O
mice	O
were	O
divided	O
into	O
2	O
groups	O
and	O
introduced	O
to	O
different	O
rooms	O
immediately	O
after	O
being	O
transferred	O
from	O
a	O
mouse	O
farm	O
.	O

Polymerase	O
chain	O
reaction	O
followed	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
were	O
performed	O
on	O
the	O
V6	O
-	O
V8	O
regions	O
of	O
bacterial	O
16S	O
rDNA	O
obtained	O
from	O
fecal	O
samples	O
at	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
8	O
weeks	O
after	O
the	O
introduction	O
.	O

Binary	O
data	O
were	O
obtained	O
from	O
banding	O
patterns	O
,	O
and	O
Euclidean	O
distances	O
for	O
each	O
week	O
were	O
calculated	O
and	O
analyzed	O
by	O
cluster	O
analysis	O
and	O
non	O
-	O
metric	O
multidimensional	O
scaling	O
.	O

Euclidean	O
distances	O
were	O
significantly	O
higher	O
at	O
weeks	O
1	O
and	O
2	O
than	O
at	O
week	O
0	O
in	O
both	O
groups	O
,	O
although	O
the	O
distances	O
between	O
the	O
2	O
groups	O
were	O
significantly	O
higher	O
after	O
week	O
1	O
than	O
week	O
0	O
.	O

The	O
distances	O
between	O
the	O
2	O
groups	O
were	O
significantly	O
higher	O
than	O
those	O
within	O
each	O
group	O
at	O
weeks	O
4	O
and	O
8	O
.	O

Mice	O
in	O
the	O
2	O
groups	O
formed	O
clusters	O
at	O
weeks	O
2	O
and	O
3	O
respectively	O
,	O
and	O
mice	O
were	O
divided	O
into	O
2	O
clusters	O
by	O
their	O
respective	O
groups	O
at	O
weeks	O
4	O
and	O
8	O
.	O

Mice	O
in	O
the	O
2	O
groups	O
were	O
distributed	O
on	O
opposite	O
sides	O
of	O
the	O
origin	O
on	O
the	O
2	O
-	O
dimensional	O
plane	O
after	O
week	O
2	O
.	O

These	O
results	O
suggest	O
that	O
mouse	O
fecal	O
flora	O
changed	O
characteristically	O
,	O
according	O
to	O
the	O
local	O
environment	O
after	O
introduction	O
.	O

An	O
OLETF	O
Allele	O
of	O
Hyperglycemic	O
QTL	O
Nidd3	O
/	O
of	O
Is	O
Dominant	O
.	O

The	O
OLETF	O
rat	O
is	O
a	O
well	O
-	O
established	O
model	O
for	O
the	O
study	O
of	O
type	O
2	O
diabetes	O
associated	O
with	O
obesity	O
and	O
has	O
been	O
shown	O
to	O
possess	O
multiple	O
hyperglycemic	O
alleles	O
in	O
its	O
genome	O
.	O

Here	O
we	O
focused	O
on	O
and	O
carefully	O
characterized	O
one	O
of	O
the	O
previously	O
reported	O
congenic	O
strains	O
,	O
F	O
.	O

O	O
-	O
Nidd3	O
/	O
of	O
that	O
carries	O
the	O
OLETF	O
allele	O
of	O
the	O
Nidd3	O
/	O
of	O
locus	O
(	O
also	O
known	O
as	O
Niddm21	O
in	O
the	O
Rat	O
Genome	O
Database	O
)	O
in	O
the	O
normoglycemic	O
F344	O
genetic	O
background	O
.	O

A	O
prominent	O
finding	O
was	O
that	O
the	O
F1	O
progeny	O
between	O
the	O
congenic	O
and	O
the	O
F344	O
stain	O
,	O
whose	O
genotype	O
is	O
heterozygote	O
at	O
the	O
Nidd3	O
/	O
of	O
locus	O
,	O
showed	O
mild	O
hyperglycemia	O
equal	O
to	O
the	O
parental	O
congenic	O
rat	O
,	O
suggesting	O
that	O
the	O
OLETF	O
allele	O
is	O
dominant	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
in	O
which	O
a	O
diabetic	O
QTL	O
has	O
been	O
directly	O
demonstrated	O
to	O
be	O
dominant	O
by	O
using	O
congenic	O
strains	O
.	O

Protease	O
production	O
by	O
different	O
thermophilic	O
fungi	O
.	O

A	O
comparative	O
study	O
was	O
carried	O
out	O
to	O
evaluate	O
protease	O
production	O
in	O
solid	O
-	O
state	O
fermentation	O
(	O
SSF	O
)	O
and	O
submerged	O
fermentation	O
(	O
SmF	O
)	O
by	O
nine	O
different	O
thermophilic	O
fungi	O
-	O
Thermoascus	O
aurantiacus	O
Miehe	O
,	O
Thermomyces	O
lanuginosus	O
,	O
T	O
.	O

lanuginosus	O
TO	O
.03	O
,	O
Aspergillus	O
flavus	O
1.2	O
,	O
Aspergillus	O
sp	O
.	O

13.33	O
,	O
Aspergillus	O
sp	O
.	O

13.34	O
,	O
Aspergillus	O
sp	O
.	O

13.35	O
,	O
Rhizomucor	O
pusillus	O
13.36	O
and	O
Rhizomucor	O
sp	O
.	O

13.37	O
-	O
using	O
substrates	O
containing	O
proteins	O
to	O
induce	O
enzyme	O
secretion	O
.	O

Soybean	O
extract	O
(	O
soybean	O
milk	O
)	O
,	O
soybean	O
flour	O
,	O
milk	O
powder	O
,	O
rice	O
,	O
and	O
wheat	O
bran	O
were	O
tested	O
.	O

The	O
most	O
satisfactory	O
results	O
were	O
obtained	O
when	O
using	O
wheat	O
bran	O
in	O
SSF	O
.	O

The	O
fungi	O
that	O
stood	O
out	O
in	O
SSF	O
were	O
T	O
.	O

lanuginosus	O
,	O
T	O
.	O

lanuginosus	O
TO	O
.03	O
,	O
Aspergillus	O
sp	O
.	O

13.34	O
,	O
Aspergillus	O
sp	O
.	O

13.35	O
,	O
and	O
Rhizomucor	O
sp	O
.	O

13.37	O
,	O
and	O
those	O
in	O
SmF	O
were	O
T	O
.	O

aurantiacus	O
,	O
T	O
.	O

lanuginosus	O
TO	O
.03	O
,	O
and	O
13.37	O
.	O

In	O
both	O
fermentation	O
systems	O
,	O
A	O
.	O

flavus	O
1.2	O
and	O
R	O
.	O

pusillus	O
13.36	O
presented	O
the	O
lowest	O
levels	O
of	O
proteolytic	O
activity	O
.	O

Involvement	O
of	O
the	O
incudostapedial	O
joint	O
anomaly	O
in	O
conductive	O
deafness	O
.	O

Conclusion	O
.	O

The	O
outcome	O
of	O
surgery	O
depends	O
on	O
complexities	O
of	O
middle	O
ear	O
anomalies	O
and	O
definite	O
diagnosis	O
can	O
only	O
be	O
achieved	O
during	O
exploratory	O
tympanotomy	O
.	O

We	O
must	O
be	O
aware	O
that	O
the	O
pathology	O
of	O
the	O
congenital	O
ossicular	O
anomalies	O
is	O
variable	O
and	O
careful	O
surgery	O
is	O
needed	O
for	O
hearing	O
improvement	O
.	O

Objective	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
congenital	O
ossicular	O
malformation	O
.	O

Subjects	O
and	O
methods	O
.	O

Fifteen	O
cases	O
of	O
ossicular	O
anomalies	O
without	O
external	O
ear	O
malformation	O
were	O
studied	O
.	O

The	O
anomaly	O
of	O
the	O
incus	O
-	O
stapes	O
complex	O
was	O
the	O
most	O
frequent	O
.	O

There	O
were	O
two	O
cases	O
of	O
fused	O
incudostapedial	O
(	O
IS	O
)	O
joint	O
,	O
which	O
is	O
an	O
extremely	O
rare	O
occurrence	O
.	O

Case	O
1	O
was	O
a	O
33	O
-	O
year	O
-	O
old	O
man	O
,	O
in	O
whom	O
otosclerosis	O
was	O
suspected	O
and	O
exploratory	O
tympanotomy	O
was	O
performed	O
.	O

The	O
IS	O
joint	O
was	O
fused	O
,	O
and	O
the	O
stapes	O
was	O
immobile	O
.	O

Small	O
fenestra	O
stapedectomy	O
was	O
performed	O
.	O

In	O
case	O
2	O
,	O
a	O
52	O
-	O
year	O
-	O
old	O
woman	O
,	O
otosclerosis	O
was	O
also	O
suspected	O
and	O
exploratory	O
tympanotomy	O
was	O
performed	O
.	O

The	O
IS	O
joint	O
was	O
fused	O
and	O
the	O
incus	O
was	O
fixed	O
.	O

After	O
the	O
long	O
process	O
of	O
the	O
incus	O
was	O
cut	O
,	O
the	O
stapes	O
became	O
mobile	O
.	O

However	O
,	O
since	O
the	O
incus	O
remained	O
immobile	O
,	O
it	O
was	O
removed	O
and	O
was	O
placed	O
on	O
the	O
stapes	O
.	O

In	O
both	O
cases	O
,	O
the	O
hearing	O
improved	O
after	O
surgery	O
.	O

The	O
averaged	O
hearing	O
gain	O
of	O
15	O
cases	O
was	O
28.8	O
dB	O
.	O

Tinnitus	O
and	O
brain	O
MRI	O
findings	O
in	O
Japanese	O
elderly	O
.	O

Conclusion	O
.	O

There	O
is	O
evidence	O
of	O
an	O
inverse	O
association	O
between	O
cerebral	O
infarction	O
and	O
tinnitus	O
in	O
this	O
study	O
.	O

The	O
effects	O
of	O
cerebral	O
infarction	O
on	O
tinnitus	O
could	O
be	O
explained	O
by	O
a	O
neurophysiological	O
model	O
of	O
tinnitus	O
.	O

Objectives	O
.	O

We	O
examined	O
the	O
relationship	O
between	O
tinnitus	O
and	O
brain	O
MRI	O
findings	O
including	O
cerebral	O
infarction	O
,	O
brain	O
atrophy	O
,	O
ventricular	O
dilatation	O
,	O
and	O
white	O
matter	O
lesions	O
.	O

Subjects	O
and	O
methods	O
.	O

This	O
was	O
a	O
cross	O
-	O
sectional	O
population	O
-	O
based	O
study	O
of	O
2193	O
subjects	O
aged	O
41	O
-	O
82	O
years	O
living	O
in	O
Aichi	O
prefecture	O
,	O
Japan	O
.	O

Detailed	O
questionnaires	O
,	O
pure	O
tone	O
audiometry	O
,	O
and	O
brain	O
MRI	O
were	O
performed	O
.	O

Results	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
in	O
a	O
multiple	O
logistic	O
analysis	O
,	O
cerebral	O
infarction	O
was	O
inversely	O
associated	O
with	O
tinnitus	O
(	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.649	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0.477	O
-	O
0.884	O
)	O
.	O

Cerebral	O
infarctions	O
of	O
the	O
basal	O
ganglia	O
(	O
OR	O
=	O
0.542	O
)	O
,	O
thalamus	O
(	O
OR	O
=	O
0.441	O
)	O
,	O
and	O
pons	O
(	O
OR	O
=	O
0.319	O
)	O
were	O
especially	O
associated	O
with	O
tinnitus	O
.	O

Brain	O
atrophy	O
,	O
ventricular	O
dilatation	O
,	O
and	O
white	O
matter	O
lesions	O
had	O
no	O
significant	O
effects	O
on	O
the	O
prevalence	O
of	O
tinnitus	O
.	O

Combination	O
of	O
Bernouilli	O
effect	O
producing	O
maneuver	O
-	O
induced	O
pharyngeal	O
narrowing	O
rate	O
with	O
body	O
mass	O
index	O
as	O
predictive	O
tool	O
for	O
obstructive	O
sleep	O
apnea	O
syndrome	O
.	O

Conclusions	O
.	O

It	O
is	O
suggested	O
that	O
the	O
combination	O
of	O
the	O
pharyngeal	O
narrowing	O
rate	O
during	O
the	O
Bernouilli	O
effect	O
producing	O
maneuver	O
(	O
BEPM	O
)	O
with	O
the	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
might	O
be	O
a	O
promising	O
predictive	O
method	O
for	O
obstructive	O
sleep	O
apnea	O
syndrome	O
(	O
OSAS	O
)	O
.	O

Objectives	O
.	O

An	O
attempt	O
was	O
made	O
to	O
clarify	O
the	O
possibility	O
that	O
the	O
dynamic	O
narrowing	O
of	O
the	O
pharynx	O
evaluated	O
by	O
nasopharyngoscopy	O
with	O
BEPM	O
,	O
a	O
forced	O
inspiration	O
through	O
the	O
nose	O
with	O
the	O
mouth	O
closed	O
,	O
might	O
be	O
a	O
reliable	O
clinical	O
daytime	O
predictor	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
developing	O
OSAS	O
.	O

Subjects	O
and	O
methods	O
.	O

Subjects	O
were	O
57	O
patients	O
complaining	O
of	O
snoring	O
and	O
sleepiness	O
during	O
daytime	O
.	O

Endoscopic	O
images	O
of	O
the	O
retropalatal	O
pharynx	O
were	O
obtained	O
and	O
their	O
area	O
was	O
measured	O
by	O
NIH	O
imaging	O
.	O

The	O
pharyngeal	O
narrowing	O
rate	O
during	O
quiet	O
nasal	O
breathing	O
and	O
that	O
during	O
BEPM	O
were	O
compared	O
to	O
assess	O
pharyngeal	O
dynamics	O
.	O

To	O
increase	O
the	O
sensitivity	O
of	O
this	O
method	O
,	O
BMI	O
was	O
added	O
to	O
the	O
pharyngeal	O
narrowing	O
rate	O
during	O
BEPM	O
.	O

Results	O
.	O

The	O
criterion	O
of	O
BEPM	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
with	O
BMI	O
at	O
a	O
cut	O
-	O
off	O
value	O
of	O
25	O
kg	O
/	O
m	O
(	O
2	O
)	O
achieved	O
a	O
sensitivity	O
of	O
93	O
%	O
,	O
while	O
the	O
specificity	O
was	O
67	O
%	O
in	O
differentiating	O
simple	O
snorers	O
from	O
OSAS	O
patients	O
(	O
apnea	O
index	O
>	O
5	O
)	O
.	O

In	O
addition	O
,	O
the	O
likelihood	O
ratio	O
of	O
the	O
method	O
was	O
found	O
to	O
be	O
2.81	O
.	O

EEG	O
observations	O
in	O
a	O
case	O
with	O
thalamic	O
syndrome	O
.	O

A	O
case	O
of	O
thalamic	O
syndrome	O
of	O
the	O
D	O
	O
	O
jerine	O
-	O
Roussy	O
type	O
is	O
presented	O
.	O

EEG	O
studies	O
reveal	O
that	O
although	O
bilaterally	O
symmetrical	O
rhythmic	O
activity	O
may	O
be	O
present	O
when	O
the	O
patient	O
is	O
awake	O
,	O
during	O
drowsiness	O
and	O
deeper	O
sleep	O
a	O
marked	O
asymmetry	O
often	O
appears	O
with	O
early	O
disappearance	O
of	O
alpha	O
activity	O
and	O
reduction	O
or	O
abolition	O
of	O
spindles	O
on	O
the	O
side	O
involved	O
.	O

Thalamic	O
integration	O
in	O
the	O
sleep	O
mechanism	O
is	O
briefly	O
discussed	O
.	O

Two	O
2,3	B
-	I
dihydrobenzofuran	I
analogues	B
of	O
hallucinogenic	O
amphetamines	B
were	O
prepared	O
and	O
evaluated	O
for	O
activity	O
in	O
the	O
two	O
-	O
lever	O
drug	O
-	O
discrimination	O
paradigm	O
in	O
rats	O
trained	O
to	O
discriminate	O
saline	O
from	O
LSD	B
tartrate	I
(	O
0.08	O
mg	O
/	O
kg	O
)	O
and	O
for	O
the	O
ability	O
to	O
displace	O
[	B
125I	I
]	I
-	I
(	I
R	I
)	I
-	I
DOI	I
[	O
(	B
125I	I
]	I
-	I
(	I
R	I
)	I
-	I
1	I
-	I
(	I
2,5	I
-	I
dimethoxy	I
-	I
4	I
-	I
iodophenyl	I
)	I
-	I
2	I
-	I
aminopropane	I
)	I
from	O
rat	O
cortical	O
homogenate	O
5	O
-	O
HT2	O
receptors	O
.	O

The	O
compounds	O
,	O
1	B
-	I
(	I
5	I
-	I
methoxy	I
-	I
2,3	I
-	I
dihydrobenzofuran	I
-	I
4	I
-	I
yl	I
)	I
-	I
2	I
-	I
aminopropane	I
(	O
6a	O
)	O
and	O
its	O
7	B
-	I
brominated	I
analogue	B
6b	O
,	O
possessed	O
activity	O
comparable	O
to	O
their	O
conformationally	O
flexible	O
counterparts	O
1	B
-	I
(	I
2,5	I
-	I
dimethoxyphenyl	I
)	I
-	I
2	I
-	I
aminopropane	I
(	O
3	O
)	O
and	O
its	O
4	B
-	I
bromo	I
derivative	B
DOB	B
(	O
5	O
)	O
,	O
respectively	O
.	O

The	O
results	O
suggest	O
that	O
the	O
dihydrofuran	B
ring	O
in	O
6a	O
and	O
6b	O
models	O
the	O
active	O
conformation	O
of	O
the	O
5	B
-	I
methoxy	I
groups	B
in	O
3	O
and	O
5	O
.	O

Free	O
energy	O
of	O
binding	O
,	O
derived	O
from	O
radioligand	O
displacement	O
KA	O
values	O
,	O
indicated	O
that	O
addition	O
of	O
the	O
bromine	B
in	O
either	O
series	O
contributes	O
2.4	O
-	O
3.2	O
kcal	O
/	O
mol	O
of	O
binding	O
energy	O
.	O

On	O
the	O
basis	O
of	O
surface	O
area	O
of	O
the	O
bromine	B
atom	B
,	O
this	O
value	O
is	O
2	O
-	O
3	O
times	O
higher	O
than	O
would	O
be	O
expected	O
on	O
the	O
basis	O
of	O
hydrophobic	O
binding	O
.	O

Thus	O
,	O
hydrophobicity	O
of	O
the	O
para	O
substituent	O
alone	O
can	O
not	O
account	O
for	O
the	O
dramatic	O
enhancement	O
of	O
hallucinogenic	O
activity	O
.	O

Although	O
this	O
substituent	O
may	O
play	O
a	O
minor	O
role	O
in	O
orienting	O
the	O
conformation	O
of	O
the	O
5	B
-	I
methoxy	I
group	B
in	O
derivatives	O
such	O
as	O
4	O
and	O
5	O
,	O
there	O
appears	O
to	O
be	O
some	O
other	O
,	O
as	O
yet	O
unknown	O
,	O
critical	O
receptor	O
interaction	O
.	O

A	O
series	O
of	O
substituted	O
1,4	B
-	I
dihydronaphthoquinones	I
,	O
hydroindoloquinones	B
,	O
benzofuran	B
-	I
4,7	I
-	I
dihydroquinones	I
,	O
and	O
benzothiophene	B
-	I
4,7	I
-	I
dihydroquinones	I
were	O
synthesized	O
and	O
evaluated	O
for	O
inhibitory	O
activity	O
against	O
5	O
-	O
lipoxygenase	O
.	O

These	O
compounds	O
were	O
found	O
to	O
be	O
active	O
in	O
vitro	O
for	O
LTC4	O
/	O
D4	O
inhibition	O
with	O
the	O
potencies	O
(	O
IC50	O
's	O
)	O
ranging	O
from	O
0.2	O
to	O
85	O
microM	O
.	O

Active	O
1,4	B
-	I
dihydronaphthoquinone	I
acetates	I
(	O
IC50	O
less	O
than	O
microM	O
)	O
were	O
evaluated	O
in	O
an	O
ex	O
vivo	O
LTB4	O
inhibition	O
assay	O
.	O

The	O
acetates	B
of	O
1,4	B
-	I
dihydronaphthoquinones	I
containing	O
the	O
alkyl	B
substituent	B
(	I
s	I
)	I
(	O
2	B
-	I
n	I
-	I
butyl	I
,	O
11	O
,	O
and	O
2,3	B
-	I
diethyl	I
,	O
15	O
)	O
exhibited	O
the	O
best	O
activity	O
in	O
LTC4	O
/	O
D4	O
inhibition	O
(	O
IC50	O
=	O
0.2	O
-	O
0.4	O
microM	O
,	O
in	O
vitro	O
)	O
as	O
well	O
as	O
in	O
LTB4	O
inhibition	O
(	O
inhibition	O
)	O
.	O

Thyrotropin	O
modulates	O
low	O
density	O
lipoprotein	O
binding	O
activity	O
in	O
FRTL	O
-	O
5	O
thyroid	O
cells	O
.	O

FRTL	O
-	O
5	O
cells	O
possess	O
high	O
affinity	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
receptors	O
which	O
bind	O
,	O
internalize	O
,	O
and	O
degrade	O
LDL	O
.	O

When	O
FRTL	O
-	O
5	O
cells	O
are	O
deprived	O
of	O
thyrotropin	O
(	O
TSH	O
)	O
the	O
binding	O
of	O
LDL	O
increases	O
more	O
than	O
2	O
-	O
fold	O
.	O

Upon	O
addition	O
of	O
TSH	O
,	O
at	O
a	O
concentration	O
of	O
1	O
x	O
(	O
-	O
)	O
M	O
or	O
greater	O
,	O
LDL	O
binding	O
decreases	O
rapidly	O
and	O
within	O
24	O
h	O
reaches	O
the	O
level	O
which	O
is	O
typical	O
of	O
FRTL	O
-	O
5	O
cells	O
chronically	O
stimulated	O
by	O
TSH	O
.	O

The	O
data	O
available	O
suggest	O
that	O
TSH	O
-	O
dependent	O
down	O
-	O
regulation	O
of	O
LDL	O
receptor	O
activity	O
is	O
exerted	O
through	O
a	O
reduction	O
of	O
the	O
number	O
of	O
active	O
LDL	O
receptors	O
,	O
with	O
no	O
change	O
in	O
affinity	O
.	O

It	O
is	O
unlikely	O
that	O
the	O
synthesis	O
of	O
LDL	O
receptors	O
is	O
impaired	O
,	O
since	O
LDL	O
receptor	O
messenger	O
RNA	O
is	O
not	O
decreased	O
by	O
TSH	O
.	O

The	O
effect	O
of	O
the	O
hormone	O
on	O
LDL	O
receptor	O
activity	O
can	O
be	O
mimicked	O
by	O
8	B
-	I
Br	I
-	I
cAMP	I
and	O
is	O
completely	O
abolished	O
by	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	B
but	O
not	O
by	O
actinomycin	B
D	I
.	O

TSH	O
regulation	O
of	O
LDL	O
receptor	O
activity	O
is	O
lost	O
in	O
v	O
-	O
ras	O
Ki	O
-	O
transformed	O
FRTL	O
-	O
5	O
cells	O
(	O
Ki	O
Mol	O
)	O
which	O
also	O
have	O
lost	O
TSH	O
dependence	O
for	O
adenylate	O
cyclase	O
activation	O
and	O
growth	O
.	O

However	O
,	O
8	B
-	I
Br	I
-	I
cAMP	I
decreases	O
LDL	O
binding	O
in	O
Ki	O
Mol	O
FRTL	O
-	O
5	O
cells	O
.	O

The	O
reduced	O
availability	O
of	O
LDL	O
receptor	O
in	O
TSH	O
-	O
stimulated	O
FRTL	O
-	O
5	O
cells	O
may	O
be	O
related	O
to	O
the	O
increased	O
membrane	O
fluidity	O
(	O
Beguinot	O
,	O
F	O
.	O
,	O
Beguinot	O
,	O
L	O
.	O
,	O
Tramontano	O
,	O
D	O
.	O
,	O
Duilio	O
,	O
C	O
.	O
,	O
Formisano	O
,	O
S	O
.	O
,	O
Bifulco	O
,	O
M	O
.	O
,	O
Ambesi	O
-	O
Impiombato	O
,	O
F	O
.	O

S	O
.	O
,	O
and	O
Aloj	O
,	O
S	O
.	O

M	O
.	O
(	O
1987	O
)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O
262	O
,	O
1575	O
-	O
1582	O
)	O
or	O
may	O
reflect	O
increased	O
degradation	O
of	O
LDL	O
receptors	O
.	O

We	O
propose	O
that	O
a	O
lower	O
cholesterol	O
uptake	O
is	O
needed	O
in	O
an	O
actively	O
proliferating	O
cell	O
population	O
,	O
to	O
increase	O
the	O
production	O
of	O
isoprenoids	B
whether	O
it	O
be	O
for	O
cholesterol	B
biosynthesis	O
or	O
for	O
the	O
synthesis	O
of	O
other	O
compounds	O
requiring	O
isoprenoid	O
precursors	O
.	O

A	O
series	O
of	O
new	O
5	B
-	I
(	I
1	I
-	I
hydroxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
-	I
2	I
'	I
-	I
deoxyuridine	I
and	O
uridine	B
compounds	B
(	O
11	O
,	O
16	O
)	O
was	O
synthesized	O
by	O
the	O
regiospecific	O
addition	O
of	O
HOI	B
to	O
the	O
vinyl	B
substituent	B
of	O
5	B
-	I
vinyl	I
-	I
2	I
'	I
-	I
deoxyuridine	I
(	O
)	O
,	O
5	B
-	I
vinyl	I
-	I
2	I
'	I
-	I
fluoro	I
-	I
2	I
'	I
-	I
deoxyuridine	I
(	O
)	O
,	O
5	B
-	I
vinyluridine	I
(	O
)	O
,	O
and	O
(	B
E	I
)	I
-	I
5	I
-	I
(	I
2	I
-	I
iodovinyl	I
)	I
-	I
2	I
'	I
-	I
deoxyuridine	I
(	O
4b	O
)	O
.	O

Treatment	O
of	O
the	O
iodohydrins	B
11a	O
-	O
c	O
with	O
methanolic	B
sulfuric	I
acid	I
afforded	O
the	O
corresponding	O
5	B
-	I
(	I
1	I
-	I
methoxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
derivatives	B
(	O
12a	O
-	O
c	O
)	O
.	O

In	O
contrast	O
,	O
reaction	O
of	O
5	B
-	I
(	I
1	I
-	I
hydroxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
-	I
2	I
'	I
-	I
deoxyuridine	I
(	O
11a	O
)	O
with	O
sodium	B
carbonate	I
in	O
methanol	B
afforded	O
a	O
mixture	O
of	O
5	B
-	I
(	I
1	I
-	I
hydroxy	I
-	I
2	I
-	I
methoxyethyl	I
)	I
-	I
2	I
'	I
-	I
deoxyuridine	I
(	O
13	O
)	O
and	O
2,3	B
-	I
dihydro	I
-	I
3	I
-	I
hydroxy	I
-	I
5	I
-	I
(	I
2	I
'	I
-	I
deoxy	I
-	I
beta	I
-	I
D	I
-	I
ribofuranosyl	I
)	I
-	I
furano	I
[	I
2,3	I
-	I
d	I
]	I
pyrimidin	I
-	I
6	I
(	I
5H	I
)	I
-	I
one	I
(	O
14	O
)	O
.	O

The	O
most	O
active	O
compound	O
,	O
5	B
-	I
(	I
1	I
-	I
methoxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
-	I
2	I
'	I
-	I
deoxyuridine	I
(	O
12a	O
,	O
ID50	O
=	O
0.1	O
micrograms	O
/	O
mL	O
)	O
,	O
which	O
exhibited	O
antiviral	O
activity	O
(	O
HSV	O
-	O
1	O
)	O
-	O
fold	O
higher	O
than	O
that	O
of	O
the	O
5	B
-	I
(	I
1	I
-	I
hydroxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
analogue	B
(	O
11a	O
)	O
,	O
was	O
less	O
active	O
than	O
IVDU	B
or	O
acyclovir	B
(	O
ID50	O
=	O
0.01	O
-	O
0.1	O
micrograms	O
/	O
mL	O
range	O
)	O
.	O

The	O
C	B
-	I
5	I
substituent	B
in	O
the	O
2	B
'	I
-	I
deoxyuridine	I
series	B
was	O
a	O
determinant	O
of	O
cytotoxic	O
activity	O
,	O
as	O
determined	O
in	O
the	O
in	O
vitro	O
L1210	O
screen	O
,	O
where	O
the	O
relative	O
activity	O
order	O
was	O
CH	B
(	I
OH	I
)	I
CHI2	I
(	O
16	O
)	O
greater	O
than	O
CH	B
(	I
OMe	I
)	I
CH2I	I
(	O
12a	O
)	O
greater	O
than	O
CH	B
(	I
OH	I
)	I
CH2I	I
(	O
11a	O
)	O
congruent	O
to	O
CH	B
(	I
OH	I
)	I
CH2OMe	I
(	O
13	O
)	O
.	O

The	O
2	B
'	I
-	I
substituent	O
was	O
also	O
a	O
determinant	O
of	O
cytotoxic	O
activity	O
in	O
the	O
5	B
-	I
(	I
1	I
-	I
hydroxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
(	O
11a	O
-	O
c	O
)	O
and	O
5	B
-	I
(	I
1	I
-	I
methoxy	I
-	I
2	I
-	I
iodoethyl	I
)	I
series	B
of	O
compounds	O
,	O
where	O
the	O
relative	O
activity	O
profile	O
was	O
2	B
'	I
-	I
deoxyuridine	I
greater	O
than	O
2	B
'	I
-	I
fluoro	I
-	I
2	I
'	I
-	I
deoxyuridine	I
greater	O
than	O
uridine	B
(	O
11a	O
greater	O
than	O
11b	O
greater	O
than	O
or	O
equal	O
to	O
11c	O
;	O
12a	O
greater	O
than	O
12b	O
greater	O
than	O
12c	O
)	O
.	O

The	O
most	O
active	O
cytotoxic	O
agent	O
(	O
16	O
)	O
,	O
possessing	O
a	O
5	B
-	I
(	I
1	I
-	I
hydroxy	I
-	I
2,2	I
-	I
diiodoethyl	I
)	I
substituent	B
(	O
ED50	O
=	O
0.77	O
micrograms	O
/	O
mL	O
)	O
,	O
exhibited	O
an	O
activity	O
approaching	O
that	O
of	O
melphalan	B
(	O
ED50	O
=	O
0.15	O
micrograms	O
/	O
mL	O
)	O
.	O

All	O
compounds	O
tested	O
,	O
except	O
for	O
13	O
and	O
14	O
,	O
exhibited	O
high	O
affinity	O
(	O
Ki	O
=	O
0.035	O
-	O
0.22	O
mM	O
range	O
relative	O
to	O
deoxyuridine	B
,	O
Ki	O
=	O
0.125	O
)	O
for	O
the	O
murine	O
NBMPR	O
-	O
sensitive	O
erythrocyte	O
nucleoside	O
transport	O
system	O
,	O
suggesting	O
that	O
these	O
iodohydrins	B
are	O
good	O
permeants	O
of	O
cell	O
membranes	O
.	O

The	O
thermal	O
Fischer	O
indolization	O
of	O
hydrazones	B
resulting	O
from	O
4	B
-	I
hydrazino	I
-	I
5	I
-	I
methyl	I
-	I
1H	I
-	I
pyridin	I
-	I
2	I
-	I
one	I
and	O
various	O
beta	B
-	I
and	O
alpha	B
-	I
tetralones	I
led	O
to	O
4	B
-	I
methyl	I
-	I
6,7	I
-	I
dihydro	I
-	I
2H	I
,	I
5H	I
-	I
pyrido	I
[	I
4,3	I
-	I
b	I
]	I
benzo	I
[	I
e	I
]	I
indol	I
-	I
1	I
-	I
ones	I
and	O
4	B
-	I
methyl	I
-	I
11	I
-	I
dihydro	I
-	I
2H	I
,	I
5H	I
-	I
pyrido	I
[	I
4,3	I
-	I
b	I
]	I
benzo	I
[	I
g	I
]	I
indol	I
-	I
1	I
-	I
ones	I
,	O
respectively	O
.	O

After	O
aromatization	O
,	O
these	O
compounds	O
were	O
transformed	O
by	O
phosphorus	B
oxychloride	I
,	O
giving	O
1	B
-	I
chloro	I
-	I
4	I
-	I
methyl	I
-	I
5H	I
-	I
pyrido	I
[	I
4,3	I
-	I
b	I
]	I
benzo	I
[	I
e	I
]	I
-	I
and	O
-	B
benzo	I
[	I
g	I
]	I
indoles	I
which	O
were	O
substituted	O
by	O
[	B
(	I
dialkylamino	I
)	I
alkyl	I
]	I
amines	I
.	O

The	O
resulting	O
1	B
-	I
[	I
[	I
(	I
dialkylamino	I
)	I
alkyl	I
]	I
amino	I
]	I
-	I
4	I
-	I
methyl	I
-	I
5H	I
-	I
pyrido	I
-	I
[	I
4,3	I
-	I
b	I
]	I
benzo	I
[	I
e	I
]	I
-	I
and	O
-	B
benzo	I
[	I
g	I
]	I
indoles	I
,	O
as	O
well	O
as	O
hydroxy	B
derivatives	B
obtained	O
by	O
demethylation	O
of	O
methoxylated	O
compounds	O
with	O
hydrobromic	B
acid	I
,	O
were	O
tested	O
for	O
antitumor	O
activity	O
in	O
vitro	O
(	O
leukemic	O
and	O
solid	O
tumor	O
cells	O
)	O
and	O
in	O
vivo	O
on	O
various	O
experimental	O
tumor	O
models	O
using	O
the	O
standard	O
NCI	O
protocols	O
.	O

1	B
-	I
[	I
[	I
3	I
-	I
(	I
Dialkylamino	I
)	I
propyl	I
]	I
-	I
amino	I
]	I
-	I
4	I
-	I
methyl	I
-	I
9	I
-	I
hydroxy	I
-	I
5H	I
-	I
pyrido	I
[	I
4,3	I
-	I
b	I
]	I
benzo	I
[	I
e	I
]	I
indoles	I
appeared	O
as	O
a	O
promising	O
new	O
class	O
of	O
antineoplastic	O
agents	O
.	O

2944474	O
Effect	O
of	O
recombinant	O
human	O
fibroblast	O
interferon	O
and	O
mezerein	B
on	O
growth	O
,	O
differentiation	O
,	O
immune	O
interferon	O
binding	O
and	O
tumor	O
associated	O
antigen	O
expression	O
in	O
human	O
melanoma	O
cells	O
.	O

The	O
combination	O
of	O
recombinant	O
human	O
fibroblast	O
interferon	O
(	O
INF	O
-	O
delta	O
)	O
and	O
the	O
antileukemic	O
compound	O
mezerein	B
(	O
MEZ	B
)	O
results	O
in	O
a	O
synergistic	O
suppression	O
in	O
the	O
growth	O
of	O
human	O
melanoma	O
cells	O
and	O
a	O
concomitant	O
increase	O
in	O
melanin	B
synthesis	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
further	O
analyzed	O
this	O
synergistic	O
interaction	O
and	O
have	O
also	O
evaluated	O
the	O
effect	O
of	O
IFN	O
-	O
delta	O
and	O
MEZ	B
,	O
alone	O
and	O
in	O
combination	O
,	O
on	O
recombinant	O
human	O
gamma	O
interferon	O
(	O
IFN	O
-	O
gamma	O
)	O
binding	O
and	O
Class	O
I	O
HLA	O
and	O
melanoma	O
associated	O
antigen	O
(	O
MAA	O
)	O
expression	O
in	O
the	O
HO	O
-	O
1	O
human	O
melanoma	O
cell	O
line	O
.	O

Single	O
cell	O
clones	O
isolated	O
from	O
the	O
HO	O
-	O
1	O
cell	O
line	O
varied	O
in	O
their	O
sensitivity	O
to	O
the	O
antiproliferative	O
effects	O
of	O
IFN	O
-	O
delta	O
and	O
MEZ	B
.	O

With	O
all	O
twelve	O
clones	O
,	O
however	O
,	O
the	O
combination	O
of	O
IFN	O
-	O
delta	O
plus	O
MEZ	B
was	O
more	O
growth	O
inhibitory	O
than	O
either	O
agent	O
used	O
alone	O
,	O
even	O
in	O
HO	O
-	O
1	O
subclones	O
displaying	O
relative	O
resistance	O
to	O
IFN	O
-	O
delta	O
.	O

By	O
continuous	O
growth	O
in	O
gradually	O
increasing	O
concentrations	O
of	O
IFN	O
-	O
delta	O
,	O
a	O
variant	O
population	O
of	O
HO	O
-	O
1	O
cells	O
,	O
HO	O
-	O
1	O
delta	O
R	O
-	O
D	O
,	O
was	O
generated	O
which	O
was	O
more	O
resistant	O
to	O
the	O
antigrowth	O
effects	O
of	O
IFN	O
-	O
delta	O
than	O
the	O
original	O
HO	O
-	O
1	O
parental	O
cell	O
line	O
.	O

In	O
the	O
IFN	O
delta	O
R	O
-	O
D	O
cell	O
line	O
the	O
combination	O
of	O
IFN	O
-	O
delta	O
plus	O
MEZ	B
synergistically	O
suppressed	O
growth	O
.	O

Exposure	O
of	O
HO	O
-	O
1	O
cells	O
to	O
units	O
/	O
ml	O
IFN	O
-	O
delta	O
or	O
ng	O
/	O
ml	O
MEZ	B
for	O
96	O
hr	O
resulted	O
in	O
no	O
change	O
or	O
an	O
increase	O
in	O
the	O
binding	O
of	O
labelled	O
IFN	O
-	O
gamma	O
to	O
surface	O
receptors	O
,	O
whereas	O
the	O
combination	O
of	O
IFN	O
-	O
delta	O
plus	O
MEZ	B
increased	O
IFN	O
-	O
gamma	O
binding	O
2	O
-	O
to	O
-	O
4	O
-	O
fold	O
in	O
HO	O
-	O
1	O
cells	O
.	O

This	O
increase	O
was	O
the	O
result	O
of	O
an	O
increase	O
in	O
the	O
number	O
of	O
receptors	O
on	O
treated	O
cells	O
coupled	O
with	O
a	O
protection	O
against	O
a	O
decrease	O
in	O
receptors	O
observed	O
for	O
confluent	O
untreated	O
cells	O
.	O

Changes	O
in	O
IFN	O
-	O
gamma	O
binding	O
resulting	O
from	O
treatment	O
with	O
IFN	O
-	O
delta	O
plus	O
MEZ	B
were	O
not	O
associated	O
with	O
alterations	O
in	O
the	O
binding	O
affinity	O
of	O
INF	O
-	O
gamma	O
to	O
its	O
receptor	O
.	O

Changes	O
were	O
also	O
observed	O
in	O
the	O
expression	O
of	O
HLA	O
Class	O
I	O
antigens	O
and	O
MAAs	O
following	O
treatment	O
of	O
HO	O
-	O
1	O
cells	O
with	O
IFN	O
-	O
delta	O
,	O
MEZ	B
or	O
IFN	O
-	O
delta	O
plus	O
MEZ	B
.	O

IFN	O
-	O
delta	O
and	O
MEZ	B
increased	O
the	O
expression	O
of	O
HLA	O
Class	O
I	O
antigens	O
a	O
96	O
kd	O
MAA	O
defined	O
by	O
MoAb	O
CL203	O
,	O
a	O
kd	O
MAA	O
defined	O
by	O
MoAb	O
376.96	O
and	O
a	O
115	O
kd	O
MAA	O
defined	O
by	O
MoAb	O
345.134	O
but	O
decreased	O
the	O
expression	O
of	O
a	O
high	O
molecular	O
weight	O
-	O
melanoma	O
associated	O
antigen	O
(	O
HMW	O
-	O
MAA	O
)	O
defined	O
by	O
MoAb	O
325.28	O
S	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
WORDS	O
)	O

Conversion	O
of	O
the	O
8	B
-	I
phenolic	I
1,2,3,4,5,6	I
-	I
hexahydro	I
-	I
2,6	I
-	I
methano	I
-	I
3	I
-	I
benzazocines	I
to	O
the	O
corresponding	O
8	B
-	I
thiophenolic	I
analogues	B
was	O
achieved	O
by	O
three	O
different	O
routes	O
.	O

Diazotization	O
of	O
8	B
-	I
amino	I
-	I
2,6	I
-	I
methano	I
-	I
3	I
-	I
benzazocine	I
(	O
2	O
)	O
followed	O
by	O
the	O
reaction	O
with	O
CH3SNa	B
afforded	O
8	B
-	I
(	I
methylthio	I
)	I
-	I
1,2,3,4,5,6	I
-	I
hexahydro	I
-	I
2,6	I
-	I
methano	I
-	I
3	I
-	I
benzazocine	I
(	O
3	O
)	O
.	O

Another	O
route	O
using	O
Grewe	O
cyclization	O
was	O
also	O
examined	O
for	O
the	O
synthesis	O
of	O
3	O
.	O

As	O
the	O
most	O
effective	O
route	O
,	O
Newman	O
-	O
Kwart	O
rearrangement	O
of	O
benzazocines	O
was	O
selected	O
and	O
closely	O
investigated	O
.	O

8	B
-	I
(	I
N	I
,	I
N	I
-	I
Dimethylthiocarbamoyl	I
)	I
oxy	I
derivatives	B
(	O
6a	O
-	O
e	O
)	O
rearranged	O
to	O
8	B
-	I
(	I
N	I
,	I
N	I
-	I
dimethylcarbamoyl	I
)	I
thio	I
derivatives	B
(	O
7a	O
-	O
e	O
)	O
in	O
good	O
yields	O
.	O

Reductive	O
cleavage	O
of	O
7a	O
-	O
e	O
and	O
subsequent	O
methylation	O
or	O
acylations	O
gave	O
the	O
title	O
compounds	O
(	O
3	O
,	O
8	O
-	O
24	O
)	O
.	O

Although	O
analgesic	O
activities	O
of	O
sulfur	O
-	O
containing	O
benzazocines	B
decreased	O
compared	O
to	O
the	O
corresponding	O
hydroxy	B
compounds	B
,	O
the	O
N	B
-	I
methyl	I
derivative	B
(	O
S	B
-	I
metazocine	I
,	O
8	O
)	O
showed	O
potent	O
analgesic	O
activity	O
.	O

A	O
series	O
of	O
analogues	O
of	O
the	O
analgesic	O
dipeptide	O
derivative	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
has	O
been	O
designed	O
to	O
determine	O
the	O
influence	O
of	O
the	O
(	B
2	I
-	I
nitrophenyl	I
)	I
sulfenyl	I
(	O
NPS	B
)	O
moiety	B
on	O
the	O
activity	O
.	O

The	O
syntheses	O
and	O
antinociceptive	O
effects	O
of	O
these	O
analogues	O
of	O
general	O
formula	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
R	O
)	O
-	O
OMe	O
[	O
R	O
=	O
phenylsulfenyl	B
(	O
PS	B
)	O
(	O
9	O
)	O
;	O
R	O
=	O
(	O
2	B
-	I
carbomethyoxyphenyl	I
)	I
sulfenyl	I
(	O
CmPS	B
)	O
(	O
)	O
;	O
R	O
=	O
(	O
4	B
-	I
nitrophenyl	I
)	I
sulfenyl	I
(	O
pNPS	B
)	O
(	O
11	O
)	O
;	O
R	O
=	O
(	O
2,4	B
-	I
dinitrophenyl	I
)	I
sulfenyl	I
(	O
DNPS	B
)	O
(	O
12	O
)	O
;	O
R	O
=	O
[	B
2	I
-	I
(	I
acetylamino	I
)	I
-	I
2	I
-	I
carbomethoxyethyl	I
]	I
sulfenyl	I
(	O
AacCmES	B
)	O
(	O
13	O
)	O
;	O
R	O
=	O
[	B
2	I
-	I
(	I
acetylamino	I
)	I
phenyl	I
]	I
sulfenyl	I
(	O
AacPS	B
)	O
(	O
17	O
)	O
;	O
R	O
=	O
tert	B
-	I
butylsulfenyl	I
(	O
t	B
-	I
BuS	I
)	O
(	O
23	O
)	O
;	O
R	O
=	O
(	B
2	I
-	I
carbomethoxyethyl	I
)	I
sulfenyl	I
(	O
CmES	B
)	O
(	O
24	O
)	O
]	O
are	O
described	O
.	O

Reaction	O
of	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
-	O
OMe	O
(	O
3	O
)	O
with	O
PS	B
-	O
,	O
CmPS	B
-	O
,	O
pNPS	B
-	O
,	O
DNPS	B
-	O
,	O
and	O
AacCmES	B
-	I
Cl	I
afforded	O
the	O
corresponding	O
2	B
-	I
(	I
sulfenyl	I
)	I
tryptophan	I
derivatives	B
,	O
which	O
on	O
treatment	O
with	O
boron	B
-	I
tris	I
(	I
trifluoroacetate	I
)	I
/	O
trifluoroacetic	B
acid	I
or	O
trimethylsilyl	B
iodide	I
in	O
acetonitrile	B
(	O
Me3SiI	B
/	O
CH3CN	B
)	O
provided	O
9	O
-	O
13	O
,	O
respectively	O
.	O

Sulfenylation	O
of	O
3	O
with	O
NPS	B
-	I
Cl	I
gave	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
,	O
which	O
,	O
on	O
catalytic	O
hydrogenation	O
of	O
the	O
nitro	O
group	O
using	O
Pd	O
/	O
C	O
followed	O
by	O
acetylation	O
of	O
the	O
resulting	O
amino	O
function	O
and	O
removal	O
of	O
the	O
protecting	O
Z	O
groups	O
,	O
gave	O
17	O
.	O

Condensation	O
of	O
2	B
-	I
(	I
tert	I
-	I
butylsulfenyl	I
)	I
-	I
and	O
2	B
-	I
[	I
(	I
2	I
-	I
carbomethoxyethyl	I
)	I
sulfenyl	I
]	I
tryptophan	I
methyl	I
ester	I
,	O
obtained	O
by	O
reaction	O
of	O
methyl	B
3a	I
-	I
hydroxy	I
-	I
1,2,3,3	I
a	I
,	I
8,8	I
a	I
-	I
hexahydropyrrolo	I
[	I
2,3	I
-	I
b	I
]	I
indole	I
-	I
2	I
-	I
carboxyla	I
te	I
with	O
the	O
corresponding	O
thiol	O
,	O
with	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
OSu	O
afforded	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
t	O
-	O
BuS	O
)	O
-	O
OMe	O
and	O
Z	O
-	O
Lys	O
(	O
Z	O
)	O
-	O
Trp	O
(	O
CmES	O
)	O
-	O
OMe	O
,	O
which	O
on	O
treatment	O
with	O
Me3SiI	B
/	O
CH3CN	B
provided	O
23	O
and	O
24	O
,	O
respectively	O
.	O

Intracerebroventricular	O
administration	O
of	O
elicited	O
a	O
naloxone	B
-	O
reversible	O
antinociceptive	O
effect	O
in	O
mice	O
similar	O
to	O
that	O
of	O
H	O
-	O
Lys	O
-	O
Trp	O
(	O
NPS	O
)	O
-	O
OMe	O
.	O

No	O
analgesia	O
was	O
however	O
found	O
with	O
the	O
phenylsulfenyl	B
or	O
acyclic	B
sulfenyl	I
substituted	I
dipeptides	I
9	O
,	O
11	O
,	O
and	O
17	O
or	O
13	O
,	O
23	O
,	O
and	O
24	O
.	O

The	O
Trp	B
(	I
DNPS	I
)	I
-	O
containing	O
analogue	O
was	O
neurotoxic	O
.	O

Structure	O
-	O
activity	O
studies	O
indicate	O
that	O
the	O
role	O
of	O
the	O
NPS	B
and	O
CmPS	B
moieties	B
could	O
be	O
related	O
to	O
the	O
adoption	O
of	O
a	O
preferential	O
active	O
conformation	O
.	O

A	O
series	O
of	O
22	B
-	I
hydroxycholesterol	I
derivatives	B
with	O
a	O
modified	O
side	O
chain	O
terminus	O
was	O
prepared	O
.	O

These	O
agents	O
were	O
evaluated	O
in	O
vitro	O
and	O
in	O
vivo	O
for	O
their	O
ability	O
to	O
suppress	O
HMG	O
CoA	O
reductase	O
,	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
cholesterol	B
biosynthesis	O
.	O

In	O
tissue	O
culture	O
assays	O
,	O
22	B
-	I
hydroxycholesterol	I
as	O
well	O
as	O
the	O
side	O
chain	O
modified	O
analogues	O
were	O
potent	O
inhibitors	O
of	O
HMG	O
CoA	O
reductase	O
.	O

However	O
,	O
only	O
those	O
sterols	O
with	O
a	O
modified	O
side	O
chain	O
terminus	O
were	O
effective	O
suppressors	O
of	O
liver	O
reductase	O
when	O
administered	O
ig	O
to	O
rats	O
.	O

22	B
-	I
Hydroxy	I
-	I
25	I
-	I
methylcholesterol	I
(	O
4a	O
)	O
and	O
25	B
-	I
fluoro	I
-	I
22	I
-	I
hydroxycholesterol	I
(	O
15a	O
)	O
significantly	O
lowered	O
serum	O
cholesterol	O
levels	O
when	O
administered	O
ig	O
to	O
primates	O
;	O
25	B
-	I
chloro	I
-	I
22	I
-	I
hydroxycholesterol	I
(	O
15b	O
)	O
and	O
the	O
analogue	O
with	O
a	O
cyclopropyl	B
terminus	O
,	O
,	O
were	O
ineffective	O
.	O

The	O
cholesterol	B
-	O
lowering	O
sterols	B
did	O
not	O
significantly	O
alter	O
lipoprotein	O
levels	O
;	O
however	O
,	O
the	O
two	O
compounds	O
have	O
been	O
shown	O
to	O
inhibit	O
acyl	O
-	O
coenzyme	O
A	O
:	O
cholesterol	O
acyl	O
-	O
transferase	O
(	O
ACAT	O
)	O
in	O
tissue	O
culture	O
studies	O
.	O

Metabolism	O
of	O
D	B
-	I
and	O
L	B
-	I
glyceraldehyde	I
in	O
adipose	O
tissue	O
:	O
a	O
stereochemical	O
probe	O
for	O
glycerokinase	O
activity	O
.	O

Distributions	O
of	O
(	B
14	I
)	I
C	I
have	O
been	O
determined	O
in	O
free	O
glycerol	B
,	O
in	O
glycerol	B
from	O
triglycerides	B
,	O
in	O
glucose	B
from	O
glycogen	B
,	O
and	O
in	O
lactate	O
after	O
incubation	O
of	O
d	B
-	I
glyceraldehyde	I
-	I
3	I
-	I
(	I
14	I
)	I
C	I
and	O
l	B
-	I
glyceraldehyde	I
-	I
3	I
-	I
(	I
14	I
)	I
C	I
with	O
rat	O
adipose	O
tissue	O
.	O

The	O
distributions	O
are	O
interpreted	O
in	O
terms	O
of	O
presently	O
accepted	O
possible	O
reactions	O
for	O
the	O
initial	O
metabolism	O
of	O
glyceraldehyde	B
.	O

Formation	O
of	O
glycerol	B
-	I
1	I
-	I
(	I
14	I
)	I
C	I
from	O
d	B
-	I
glyceraldehyde	I
-	I
3	I
-	I
(	I
14	I
)	I
C	I
indicates	O
that	O
in	O
adipose	O
tissue	O
glyceraldehyde	B
is	O
reduced	O
to	O
glycerol	B
.	O

Incorporation	O
of	O
(	B
14	I
)	I
C	I
from	O
d	B
-	I
glyceraldehyde	I
-	I
3	I
-	I
(	I
14	I
)	I
C	I
into	O
carbon	B
3	O
of	O
the	O
glycerol	B
of	O
triglyceride	B
indicates	O
that	O
d	B
-	I
glyceraldehyde	I
is	O
either	O
phosphorylated	O
or	O
oxidized	O
to	O
d	B
-	I
glyceric	I
acid	I
,	O
or	O
both	O
,	O
in	O
its	O
initial	O
metabolism	O
.	O

Incorporation	O
of	O
(	B
14	I
)	I
C	I
from	O
l	B
-	I
glyceraldehyde	I
-	I
3	I
-	I
(	I
14	I
)	I
C	I
into	O
carbon	B
3	O
of	O
glycerol	B
indicates	O
that	O
l	B
-	I
glyceraldehyde	I
is	O
reduced	O
to	O
glycerol	B
,	O
which	O
is	O
phosphorylated	O
and	O
(	O
or	O
)	O
converted	O
to	O
d	B
-	I
glyceric	I
acid	I
via	O
l	B
-	I
glyceric	I
acid	I
.	O

Some	O
(	B
14	I
)	I
C	I
from	O
l	B
-	I
glyceraldehyde	I
-	I
3	I
-	I
(	I
14	I
)	I
C	I
is	O
incorporated	O
into	O
carbon	B
1	O
of	O
glycerol	B
of	O
triglycerides	B
and	O
carbon	B
4	O
of	O
glycogen	B
;	O
the	O
explanation	O
for	O
this	O
incorporation	O
is	O
uncertain	O
.	O

596853	O
[	O
Synthesis	O
and	O
properties	O
of	O
carminomycinone	B
derivatives	B
]	O

The	O
possibility	O
of	O
chemical	O
modification	O
of	O
carminomycinone	B
-	I
aglycone	I
(	O
II	O
)	O
of	O
carminomicin	B
,	O
a	O
side	O
product	O
in	O
the	O
antibiotic	O
production	O
was	O
studied	O
.	O

The	O
methyl	B
group	B
C	B
-	I
14	I
was	O
functionilized	O
by	O
introducing	O
the	O
bromine	B
atom	B
and	O
performing	O
a	O
number	O
of	O
exchange	O
reactions	O
with	O
the	O
bromine	B
atom	B
.	O

It	O
was	O
found	O
that	O
under	O
definite	O
conditions	O
(	O
1	O
.	O
1	O
equiv	O
.	O

Br2	B
in	O
dioxane	B
,	O
degrees	O
,	O
24	O
hours	O
)	O
carminomycinone	B
(	O
II	O
)	O
was	O
subjected	O
to	O
selective	O
bromination	O
into	O
the	O
side	O
acetyl	B
group	B
with	O
formation	O
of	O
14	B
-	I
bromcarminomycinone	I
(	O
III	O
)	O
.	O

On	O
interaction	O
with	O
anhydrous	O
potassium	B
acetate	I
14	I
-	I
bromcarminomycinone	I
(	O
III	O
)	O
yield	O
14	B
-	I
acetoxycarminomycinone	I
(	O
IV	O
)	O
.	O

In	O
its	O
turn	O
the	O
latter	O
compound	O
(	O
IV	O
)	O
easily	O
hydrolized	O
to	O
14	B
-	I
oxycarminomycinone	I
(	O
V	O
)	O
in	O
treatment	O
with	O
aqueous	O
alkali	O
or	O
acid	O
.	O

14	B
-	I
oxycarminomycinone	I
(	O
V	O
)	O
was	O
also	O
prepared	O
with	O
a	O
high	O
yield	O
(	O
per	O
cent	O
)	O
by	O
direct	O
alkaline	O
hydrolysis	O
of	O
14	B
-	I
bromcarminomycinone	I
(	O
III	O
)	O
in	O
treatment	O
with	O
0.1	O
N	O
solution	O
of	O
sodium	B
carbonate	I
in	O
a	O
mixture	O
of	O
dioxane	B
and	O
water	O
.	O

The	O
structure	O
of	O
14	O
-	O
substituted	O
derivatives	B
of	O
carminomycinone	B
was	O
proved	O
by	O
analytical	O
and	O
spectral	O
data	O
and	O
confirmed	O
by	O
their	O
transformation	O
.	O

Thus	O
,	O
according	O
to	O
the	O
data	O
of	O
mass	O
-	O
spectrometry	O
14	B
-	I
oxycarminomycinone	I
(	O
V	O
)	O
had	O
a	O
molecular	O
weight	O
of	O
c	O
.	O

u	O
.	O

In	O
treatment	O
with	O
an	O
excess	O
of	O
acetic	B
anhydride	I
in	O
pyridine	B
it	O
formed	O
a	O
hexa	B
-	I
acetyl	I
derivative	B
,	O
i.e.	O
4	B
,	I
6	I
,	I
7	I
,	I
9	I
,	I
11	I
,	I
14	I
-	I
hexa	I
-	I
acetyl	I
-	I
14	I
-	I
oxycarminomycinone	I
(	O
VI	O
)	O
.	O

The	O
aglycones	B
(	O
III	O
-	O
V	O
)	O
prepared	O
by	O
us	O
may	O
serve	O
a	O
starting	O
material	O
in	O
chemical	O
synthesis	O
,	O
as	O
well	O
as	O
biosynthesis	O
of	O
semi	O
-	O
synthetic	O
preparations	O
of	O
the	O
carminomycin	B
series	B
.	O

6264792	O
Inhibition	O
of	O
renin	O
secretion	O
by	O
intrarenal	O
alpha	O
-	O
adrenoceptor	O
blockade	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
renal	O
alpha	O
-	O
adrenoceptors	O
can	O
mediate	O
tonic	O
neural	O
stimulation	O
of	O
renin	O
secretion	O
.	O

The	O
effect	O
of	O
alpha	O
-	O
adrenoceptor	O
blockade	O
by	O
phenoxybenzamine	B
(	O
POB	B
)	O
or	O
prazosin	B
on	O
renin	O
secretion	O
rate	O
(	O
RSR	O
)	O
was	O
studied	O
in	O
pentobarbital	B
-	O
anesthetized	O
dogs	O
in	O
which	O
renal	O
perfusion	O
pressure	O
was	O
held	O
constant	O
with	O
an	O
adjustable	O
aortic	O
clamp	O
.	O

POB	B
alone	O
(	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O
min	O
-	O
1	O
iv	O
)	O
did	O
not	O
change	O
arterial	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
.	O

However	O
,	O
when	O
beta	O
-	O
adrenoceptors	O
were	O
blocked	O
by	O
intravenous	O
propranolol	B
,	O
intravenous	O
POB	B
infusion	O
(	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
decreased	O
PRA	O
and	O
RSR	O
to	O
48	O
+	O
/	O
-	O
8	O
and	O
21	O
+	O
/	O
-	O
9	O
%	O
of	O
previous	O
levels	O
within	O
min	O
.	O

This	O
effect	O
was	O
abolished	O
by	O
acute	O
bilateral	O
renal	O
denervation	O
.	O

Direct	O
intrarenal	O
POB	B
infusion	O
(	O
or	O
3.3	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
decreased	O
RSR	O
,	O
whereas	O
intravenous	O
POB	B
(	O
3.3	O
micrograms	O
.	O

kg	O
-	O
1	O
.	O
min	O
-	O
1	O
)	O
had	O
no	O
effect	O
on	O
either	O
RSR	O
or	O
PRA	O
in	O
propranolol	B
-	O
pretreated	O
dogs	O
.	O

Prazosin	B
(	O
1	O
microgram	O
.	O

kg	O
-	O
1	O
.	O
min	O
-	O
1	O
iv	O
)	O
also	O
significantly	O
decreased	O
PRA	O
.	O

These	O
data	O
indicate	O
that	O
when	O
beta	O
-	O
adrenoceptors	O
are	O
blocked	O
by	O
propranolol	B
,	O
tonic	O
neural	O
stimulation	O
of	O
renin	O
secretion	O
is	O
mediated	O
by	O
renal	O
alpha	O
-	O
adrenoceptors	O
.	O

Adenosine	O
5	O
'	O
-	O
triphosphate	O
(	O
ATP	B
)	O
derivatives	B
of	O
the	O
types	O
N6	B
-	I
R	I
-	I
ATP	I
[	O
R	O
=	O
(	B
CH2	I
)	I
nNHCOCH2I	I
,	O
(	B
CH2	I
)	I
nNHCO	I
-	I
(	I
CH2	I
)	I
mNHCOCH2I	I
,	O
or	O
(	B
CH2	I
)	I
nCON	I
(	I
Me	I
)	I
(	I
CH2	I
)	I
mN	I
(	I
Me	I
)	I
CO	I
(	I
CH2	I
)	I
nNHCOCH2I	I
]	O
,	O
N6	B
-	I
Me	I
-	I
N6	I
-	I
R	I
-	I
ATP	I
[	O
R	O
=	O
(	B
CH2	I
)	I
nN	I
-	I
(	I
Me	I
)	I
CO	I
(	I
CH2	I
)	I
mNHCOCH2I	I
]	O
,	O
and	O
8	B
-	I
R	I
-	I
ATP	I
[	O
R	O
=	O
NM	B
(	I
CH2	I
)	I
nNHCOCH2I	I
]	O
with	O
5	O
-	O
-	O
19	O
spacer	O
atoms	O
between	O
N6	O
or	O
C	O
-	O
8	O
and	O
iodine	B
have	O
been	O
evaluated	O
as	O
potential	O
exo	O
-	O
ATP	B
-	O
site	O
-	O
directed	O
reagents	O
for	O
phosphokinases	O
.	O

Substrate	O
and	O
inhibitor	O
properties	O
indicated	O
that	O
the	O
compounds	O
possessed	O
affinity	O
for	O
the	O
ATP	B
sites	O
of	O
the	O
muscle	O
(	O
M	O
)	O
,	O
kidney	O
(	O
K	O
)	O
,	O
and	O
liver	O
(	O
L	O
)	O
isozymes	O
of	O
rat	O
pyruvate	O
kinase	O
(	O
PK	O
)	O
,	O
of	O
E	O
.	O

coli	O
thymidine	O
kinase	O
(	O
TK	O
)	O
,	O
and	O
of	O
yeast	O
hexokinase	O
(	O
HK	O
)	O
and	O
rat	O
KH	O
I	O
,	O
II	O
,	O
and	O
III	O
isozymes	O
.	O

Tests	O
for	O
time	O
-	O
dependent	O
loss	O
of	O
enzyme	O
activity	O
(	O
inactivation	O
)	O
were	O
performed	O
under	O
conditions	O
in	O
which	O
a	O
large	O
proportion	O
of	O
each	O
phosphokinase	O
was	O
present	O
as	O
an	O
enzyme	O
-	O
inhibitor	O
complex	O
.	O

No	O
ATP	B
-	O
site	O
-	O
directed	O
inactivations	O
resulted	O
when	O
the	O
M	O
,	O
L	O
,	O
or	O
K	O
isozymes	O
of	O
PK	O
were	O
exposed	O
for	O
8	O
h	O
,	O
22	O
degrees	O
C	O
,	O
to	O
5	O
mM	O
levels	O
of	O
18	O
ATP	B
derivatives	B
or	O
6	O
analogous	O
ADP	B
derivatives	B
or	O
when	O
yeast	O
HK	O
or	O
rat	O
KH	O
I	O
,	O
II	O
,	O
or	O
III	O
was	O
exposed	O
for	O
6	O
h	O
,	O
22	O
degrees	O
C	O
,	O
to	O
5	O
mM	O
levels	O
of	O
28	O
ATP	B
derivatives	B
.	O

Escherichia	O
coli	O
TK	O
was	O
inactivated	O
by	O
6	O
of	O
25	O
ATP	O
derivatives	O
tested	O
at	O
mM	O
,	O
6	O
h	O
,	O
0	O
degrees	O
C	O
;	O
inactivation	O
was	O
slowed	O
by	O
MgATP	B
in	O
the	O
case	O
of	O
N6	B
-	I
CH3	I
-	I
N6	I
-	I
R	I
-	I
ATP	I
[	O
R	O
=	O
(	B
CH2	I
)	I
4N	I
(	I
CH3	I
)	I
CO	I
(	I
CH2	I
)	I
5NHCOCH2I	I
]	O
.	O

Only	O
1	O
%	O
of	O
298	O
enzyme	O
-	O
inhibitor	O
combinations	O
exhibited	O
ATP	B
-	O
site	O
-	O
directed	O
inactivation	O
,	O
signifying	O
that	O
few	O
suitably	O
positioned	O
and	O
sufficiently	O
reactive	O
nucleophilic	O
groups	O
were	O
present	O
near	O
the	O
enzymic	O
ATP	B
sites	O
.	O

Studies	O
have	O
now	O
shown	O
that	O
exo	O
-	O
active	O
-	O
site	O
-	O
directed	O
reagents	O
can	O
act	O
as	O
isozyme	O
-	O
or	O
species	O
-	O
selective	O
enzyme	O
inhibitors	O
.	O

The	O
present	O
survey	O
indicates	O
that	O
in	O
many	O
cases	O
such	O
reagents	O
may	O
be	O
difficult	O
of	O
access	O
when	O
data	O
are	O
not	O
available	O
regarding	O
structural	O
or	O
physicochemical	O
features	O
of	O
the	O
target	O
enzyme	O
adjacent	O
to	O
its	O
catalytic	O
site	O
.	O

The	O
synthesis	O
of	O
aminoaceto	B
-	I
2	I
'	I
,	I
6	I
'	I
-	I
xylidides	I
substituted	B
on	O
the	O
amide	B
nitrogen	B
with	O
2	B
-	I
(	I
diethylamino	I
)	I
ethyl	I
,	O
2	B
-	I
aminoethyl	I
,	O
2	B
-	I
hydroxyethyl	I
,	O
and	O
2	B
-	I
ethoxyethyl	I
groups	B
is	O
described	O
.	O

The	O
2	B
-	I
aminoethyl	I
derivatives	B
were	O
prepared	O
by	O
treatment	O
of	O
N	B
-	I
(	I
2	I
-	I
phthalimidoethyl	I
)	I
-	I
2	I
'	I
,	I
6	I
'	I
-	I
xylidine	I
with	O
chloroacetyl	B
chloride	I
,	O
followed	O
by	O
treatment	O
with	O
either	O
potassium	B
phthalmide	I
or	O
diethylamine	B
.	O

Hydrazinolysis	O
of	O
the	O
phthalimides	B
liberated	O
the	O
free	O
amines	B
.	O

The	O
remaining	O
target	O
compounds	O
were	O
produced	O
by	O
alkylation	O
of	O
lidocaine	B
or	O
of	O
2	B
-	I
phthalimidoaceto	I
-	I
2	I
'	I
,	I
6	I
'	I
-	I
xylidide	I
with	O
the	O
appropriate	O
halide	B
and	O
sodium	B
hydride	I
,	O
followed	O
by	O
hydrazinolysis	O
where	O
necessary	O
.	O

All	O
target	O
compounds	O
were	O
evaluated	O
for	O
antiarrhythmic	O
efficacy	O
against	O
chloroform	B
-	O
induced	O
ventricular	O
tachycardia	O
,	O
as	O
well	O
as	O
for	O
acute	O
CNS	O
toxicity	O
in	O
mice	O
.	O

Most	O
of	O
the	O
target	O
compounds	O
were	O
more	O
potent	O
than	O
the	O
corresponding	O
secondary	O
amides	O
and	O
had	O
improved	O
therapeutic	O
margins	O
toward	O
CNS	O
toxicity	O
.	O

The	O
diamines	O
N	B
-	I
(	I
2	I
-	I
aminoethyl	I
)	I
-	I
2	I
-	I
aminoaceto	I
-	I
2	I
'	I
,	I
6	I
'	I
-	I
xylidide	I
(	O
13	O
)	O
and	O
N	B
-	I
(	I
2	I
-	I
aminoethyl	I
)	I
-	I
-	I
2	I
-	I
(	I
diethylamino	I
)	I
aceto	I
-	I
2	I
'	I
,	I
6	I
'	I
-	I
xylidide	I
(	O
29	O
)	O
are	O
especially	O
promising	O
in	O
this	O
respect	O
.	O

Several	O
compounds	O
were	O
tested	O
as	O
spinal	O
anesthetics	O
.	O

Evidence	O
for	O
messenger	O
ribonucleic	O
acid	O
of	O
an	O
ammonium	O
-	O
inducible	O
glutamate	O
dehydrogenase	O
and	O
synthesis	O
,	O
covalent	O
modification	O
,	O
and	O
degradation	O
of	O
enzyme	O
subunits	O
in	O
uninduced	O
Chlorella	O
sorokiniana	O
cells	O
.	O

The	O
cells	O
of	O
Chlorella	O
sorokiniana	O
cultured	O
in	O
nitrate	B
medium	O
contain	O
no	O
detectable	O
catalytic	O
activity	O
of	O
an	O
ammonium	O
-	O
inducible	O
nicotinamide	O
adenine	O
dinucleotide	O
phosphate	O
-	O
specific	O
glutamate	O
dehydrogenase	O
(	O
NADP	O
-	O
GDH	O
)	O
.	O

However	O
,	O
several	O
lines	O
of	O
experimental	O
evidence	O
indicated	O
that	O
the	O
NADP	O
-	O
GDH	O
messenger	O
ribonucleic	O
acid	O
was	O
present	O
at	O
high	O
levels	O
and	O
was	O
being	O
translated	O
in	O
uninduced	O
cells	O
.	O

First	O
,	O
binding	O
studies	O
with	O
125I	O
-	O
labeled	O
anti	O
-	O
NADP	O
-	O
GDH	O
immunoglobulin	O
G	O
and	O
total	O
polysomes	O
isolated	O
from	O
uninduced	O
and	O
induced	O
cells	O
showed	O
that	O
NADP	O
-	O
GDH	O
subunits	O
were	O
being	O
synthesized	O
on	O
polysomes	O
from	O
both	O
types	O
of	O
cells	O
.	O

Second	O
,	O
when	O
polyadenylic	B
acid	I
-	O
containing	O
ribonucleic	O
acid	O
was	O
extracted	O
from	O
polysomes	O
from	O
uninduced	O
and	O
induced	O
cells	O
and	O
placed	O
into	O
a	O
messenger	O
ribonucleic	O
acid	O
-	O
dependent	O
in	O
vitro	O
translation	O
system	O
,	O
NADP	O
-	O
GDH	O
subunits	O
were	O
synthesized	O
from	O
the	O
ribonucleic	O
acid	O
from	O
both	O
sources	O
.	O

Third	O
,	O
when	O
ammonia	B
was	O
added	O
to	O
uninduced	O
cells	O
,	O
NADP	O
-	O
GDH	O
antigen	O
accumulated	O
without	O
an	O
apparent	O
induction	O
lag	O
.	O

Fourth	O
,	O
by	O
use	O
of	O
a	O
specific	O
immunoprecipitation	O
procedure	O
coupled	O
to	O
pulse	O
-	O
chase	O
studies	O
with	O
[	B
35S	I
]	I
sulfate	I
,	O
it	O
was	O
shown	O
that	O
the	O
NADP	O
-	O
GDH	O
subunits	O
are	O
rapidly	O
synthesized	O
,	O
covalently	O
modified	O
,	O
and	O
then	O
degraded	O
in	O
uninduced	O
cells	O
.	O

Hypoxic	O
cells	O
are	O
an	O
important	O
target	O
for	O
antitumor	O
therapy	O
because	O
tumors	O
are	O
typically	O
characterized	O
by	O
such	O
cells	O
.	O

Virtually	O
all	O
tumors	O
which	O
are	O
present	O
as	O
solid	O
masses	O
contain	O
hypoxic	O
cells	O
,	O
while	O
normal	O
cells	O
generally	O
have	O
an	O
adequate	O
supply	O
of	O
oxygen	O
.	O

Accordingly	O
,	O
antitumor	O
agents	O
can	O
be	O
made	O
selective	O
for	O
tumors	O
by	O
virtue	O
of	O
high	O
activity	O
under	O
hypoxic	O
conditions	O
.	O

The	O
initial	O
purpose	O
of	O
this	O
work	O
was	O
to	O
determine	O
the	O
influence	O
of	O
different	O
groups	O
in	O
position	O
3	O
.	O

Thus	O
,	O
the	O
synthesis	O
of	O
some	O
3	B
-	I
NH	I
-	I
substituted	I
derivatives	B
(	O
2a	O
,	O
3a	O
,	O
4a	O
)	O
starting	O
from	O
3	B
-	I
amino	I
-	I
2	I
-	I
quinoxalinecarbonitrile	I
1,4	I
-	I
di	I
-	I
N	I
-	I
oxide	I
(	O
1a	O
)	O
is	O
described	O
.	O

Reductive	O
deamination	O
of	O
compounds	O
1a	O
-	O
k	O
provides	O
the	O
2	B
-	I
quinoxalinecarbonitriles	I
5a	O
-	O
k	O
,	O
which	O
are	O
more	O
potent	O
,	O
while	O
selectivity	O
is	O
maintained	O
or	O
increased	O
in	O
some	O
derivatives	O
.	O

The	O
compound	O
7	B
-	I
(	I
4	I
-	I
nitrophenyl	I
)	I
-	I
2	I
-	I
quinoxalinecarbonitrile	I
1,4	I
-	I
di	I
-	I
N	I
-	I
oxide	I
(	O
5k	O
)	O
is	O
-	O
fold	O
more	O
potent	O
than	O
tirapazamine	B
(	O
3	B
-	I
amino	I
-	I
1,2,4	I
-	I
benzotriazine	I
1,4	I
-	I
di	I
-	I
N	I
-	I
oxide	I
)	O
,	O
which	O
has	O
been	O
used	O
as	O
a	O
standard	O
.	O

Three	O
derivatives	O
(	O
5	O
g	O
,	O
i	O
,	O
k	O
)	O
show	O
a	O
hypoxic	O
cytotoxicity	O
ratio	O
(	O
HCR	O
)	O
&	O
gt	O
;	O
or	O
=	O
,	O
better	O
than	O
that	O
of	O
tirapazamine	B
(	O
HCR	O
=	O
75	O
)	O
in	O
V79	O
cells	O
.	O

Replacement	O
of	O
the	O
3	B
-	I
amino	I
group	B
by	O
chlorine	B
affords	O
the	O
potent	O
but	O
nonselective	O
3	B
-	I
chloro	I
derivatives	B
6a	O
-	O
k	O
showing	O
similar	O
toxicities	O
under	O
both	O
aerobic	O
and	O
hypoxic	O
conditions	O
.	O

These	O
compounds	O
were	O
used	O
as	O
intermediates	O
for	O
the	O
synthesis	O
of	O
a	O
new	O
series	O
of	O
water	O
-	O
soluble	O
compounds	O
derived	O
from	O
3	B
-	I
[	I
[	I
(	I
N	I
,	I
N	I
-	I
dialkylamino	I
)	I
alkyl	I
[	I
amino	I
]	I
-	I
2	I
-	I
quinoxalinecarbonitrile	I
1,4	I
-	I
di	I
-	I
N	I
-	I
oxides	I
-	O
i	O
and	O
11a	O
-	O
i	O
.	O

The	O
7	B
-	I
chloro	I
and	O
the	O
7	B
-	I
trifluoromethyl	I
derivatives	B
,	O
f	O
have	O
demonstrated	O
high	O
potency	O
(	O
0.4	O
and	O
0.3	O
microM	O
)	O
and	O
excellent	O
selectivity	O
(	O
HCR	O
=	O
and	O
)	O
.	O

Several	O
7	B
-	I
chloro	I
analogues	B
,	O
12b	O
,	O
13b	O
.1	O
,	O
b	O
.2	O
,	O
and	O
14b	O
,	O
and	O
the	O
dimer	O
16b	O
have	O
been	O
prepared	O
and	O
evaluated	O
in	O
order	O
to	O
determine	O
the	O
optimum	O
lateral	O
chain	O
in	O
position	O
3	O
,	O
which	O
appears	O
to	O
be	O
the	O
[	O
(	B
N	I
,	I
N	I
-	I
dimethylamino	I
)	I
propyl	I
]	I
amino	I
moiety	B
.	O

The	O
determination	O
of	O
the	O
structure	O
and	O
function	O
of	O
the	O
sigma	O
receptor	O
subtypes	O
and	O
their	O
physiological	O
role	O
(	O
s	O
)	O
has	O
been	O
impeded	O
by	O
the	O
unavailability	O
of	O
selective	O
ligands	O
.	O

We	O
have	O
developed	O
a	O
new	O
class	O
of	O
sigma	O
subtype	O
selective	O
receptor	O
ligands	O
that	O
are	O
(	B
E	I
)	I
-	I
8	I
-	I
benzylidene	I
derivatives	B
of	O
the	O
synthetic	O
opioid	O
(	B
+	I
/	I
-	I
)	I
-	I
,	O
(	B
+	I
)	I
-	I
,	O
and	O
(	B
-	I
)	I
-	I
2	I
-	I
methyl	I
-	I
5	I
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
morphan	I
-	I
7	I
-	I
one	I
(	O
1	O
)	O
.	O

The	O
derivatives	O
can	O
be	O
prepared	O
by	O
reaction	O
of	O
1	O
,	O
(	O
+	O
)	O
-	O
1	O
,	O
and	O
(	O
-	O
)	O
-	O
1	O
with	O
the	O
appropriate	O
benzaldehyde	B
under	O
Claisen	O
-	O
Schmidt	O
conditions	O
.	O

Incorporation	O
of	O
substituted	O
(	B
E	I
)	I
-	I
8	I
-	I
benzylidene	I
moieties	B
onto	O
the	O
7	O
-	O
keto	O
precursor	O
of	O
(	B
+	I
)	I
-	I
2	I
-	I
methyl	I
-	I
5	I
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
morphan	I
,	O
(	O
+	O
)	O
-	O
1	O
,	O
produces	O
compounds	O
(	O
-	O
)	O
-	O
2	O
through	O
(	O
-	O
)	O
-	O
7	O
(	O
5.8	O
-	O
32.0	O
nM	O
,	O
sigma	O
1	O
)	O
,	O
which	O
have	O
between	O
a	O
25	O
-	O
and	O
131	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
sigma	O
1	O
receptor	O
subtype	O
relative	O
to	O
the	O
keto	O
precursor	O
(	O
+	O
)	O
-	O
1	O
(	O
Ki	O
=	O
762	O
nM	O
,	O
sigma	O
1	O
)	O
.	O

Compound	O
(	O
-	O
)	O
-	O
2	O
is	O
the	O
most	O
selective	O
of	O
this	O
group	O
(	O
16	O
-	O
fold	O
)	O
for	O
the	O
sigma	O
1	O
subtype	O
versus	O
sigma	O
2	O
.	O

Substitution	O
of	O
an	O
(	B
E	I
)	I
-	I
8	I
-	I
benzylidene	I
moiety	O
onto	O
the	O
7	O
-	O
keto	O
precursor	O
of	O
(	O
-	O
)	O
-	O
2	O
-	O
methyl	O
-	O
5	O
-	O
(	O
3	O
-	O
hydroxyphenyl	O
)	O
morphan	O
,	O
(	O
-	O
)	O
-	O
1	O
,	O
produces	O
compounds	O
(	O
+	O
)	O
-	O
2	O
-	O
(	O
+	O
)	O
-	O
9	O
(	O
6.4	O
-	O
52.6	O
nM	O
,	O
sigma	O
2	O
)	O
,	O
which	O
have	O
at	O
least	O
a	O
475	O
-	O
3906	O
-	O
fold	O
increase	O
in	O
affinity	O
for	O
the	O
sigma	O
2	O
receptor	O
subtype	O
relative	O
to	O
the	O
keto	O
precursor	O
(	O
-	O
)	O
-	O
1	O
(	O
Ki	O
=	O
25	O
x	O
(	O
3	O
)	O
nM	O
)	O
.	O

This	O
enhancement	O
of	O
sigma	O
2	O
receptor	O
affinity	O
is	O
accompanied	O
by	O
substantial	O
selectivity	O
of	O
all	O
of	O
these	O
dextrorotatory	O
products	O
for	O
the	O
sigma	O
2	O
relative	O
to	O
the	O
sigma	O
1	O
subtype	O
(	O
32	O
-	O
238	O
-	O
fold	O
)	O
,	O
and	O
thus	O
,	O
they	O
are	O
among	O
the	O
most	O
sigma	O
2	O
selective	O
compounds	O
currently	O
known	O
.	O

Furthermore	O
,	O
the	O
sigma	O
1	O
subtype	O
is	O
highly	O
enantioselective	O
for	O
the	O
levorotatory	O
isomers	O
,	O
(	O
-	O
)	O
-	O
2	O
-	O
(	O
-	O
)	O
-	O
7	O
(	O
41	O
-	O
1034	O
-	O
fold	O
)	O
,	O
whereas	O
the	O
sigma	O
2	O
subtype	O
is	O
only	O
somewhat	O
enantioselective	O
for	O
the	O
dextrorotatory	O
isomers	O
,	O
(	O
+	O
)	O
-	O
2	O
-	O
(	O
+	O
)	O
-	O
7	O
(	O
2.6	O
-	O
9.3	O
-	O
fold	O
)	O
.	O

All	O
of	O
these	O
derivatives	O
retain	O
substantial	O
affinity	O
for	O
the	O
mu	O
opioid	O
receptor	O
.	O

Despite	O
the	O
high	O
affinity	O
of	O
the	O
dextrorotatory	O
derivatives	O
for	O
the	O
mu	O
opioid	O
receptor	O
,	O
the	O
high	O
affinity	O
and	O
selectivity	O
for	O
sigma	O
2	O
over	O
sigma	O
1	O
sites	O
will	O
surely	O
prove	O
beneficial	O
as	O
tools	O
for	O
the	O
delineation	O
of	O
the	O
function	O
and	O
physiological	O
role	O
of	O
sigma	O
2	O
receptors	O
.	O

N	O
,	O
O	O
-	O
Dicarbethoxy	O
-	O
4	O
-	O
chlorobenzenesulfohydroxamate	O
(	O
1c	O
)	O
and	O
O	B
-	I
carbethoxy	I
-	I
N	I
-	I
hydroxysaccharin	I
(	O
6	O
)	O
,	O
both	O
potential	O
carbethoxylating	O
agents	O
,	O
inhibited	O
yeast	O
aldehyde	O
dehydrogenase	O
(	O
AlDH	O
)	O
with	O
IC50	O
's	O
of	O
24	O
and	O
56	O
microM	O
,	O
respectively	O
.	O

The	O
esterase	O
activity	O
of	O
the	O
enzyme	O
was	O
commensurably	O
inhibited	O
.	O

AlDH	O
activity	O
was	O
only	O
partially	O
restored	O
on	O
incubation	O
with	O
mercaptoethanol	B
(	O
mM	O
)	O
for	O
1	O
h	O
.	O

On	O
incubation	O
with	O
rat	O
plasma	O
,	O
1c	O
liberated	O
nitroxyl	B
,	O
a	O
potent	O
inhibitor	O
of	O
AlDH	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
nitroxyl	B
generation	O
from	O
6	O
was	O
minimal	O
,	O
a	O
result	O
compatible	O
with	O
a	O
previous	O
observation	O
that	O
nitroxyl	B
generation	O
from	O
N	B
-	I
hydroxysaccharin	I
(	O
7	O
)	O
,	O
the	O
product	O
of	O
the	O
hydrolysis	O
of	O
the	O
carbethoxy	B
group	B
of	O
6	O
,	O
was	O
minimal	O
at	O
physiological	O
pH	O
.	O

Since	O
chemical	O
carbethoxylating	O
agents	O
represented	O
by	O
the	O
O	B
-	I
carbethoxylated	I
N	I
-	I
hydroxyphthalimide	I
,	O
1	B
-	I
hydroxybenzotriazole	I
,	O
and	O
N	B
-	I
hydroxysuccinimide	I
(	O
8	O
,	O
9	O
,	O
and	O
,	O
respectively	O
)	O
likewise	O
inhibited	O
yeast	O
AlDH	O
,	O
albeit	O
with	O
IC50	O
's	O
1	O
order	O
of	O
magnitude	O
higher	O
,	O
we	O
postulate	O
that	O
1c	O
and	O
6	O
act	O
as	O
irreversible	O
inhibitors	O
of	O
AlDH	O
by	O
carbethoxylating	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

8654448	O
Activity	O
of	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
on	O
Escherichia	O
coli	O
isolates	O
exhibiting	O
various	O
patterns	O
of	O
resistance	O
to	O
beta	B
-	I
lactam	I
agents	O
.	O

The	O
efficacy	O
of	O
the	O
clinically	O
available	O
beta	O
-	O
lactam	O
/	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
(	O
amoxicillin	B
/	O
clavulanic	B
acid	I
(	O
CA	B
)	O
,	O
ticarcillin	B
/	O
CA	B
,	O
amoxicillin	B
/	O
sulbactam	B
,	O
and	O
piperacillin	B
/	O
tazobactam	B
)	O
was	O
evaluated	O
on	O
amoxicillin	B
-	O
resistant	O
Escherichia	O
coli	O
isolates	O
having	O
the	O
main	O
patterns	O
of	O
beta	B
-	I
lactam	I
resistance	O
.	O

The	O
patterns	O
,	O
which	O
reflect	O
the	O
production	O
of	O
various	O
beta	O
-	O
lactamase	O
enzymes	O
,	O
were	O
analyzed	O
by	O
a	O
principal	O
component	O
analysis	O
of	O
susceptibility	O
to	O
11	O
beta	B
-	I
lactam	I
antibiotics	O
or	O
beta	B
-	I
lactam	I
/	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
.	O

Sixty	O
-	O
two	O
percent	O
of	O
strains	O
were	O
not	O
very	O
susceptible	O
to	O
penicillins	B
,	O
cephalothin	B
,	O
or	O
any	O
beta	B
-	I
lactam	I
/	O
beta	O
-	O
lactamase	O
inhibitor	O
combinations	O
except	O
for	O
piperacillin	B
/	O
tazobactam	B
;	O
these	O
strains	O
may	O
represent	O
high	O
-	O
level	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
(	O
so	O
-	O
called	O
penicillinase	O
)	O
production	O
phenotype	O
or	O
inhibitor	O
-	O
resistant	O
TEM	O
-	O
like	O
enzyme	O
production	O
phenotype	O
.	O

Of	O
the	O
strains	O
,	O
14.7	O
%	O
were	O
resistant	O
to	O
amoxicillin	B
and	O
ticarcillin	B
compatible	O
with	O
low	O
-	O
level	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
production	O
phenotype	O
;	O
5.7	O
%	O
were	O
cefoxitin	B
resistant	O
and	O
were	O
postulated	O
to	O
present	O
a	O
high	O
-	O
level	O
cephalosporinase	O
production	O
phenotype	O
;	O
and	O
2.6	O
%	O
were	O
resistant	O
to	O
cephalothin	B
only	O
,	O
attributable	O
to	O
a	O
low	O
-	O
level	O
cephalosporinase	O
production	O
phenotype	O
.	O

Three	O
percent	O
of	O
strains	O
were	O
intermediate	O
or	O
resistant	O
to	O
cefotaxime	B
and	O
may	O
produce	O
an	O
extended	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
,	O
and	O
the	O
remaining	O
strains	O
(	O
12	O
%	O
)	O
,	O
resistant	O
to	O
all	O
tested	O
antibiotics	O
except	O
for	O
cefotaxime	B
and	O
piperacillin	B
/	O
tazobactam	B
,	O
were	O
hypothesized	O
to	O
produce	O
both	O
broad	O
-	O
spectrum	O
beta	O
-	O
lactamase	O
plus	O
cephalosporinase	O
.	O

The	O
minimal	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
for	O
these	O
phenotype	O
patterns	O
indicated	O
that	O
combinations	O
of	O
CA	B
plus	O
amoxicillin	B
or	O
ticarcillin	B
,	O
or	O
sulbactam	B
plus	O
amoxicillin	B
,	O
restored	O
the	O
activity	O
of	O
penicillins	B
against	O
phenotype	O
1	O
strains	O
,	O
whereas	O
these	O
combinations	O
remained	O
inactive	O
against	O
the	O
other	O
phenotype	O
strains	O
.	O

Piperacillin	B
plus	O
tazobactam	B
showed	O
the	O
best	O
in	O
vitro	O
effect	O
against	O
the	O
strains	O
of	O
all	O
resistance	O
phenotypes	O
.	O

In	O
the	O
present	O
investigation	O
,	O
the	O
last	O
two	O
possible	O
modes	O
of	O
generating	O
conformationally	O
semirigid	O
diacylglycerol	B
(	O
DAG	B
)	O
analogues	B
embedded	O
into	O
five	O
-	O
membered	O
ring	O
lactones	B
as	O
templates	O
III	O
and	O
IV	O
are	O
investigated	O
.	O

The	O
first	O
two	O
templates	O
studied	O
in	O
previous	O
investigations	O
corresponded	O
to	O
2	B
-	I
deoxyribonolactone	I
(	O
template	O
I	O
)	O
and	O
4,4	B
-	I
disubstituted	I
gamma	I
-	I
butyrolactone	I
(	O
template	O
II	O
)	O
,	O
with	O
the	O
latter	O
producing	O
potent	O
protein	O
kinase	O
C	O
(	O
PK	O
-	O
C	O
)	O
ligands	O
with	O
low	O
nanomolar	O
binding	O
affinities	O
.	O

The	O
templates	O
reported	O
in	O
this	O
work	O
correspond	O
to	O
2,3	B
-	I
dideoxy	I
-	I
L	I
-	I
erythro	I
-	I
or	O
-	B
threo	I
-	I
hexono	I
-	I
1,4	I
-	I
lactone	I
(	O
template	O
III	O
)	O
and	O
2	B
-	I
deoxyapiolactone	I
(	O
template	O
IV	O
)	O
.	O

Compounds	O
constructed	O
with	O
the	O
dideoxy	B
-	I
L	I
-	I
erythro	I
-	I
or	O
-	B
threo	I
-	I
hexono	I
-	I
1,4	I
-	I
lactone	I
template	O
were	O
synthesized	O
stereospecifically	O
from	O
tri	B
-	I
O	I
-	I
acetyl	I
-	I
L	I
-	I
glucal	I
and	O
L	B
-	I
galactono	I
-	I
1,4	I
-	I
lactone	I
,	O
respectively	O
.	O

Compounds	O
constructed	O
with	O
the	O
2	B
-	I
deoxyapiolactone	I
template	O
were	O
synthesized	O
stereoselectively	O
from	O
di	B
-	I
O	I
-	I
isopropylidene	I
-	I
alpha	I
-	I
D	I
-	I
apiose	I
.	O

Inhibition	O
of	O
the	O
binding	O
of	O
[	B
3H	I
]	I
phorbol	I
-	I
12,13	I
-	I
dibutyrate	I
to	O
PK	O
-	O
C	O
alpha	O
showed	O
that	O
only	O
the	O
threo	B
-	I
isomer	I
,	O
5	B
-	I
O	I
-	I
tetradecanoyl	I
-	I
2,3	I
-	I
dideoxy	I
-	I
L	I
-	I
threo	I
-	I
hexono	I
-	I
1,4	I
-	I
lactone	I
(	O
2	O
)	O
was	O
a	O
good	O
PK	O
-	O
C	O
ligand	O
(	O
Ki	O
=	O
1	O
microM	O
)	O
.	O

The	O
rest	O
of	O
the	O
ligands	O
had	O
poorer	O
affinities	O
with	O
Ki	O
values	O
between	O
and	O
28	O
microM	O
.	O

With	O
these	O
results	O
,	O
the	O
order	O
of	O
importance	O
of	O
five	O
-	O
membered	O
ring	O
lactones	B
as	O
competent	O
templates	O
for	O
the	O
construction	O
of	O
semirigid	O
DAG	B
surrogates	O
with	O
effective	O
PK	O
-	O
C	O
binding	O
affinity	O
can	O
be	O
established	O
as	O
II	O
&	O
gt	O
;	O
&	O
gt	O
;	O
I	O
approximately	O
III	O
&	O
gt	O
;	O
IV	O
.	O

XBMP	O
-	O
1B	O
(	O
Xtld	O
)	O
,	O
a	O
Xenopus	O
homolog	O
of	O
dorso	O
-	O
ventral	O
polarity	O
gene	O
in	O
Drosophila	O
,	O
modifies	O
tissue	O
phenotypes	O
of	O
ventral	O
explants	O
.	O

Previously	O
we	O
have	O
isolated	O
a	O
Xenopus	O
cDNA	O
homolog	O
of	O
bone	O
morphogenetic	O
protein	O
-	O
1	O
(	O
XBMP	O
-	O
1A	O
)	O
.	O

In	O
the	O
present	O
report	O
we	O
describe	O
a	O
new	O
cDNA	O
clone	O
called	O
XBMP	O
-	O
1B	O
(	O
or	O
Xtld	O
)	O
from	O
a	O
Xenopus	O
embryonic	O
library	O
.	O

Sequence	O
analysis	O
indicates	O
that	O
these	O
two	O
clones	O
share	O
an	O
indentical	O
N	O
-	O
terminal	O
sequence	O
,	O
including	O
a	O
region	O
of	O
metalloprotease	O
domain	O
,	O
three	O
copies	O
of	O
a	O
repeat	O
first	O
found	O
in	O
complement	O
proteins	O
C1r	O
/	O
s	O
and	O
an	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
)	O
-	O
like	O
sequence	O
.	O

XBMP	O
-	O
1B	O
protein	O
has	O
an	O
additional	O
copy	O
of	O
an	O
EGF	O
-	O
like	O
sequence	O
followed	O
by	O
two	O
copies	O
of	O
complement	O
1	O
r	O
/	O
s	O
repeat	O
in	O
the	O
C	O
-	O
terminus	O
.	O

The	O
overall	O
protein	O
structure	O
predicted	O
from	O
the	O
XBMP	O
-	O
1B	O
sequence	O
reveals	O
that	O
it	O
encodes	O
a	O
protein	O
homologous	O
to	O
Drosophila	O
tolloid	O
.	O

Three	O
XBMP	O
-	O
1	O
transcripts	O
(	O
2.9	O
,	O
5.2	O
and	O
6.6	O
kb	O
)	O
were	O
detected	O
by	O
northern	O
blot	O
analysis	O
.	O

However	O
,	O
the	O
2.9	O
kb	O
transcript	O
hybridized	O
specifically	O
with	O
XBMP	O
-	O
1A	O
and	O
the	O
5.2	O
and	O
6.6	O
kb	O
transcripts	O
hybridized	O
with	O
XBMP	O
-	O
1B	O
.	O

In	O
Drosophila	O
,	O
a	O
major	O
function	O
of	O
tolloid	O
is	O
to	O
augment	O
the	O
activity	O
of	O
the	O
decapentaplegic	O
gene	O
product	O
,	O
a	O
close	O
relative	O
of	O
tumor	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
superfamily	O
members	O
,	O
BMP	O
-	O
2	O
/	O
4	O
.	O

Although	O
XBMP	O
-	O
1	O
and	O
XBMP	O
-	O
4	O
are	O
detected	O
in	O
various	O
adult	O
tissues	O
of	O
Xenopus	O
,	O
the	O
expression	O
pattern	O
of	O
these	O
two	O
genes	O
was	O
not	O
tightly	O
correlated	O
.	O

In	O
the	O
embryo	O
,	O
the	O
expression	O
of	O
XBMP	O
-	O
1	O
increased	O
gradually	O
from	O
the	O
morula	O
to	O
the	O
swimming	O
tadpole	O
stages	O
.	O

Injection	O
of	O
XBMP	O
-	O
1B	O
RNA	O
into	O
the	O
ventral	O
blastomeres	O
at	O
the	O
4	O
-	O
cell	O
stage	O
caused	O
an	O
elongation	O
of	O
the	O
ventral	O
marginal	O
zone	O
explants	O
and	O
converted	O
globin	O
-	O
positive	O
blood	O
cells	O
to	O
mesenchymal	O
and	O
muscle	O
tissues	O
at	O
later	O
stages	O
.	O

It	O
was	O
shown	O
that	O
XBMP	O
-	O
1A	O
was	O
less	O
active	O
and	O
a	O
1A	O
mutant	O
lacking	O
the	O
signal	O
sequence	O
was	O
inactive	O
.	O

Further	O
studies	O
revealed	O
that	O
injection	O
of	O
XBMP	O
-	O
1B	O
RNA	O
into	O
the	O
ventral	O
marginal	O
zone	O
induced	O
up	O
-	O
regulation	O
of	O
dorsal	O
marginal	O
zone	O
markers	O
,	O
such	O
as	O
goosecoid	O
and	O
chordin	O
,	O
at	O
the	O
gastrulation	O
stage	O
.	O

These	O
data	O
indicate	O
that	O
XBMP	O
-	O
1	O
may	O
have	O
a	O
role	O
in	O
determining	O
dorso	O
-	O
ventral	O
patterning	O
in	O
Xenopus	O
,	O
but	O
in	O
a	O
different	O
way	O
from	O
the	O
dpp	O
/	O
tolloid	O
system	O
demonstrated	O
in	O
Drosophila	O
.	O

The	O
synthesis	O
of	O
a	O
range	O
of	O
3	B
-	I
hydroxy	I
-	I
4	I
(	I
1H	I
)	I
-	I
pyridinones	I
with	O
potential	O
for	O
the	O
chelation	O
of	O
iron	B
(	I
III	I
)	I
is	O
described	O
.	O

The	O
pKa	O
values	O
of	O
respective	O
ligands	O
and	O
the	O
stability	O
constants	O
of	O
their	O
iron	B
(	I
III	I
)	I
complexes	B
are	O
presented	O
.	O

The	O
distribution	O
coefficient	O
values	O
of	O
a	O
range	O
of	O
48	O
hydroxypyridinones	B
and	O
their	O
corresponding	O
iron	B
(	I
III	I
)	I
complexes	B
between	O
1	B
-	I
octanol	I
and	O
MOPS	O
buffer	O
(	O
pH	O
7.4	O
)	O
are	O
reported	O
.	O

The	O
range	O
of	O
log	O
Dcomplex	O
values	O
covers	O
7	O
orders	O
of	O
magnitude	O
.	O

The	O
results	O
suggest	O
the	O
existence	O
of	O
a	O
biphasic	O
relationship	O
between	O
the	O
distribution	O
coefficient	O
values	O
of	O
the	O
chelator	O
and	O
the	O
corresponding	O
iron	B
(	I
III	I
)	I
complexes	B
.	O

For	O
ligands	O
with	O
a	O
log	O
Dligand	O
=	O
-	O
1	O
,	O
a	O
linear	O
relationship	O
exists	O
with	O
a	O
value	O
of	O
the	O
slope	O
2.53	O
,	O
whereas	O
with	O
ligands	O
with	O
a	O
log	O
Dligand	O
&	O
lt	O
;	O
-	O
1	O
,	O
a	O
linear	O
relationship	O
exists	O
with	O
a	O
slope	O
of	O
0.49	O
.	O

The	O
reduced	O
slope	O
for	O
the	O
more	O
hydrophilic	O
molecules	O
of	O
the	O
series	O
offers	O
some	O
advantage	O
for	O
this	O
type	O
of	O
hydroxypyridinone	B
as	O
the	O
distribution	O
coefficients	O
for	O
such	O
complexes	O
do	O
not	O
change	O
so	O
rapidly	O
with	O
increasing	O
ligand	O
hydrophilicity	O
.	O

The	O
ability	O
of	O
selected	O
3	B
-	I
hydroxypyridinones	I
to	O
facilitate	O
the	O
excretion	O
of	O
iron	O
in	O
bile	O
was	O
investigated	O
in	O
non	O
-	O
iron	O
-	O
overloaded	O
,	O
bile	O
duct	O
-	O
cannulated	O
rats	O
and	O
in	O
a	O
[	B
59Fe	I
]	I
ferritin	I
-	O
loaded	O
rat	O
model	O
.	O

Both	O
systems	O
compare	O
the	O
ability	O
of	O
chelators	O
to	O
remove	O
iron	O
from	O
the	O
liver	O
,	O
the	O
prime	O
target	O
organ	O
in	O
thalassemia	O
.	O

The	O
N	B
-	I
(	I
hydroxyalkyl	I
)	I
-	I
3	I
-	I
hydroxypyridin	I
-	I
4	I
-	I
ones	I
are	O
demonstrated	O
to	O
be	O
orally	O
active	O
under	O
the	O
in	O
vivo	O
conditions	O
adopted	O
.	O

Thus	O
both	O
1	B
-	I
(	I
hydroxyalkyl	I
)	I
-	I
and	O
1	B
-	I
(	I
carboxyalkyl	I
)	I
pyridinones	I
are	O
able	O
to	O
remove	O
iron	B
from	O
the	O
liver	O
.	O

Although	O
1	B
-	I
(	I
carboxyalkyl	I
)	I
hydroxypyridinones	I
are	O
active	O
,	O
they	O
do	O
not	O
demonstrate	O
any	O
clear	O
advantage	O
over	O
Deferiprone	B
(	O
1,2	B
-	I
dimethyl	I
-	I
3	I
-	I
hydroxypyridin	I
-	I
4	I
-	I
one	I
)	O
.	O

Indeed	O
1	B
-	I
(	I
hydroxyalkyl	I
)	I
hydroxypyridinones	I
which	O
are	O
known	O
to	O
be	O
rapidly	O
converted	O
to	O
1	B
-	I
(	I
carboxyalkyl	I
)	I
hydroxypyridinones	I
are	O
also	O
marginally	O
superior	O
to	O
Deferiprone	B
.	O

In	O
contrast	O
,	O
2	B
-	I
ethyl	I
-	I
1	I
-	I
(	I
2	I
'	I
-	I
hydroxyethyl	I
)	I
-	I
3	I
-	I
hydroxypyridin	I
-	I
4	I
-	I
one	I
,	O
which	O
is	O
not	O
metabolized	O
to	O
the	O
corresponding	O
(	B
carboxyalkyl	I
)	I
hydroxypyridinone	I
,	O
was	O
found	O
to	O
be	O
superior	O
to	O
Deferiprone	B
and	O
therefore	O
deserves	O
further	O
consideration	O
as	O
an	O
orally	O
active	O
iron	O
chelator	O
with	O
potential	O
for	O
the	O
treatment	O
of	O
iron	B
overload	O
associated	O
with	O
transfusion	O
-	O
dependent	O
thalassemia	O
.	O

Serial	O
measurements	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
value	O
of	O
serial	O
determinations	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
ANCA	O
)	O
for	O
monitoring	O
disease	O
activity	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
three	O
patients	O
with	O
histologically	O
proven	O
vasculitis	O
(	O
21	O
with	O
Wegener	O
's	O
granulomatosis	O
,	O
17	O
with	O
microscopic	O
polyangiitis	O
,	O
and	O
5	O
with	O
renal	O
-	O
limited	O
vasculitis	O
)	O
were	O
studied	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
.	O

Disease	O
activity	O
was	O
prospectively	O
assessed	O
and	O
quantified	O
by	O
the	O
Birmingham	O
Vasculitis	O
Activity	O
Score	O
.	O

A	O
total	O
of	O
347	O
sera	O
were	O
analyzed	O
for	O
ANCA	O
determination	O
.	O

RESULTS	O
:	O
Relapses	O
occurred	O
in	O
23	O
(	O
54	O
%	O
)	O
of	O
43	O
patients	O
.	O

Diagnostic	O
category	O
(	O
Wegener	O
's	O
granulomatosis	O
vs	O
micropolyangiitis	O
and	O
renal	O
-	O
limited	O
vasculitis	O
)	O
,	O
severity	O
of	O
initial	O
symptoms	O
(	O
mean	O
vasculitis	O
activity	O
score	O
,	O
mean	O
number	O
of	O
organs	O
involved	O
)	O
,	O
and	O
ANCA	O
pattern	O
[	O
cytoplasmic	O
-	O
ANCA	O
(	O
c	O
-	O
ANCA	O
)	O
vs	O
perinuclear	O
-	O
ANCA	O
(	O
p	O
-	O
ANCA	O
)	O
]	O
did	O
not	O
significantly	O
differ	O
between	O
relapsers	O
and	O
nonrelapsers	O
.	O

Lung	O
involvement	O
was	O
more	O
frequent	O
at	O
onset	O
among	O
relapsers	O
[	O
16	O
of	O
23	O
(	O
)	O
vs	O
6	O
of	O
(	O
)	O
;	O
P	O
=	O
0.02	O
]	O
.	O

Relapses	O
were	O
slightly	O
,	O
but	O
not	O
significantly	O
,	O
more	O
frequent	O
in	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
or	O
a	O
c	O
-	O
ANCA	O
pattern	O
.	O

The	O
percentage	O
of	O
relapsers	O
was	O
greater	O
in	O
patients	O
with	O
persistently	O
positive	O
ANCA	O
than	O
in	O
patients	O
with	O
negative	O
or	O
decreasing	O
ANCA	O
titers	O
(	O
86	O
%	O
vs	O
,	O
P	O
=	O
0.0001	O
)	O
.	O

However	O
,	O
the	O
predictive	O
value	O
of	O
an	O
increase	O
in	O
ANCA	O
titers	O
for	O
the	O
occurrence	O
of	O
a	O
subsequent	O
relapse	O
was	O
only	O
28	O
%	O
(	O
4	O
of	O
14	O
)	O
for	O
c	O
-	O
ANCA	O
,	O
12	O
%	O
(	O
2	O
of	O
17	O
)	O
for	O
anti	O
-	O
proteinase	O
3	O
-	O
ANCA	O
,	O
and	O
43	O
%	O
(	O
6	O
of	O
14	O
)	O
for	O
anti	O
-	O
myeloperoxidase	O
-	O
ANCA	O
.	O

An	O
increase	O
in	O
ANCA	O
occurred	O
before	O
or	O
during	O
relapse	O
in	O
33	O
%	O
(	O
of	O
)	O
of	O
cases	O
for	O
c	O
-	O
ANCA	O
/	O
anti	O
-	O
proteinase	O
3	O
antibodies	O
,	O
and	O
73	O
%	O
(	O
11	O
of	O
15	O
)	O
of	O
cases	O
for	O
anti	O
-	O
myeloperoxidase	O
antibodies	O
.	O

CONCLUSION	O
:	O
The	O
persistence	O
of	O
ANCA	O
positivity	O
is	O
strongly	O
associated	O
with	O
relapses	O
.	O

However	O
,	O
an	O
increase	O
in	O
ANCA	O
titers	O
has	O
a	O
poor	O
value	O
for	O
the	O
early	O
prediction	O
of	O
a	O
subsequent	O
relapse	O
and	O
should	O
not	O
be	O
used	O
as	O
a	O
sole	O
parameter	O
for	O
therapeutic	O
intervention	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
serial	O
anti	O
-	O
myeloperoxidase	O
determination	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
who	O
are	O
p	O
-	O
ANCA	O
positive	O
.	O

Serum	O
lipid	B
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
with	O
growth	O
hormone	O
deficiency	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
deficiency	O
on	O
serum	O
lipid	B
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
taking	O
conventional	O
replacement	O
therapy	O
and	O
to	O
determine	O
the	O
relations	O
between	O
leptin	O
and	O
gender	O
and	O
anthropometric	O
and	O
metabolic	O
variables	O
.	O

SUBJECTS	O
:	O
Twenty	O
-	O
one	O
GH	O
deficient	O
adult	O
hypopituitary	O
patients	O
(	O
15	O
women	O
,	O
six	O
men	O
)	O
and	O
21	O
(	O
14	O
women	O
,	O
seven	O
men	O
)	O
age	O
,	O
sex	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
matched	O
healthy	O
controls	O
.	O

MEASUREMENTS	O
:	O
After	O
an	O
overnight	O
fast	O
,	O
anthropometric	O
parameters	O
were	O
measured	O
and	O
body	O
composition	O
was	O
determined	O
by	O
a	O
bioelectrical	O
impedance	O
analyser	O
.	O

Venous	O
blood	O
samples	O
were	O
obtained	O
for	O
the	O
measurements	O
of	O
glucose	B
,	O
total	O
cholesterol	B
,	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B
,	O
triglyceride	B
,	O
intact	O
insulin	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF	O
-	O
1	O
)	O
and	O
leptin	O
concentrations	O
.	O

Serum	O
leptin	O
and	O
hormones	O
were	O
analysed	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Hypopituitary	O
patients	O
with	O
GH	O
deficiency	O
showed	O
significantly	O
higher	O
triglyceride	B
,	O
total	O
and	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B
and	O
lower	O
HDL	O
cholesterol	B
concentrations	O
on	O
conventional	O
replacement	O
therapy	O
.	O

The	O
unfavourable	O
lipid	B
profile	O
was	O
particularly	O
evident	O
in	O
women	O
.	O

Significantly	O
higher	O
leptin	O
concentrations	O
were	O
found	O
in	O
patients	O
compared	O
with	O
healthy	O
controls	O
with	O
similar	O
body	O
fat	O
content	O
(	O
23	O
.	O
5	O
+	O
/	O
-	O
11.8	O
ng	O
/	O
ml	O
vs	O
11.7	O
+	O
/	O
-	O
6.9	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0.01	O
)	O
.	O

This	O
difference	O
remained	O
significant	O
even	O
when	O
leptin	O
values	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
percentage	O
(	O
0.79	O
+	O
/	O
-	O
0.40	O
vs.	O
0.42	O
+	O
/	O
-	O
0.17	O
ng	O
/	O
ml	O
%	O
,	O
P	O
<	O
0.05	O
)	O
and	O
fat	O
mass	O
kg	O
(	O
1.32	O
+	O
/	O
-	O
0.81	O
vs	O
0.66	O
+	O
/	O
-	O
0.30	O
ng	O
/	O
ml	O
kg	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
observed	O
between	O
leptin	O
concentrations	O
and	O
body	O
fat	O
percentage	O
and	O
age	O
in	O
the	O
control	O
group	O
.	O

In	O
patients	O
the	O
sole	O
significant	O
relation	O
between	O
leptin	O
and	O
study	O
parameters	O
was	O
the	O
positive	O
correlation	O
observed	O
between	O
leptin	O
and	O
total	O
cholesterol	B
concentrations	O
.	O

Serum	O
leptin	O
concentrations	O
were	O
significantly	O
higher	O
in	O
women	O
than	O
men	O
in	O
the	O
control	O
group	O
,	O
but	O
not	O
in	O
the	O
patients	O
.	O

No	O
significant	O
gender	O
difference	O
was	O
observed	O
when	O
leptin	O
concentrations	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
(	O
percentage	O
and	O
kg	O
)	O
.	O

CONCLUSION	O
:	O
Growth	O
hormone	O
deficient	O
hypopituitary	O
patients	O
(	O
particularly	O
women	O
)	O
on	O
conventional	O
replacement	O
therapy	O
have	O
a	O
more	O
atherogenic	O
lipid	B
profile	O
.	O

Leptin	O
concentrations	O
are	O
increased	O
in	O
GH	O
deficient	O
adults	O
even	O
after	O
adjustment	O
for	O
percentage	O
body	O
fat	O
and	O
body	O
fat	O
mass	O
(	O
kg	O
)	O
.	O

Although	O
the	O
nature	O
of	O
our	O
data	O
does	O
not	O
allow	O
us	O
to	O
draw	O
any	O
conclusions	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
increased	O
leptin	O
concentrations	O
in	O
GH	O
deficiency	O
,	O
decreased	O
central	O
sensitivity	O
to	O
leptin	O
and	O
increased	O
leptin	O
production	O
from	O
per	O
unit	O
fat	O
mass	O
,	O
or	O
alterations	O
in	O
leptin	O
clearance	O
,	O
might	O
be	O
operative	O
.	O

At	O
physiological	O
pH	O
,	O
the	O
spatial	O
arrangement	O
of	O
the	O
three	O
charges	O
of	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
(	O
5	O
)	O
could	O
be	O
viewed	O
as	O
similar	O
to	O
those	O
found	O
in	O
certain	O
conformations	O
of	O
the	O
two	O
excitatory	O
amino	O
acids	O
(	O
EAAs	O
)	O
-	O
-	O
aspartic	B
and	O
glutamic	B
acids	I
.	O

Given	O
significant	O
binding	O
to	O
one	O
or	O
more	O
EAA	O
receptors	O
,	O
5	O
would	O
offer	O
unique	O
modeling	O
and	O
perhaps	O
biological	O
opportunities	O
.	O

We	O
have	O
previously	O
shown	O
it	O
to	O
be	O
the	O
most	O
potent	O
NMDA	B
agonist	O
known	O
,	O
with	O
a	O
unique	O
and	O
marked	O
in	O
vitro	O
neutrotoxicity	O
at	O
depolarizing	O
concentrations	O
.	O

Now	O
we	O
report	O
the	O
details	O
required	O
for	O
its	O
synthesis	O
,	O
together	O
with	O
its	O
potency	O
and	O
efficacy	O
in	O
two	O
assays	O
of	O
functional	O
activation	O
of	O
the	O
NMDA	O
receptor	O
,	O
namely	O
agonist	O
-	O
influenced	O
[	B
3H	I
]	I
MK801	I
binding	O
and	O
agonist	O
-	O
induced	O
release	O
of	O
the	O
neurotransmitter	O
[	B
3H	I
]	I
-	I
norepinephrine	I
from	O
brain	O
slices	O
.	O

In	O
both	O
these	O
assays	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
proved	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
than	O
NMDA	B
and	O
cis	B
-	I
methanoglutamate	I
.	O

It	O
was	O
more	O
potent	O
than	O
,	O
and	O
equally	O
efficacious	O
to	O
,	O
L	B
-	I
glutamate	I
in	O
[	B
3H	I
]	I
MK801	I
binding	O
.	O

The	O
structural	O
features	O
of	O
5	O
may	O
well	O
reflect	O
optimal	O
agonist	O
interaction	O
at	O
the	O
NMDA	O
receptor	O
site	O
.	O

(	O
We	O
considered	O
the	O
possibility	O
that	O
some	O
decarboxylation	O
of	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
may	O
have	O
occurred	O
during	O
testing	O
.	O

This	O
would	O
give	O
5	B
-	I
(	I
aminomethyl	I
)	I
tetrazole	I
(	O
13	O
)	O
,	O
the	O
tetrazole	B
acid	I
analog	B
of	O
glycine	B
;	O
and	O
glycine	B
is	O
involved	O
in	O
NMDA	O
receptor	O
activation	O
.	O

Compound	O
13	O
does	O
not	O
affect	O
[	B
3H	I
]	I
glycine	I
binding	O
at	O
the	O
strychnine	B
-	O
insensitive	O
glycine	B
binding	O
site	O
,	O
and	O
[	B
3H	I
]	I
MK801	I
binding	O
studies	O
showed	O
that	O
the	O
(	B
aminomethyl	I
)	I
-	I
tetrazole	I
,	O
even	O
if	O
is	O
formed	O
,	O
would	O
probably	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
tetrazol	B
-	I
5	I
-	I
ylglycine	I
at	O
the	O
NMDA	O
receptor	O
.	O

Implied	O
preference	O
for	O
seismic	O
design	O
level	O
and	O
earthquake	O
insurance	O
.	O

Seismic	O
risk	O
can	O
be	O
reduced	O
by	O
implementing	O
newly	O
developed	O
seismic	O
provisions	O
in	O
design	O
codes	O
.	O

Furthermore	O
,	O
financial	O
protection	O
or	O
enhanced	O
utility	O
and	O
happiness	O
for	O
stakeholders	O
could	O
be	O
gained	O
through	O
the	O
purchase	O
of	O
earthquake	O
insurance	O
.	O

If	O
this	O
is	O
not	O
so	O
,	O
there	O
would	O
be	O
no	O
market	O
for	O
such	O
insurance	O
.	O

However	O
,	O
perceived	O
benefit	O
associated	O
with	O
insurance	O
is	O
not	O
universally	O
shared	O
by	O
stakeholders	O
partly	O
due	O
to	O
their	O
diverse	O
risk	O
attitudes	O
.	O

This	O
study	O
investigates	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
for	O
decisionmakers	O
of	O
bounded	O
rationality	O
whose	O
preferences	O
could	O
be	O
adequately	O
represented	O
by	O
the	O
cumulative	O
prospect	O
theory	O
(	O
CPT	O
)	O
.	O

The	O
investigation	O
is	O
focused	O
on	O
assessing	O
the	O
sensitivity	O
of	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
to	O
model	O
parameters	O
of	O
the	O
CPT	O
and	O
to	O
fair	O
and	O
unfair	O
insurance	O
arrangements	O
.	O

Numerical	O
results	O
suggest	O
that	O
human	O
cognitive	O
limitation	O
and	O
risk	O
perception	O
can	O
affect	O
the	O
implied	O
seismic	O
design	O
preference	O
by	O
the	O
CPT	O
significantly	O
.	O

The	O
mandatory	O
purchase	O
of	O
fair	O
insurance	O
will	O
lead	O
the	O
implied	O
seismic	O
design	O
preference	O
to	O
the	O
optimum	O
design	O
level	O
that	O
is	O
dictated	O
by	O
the	O
minimum	O
expected	O
lifecycle	O
cost	O
rule	O
.	O

Unfair	O
insurance	O
decreases	O
the	O
expected	O
gain	O
as	O
well	O
as	O
its	O
associated	O
variability	O
,	O
which	O
is	O
preferred	O
by	O
risk	O
-	O
averse	O
decisionmakers	O
.	O

The	O
obtained	O
results	O
of	O
the	O
implied	O
preference	O
for	O
the	O
combination	O
of	O
the	O
seismic	O
design	O
level	O
and	O
insurance	O
option	O
suggest	O
that	O
property	O
owners	O
,	O
financial	O
institutions	O
,	O
and	O
municipalities	O
can	O
take	O
advantage	O
of	O
affordable	O
insurance	O
to	O
establish	O
successful	O
seismic	O
risk	O
management	O
strategies	O
.	O

Oribatid	O
Mite	O
Communities	O
in	O
the	O
Canopy	O
of	O
Montane	O
Abies	O
amabilis	O
and	O
Tsuga	O
heterophylla	O
Trees	O
on	O
Vancouver	O
Island	O
,	O
British	O
Columbia	O
.	O

To	O
study	O
the	O
oribatid	O
mite	O
community	O
inhabiting	O
microhabitats	O
in	O
the	O
canopy	O
of	O
montane	O
Abies	O
amabilis	O
[	O
(	O
Douglas	O
ex	O
D	O
.	O

Don	O
)	O
Lindl	O
.	O
]	O
and	O
Tsuga	O
heterophylla	O
[	O
(	O
Raf	O
.	O
)	O

Sarg	O
]	O
tree	O
species	O
across	O
five	O
elevational	O
sites	O
,	O
we	O
collected	O
branch	O
tips	O
and	O
foliose	O
/	O
crustose	O
lichen	O
samples	O
over	O
three	O
time	O
periods	O
.	O

Thirty	O
-	O
three	O
species	O
of	O
oribatid	O
mites	O
were	O
identified	O
from	O
the	O
study	O
area	O
.	O

Mite	O
species	O
richness	O
and	O
abundance	O
was	O
significantly	O
affected	O
by	O
microhabitat	O
,	O
and	O
this	O
association	O
was	O
independent	O
of	O
sampling	O
time	O
.	O

At	O
the	O
microhabitat	O
scale	O
,	O
distinct	O
species	O
assemblages	O
were	O
associated	O
with	O
lichen	O
and	O
branch	O
tip	O
habitats	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
,	O
tree	O
species	O
.	O

Conifer	O
specificity	O
was	O
most	O
apparent	O
in	O
the	O
closely	O
related	O
species	O
of	O
Jugatala	O
,	O
where	O
Jugatala	O
tuberosa	O
Ewing	O
was	O
only	O
found	O
on	O
branch	O
tips	O
from	O
A	O
.	O

amabilis	O
and	O
Jugatala	O
sp	O
.	O
was	O
primarily	O
found	O
on	O
branch	O
tips	O
from	O
T	O
.	O

heterophylla	O
.	O

Microhabitat	O
specificity	O
was	O
most	O
pronounced	O
in	O
Dendrozetes	O
sp	O
.	O

where	O
most	O
individuals	O
were	O
found	O
on	O
branch	O
tips	O
and	O
Anachiperia	O
geminus	O
Lindo	O
et	O
al.	O
that	O
occurred	O
primarily	O
on	O
lichens	O
.	O

Principal	O
components	O
analysis	O
of	O
oribatid	O
mite	O
community	O
composition	O
further	O
showed	O
a	O
high	O
degree	O
of	O
association	O
with	O
microhabitat	O
and	O
tree	O
species	O
.	O

Habitat	O
profiles	O
are	O
difficult	O
to	O
discern	O
for	O
many	O
species	O
because	O
tree	O
,	O
microhabitat	O
,	O
and	O
elevation	O
preferences	O
confound	O
distribution	O
patterns	O
.	O

Given	O
the	O
significant	O
tree	O
-	O
microhabitat	O
associations	O
in	O
species	O
composition	O
in	O
this	O
montane	O
canopy	O
study	O
,	O
we	O
suggest	O
that	O
sampling	O
multiple	O
microhabitats	O
across	O
elevations	O
to	O
look	O
for	O
patterns	O
in	O
community	O
structure	O
offers	O
opportunities	O
to	O
explicitly	O
test	O
organizing	O
principles	O
in	O
community	O
ecology	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

A	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
a	O
sudden	O
onset	O
of	O
right	O
-	O
sided	O
hearing	O
disturbance	O
.	O

His	O
hearing	O
disturbance	O
improved	O
gradually	O
,	O
however	O
,	O
dysarthria	O
,	O
right	O
-	O
sided	O
facial	O
weakness	O
and	O
dysesthesia	O
,	O
and	O
gait	O
disturbance	O
was	O
developed	O
11	O
days	O
after	O
the	O
onset	O
of	O
hearing	O
disturbance	O
.	O

MR	O
imaging	O
revealed	O
fresh	O
infarctions	O
of	O
the	O
right	O
dorsolateral	O
pons	O
and	O
middle	O
cerebellar	O
peduncle	O
localized	O
in	O
the	O
territory	O
of	O
anterior	O
inferior	O
cerebellar	O
artery	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

The	O
synthesis	O
of	O
2	B
'	I
-	I
fluoro	I
-	I
-	I
propargyl	I
-	I
5,8	I
-	I
dideazafolic	I
acid	I
and	O
its	O
2	B
-	I
desamino	I
,	O
2	B
-	I
desamino	I
-	I
2	I
-	I
hydroxymethyl	I
,	O
and	O
2	B
-	I
desamino	I
-	I
2	I
-	I
methoxy	I
analogues	B
is	O
described	O
.	O

In	O
general	O
the	O
synthetic	O
route	O
involved	O
the	O
coupling	O
of	O
diethyl	B
N	I
-	I
[	I
2	I
-	I
fluoro	I
-	I
4	I
-	I
(	I
prop	I
-	I
2	I
-	I
ynylamino	I
)	I
benzoyl	I
]	I
-	I
L	I
-	I
glutamate	I
with	O
the	O
appropriate	O
6	B
-	I
(	I
bromomethyl	I
)	I
quinazoline	I
followed	O
by	O
deprotection	O
with	O
mild	O
alkali	O
.	O

These	O
four	O
compounds	O
together	O
with	O
the	O
2	B
-	I
desamino	I
-	I
2	I
-	I
methyl	I
analogue	B
were	O
tested	O
for	O
their	O
activity	O
against	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O

They	O
were	O
also	O
examined	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
the	O
L1210	O
cell	O
line	O
and	O
of	O
two	O
mutant	O
L1210	O
cell	O
lines	O
,	O
the	O
L1210	O
:	O
R7A	O
that	O
overproduces	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
the	O
L1210	O
:	O
1565	O
that	O
has	O
impaired	O
uptake	O
of	O
reduced	O
folates	O
.	O

Compared	O
with	O
their	O
non	O
-	O
fluorinated	O
parent	O
compounds	O
,	O
the	O
2	B
'	I
-	I
fluoro	I
analogues	B
were	O
all	O
approximately	O
2	O
-	O
fold	O
more	O
potent	O
as	O
TS	O
inhibitors	O
.	O

Similarly	O
,	O
they	O
also	O
showed	O
improved	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
(	O
1.5	O
-	O
5	O
-	O
fold	O
)	O
,	O
and	O
this	O
activity	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
thymidine	O
.	O

All	O
had	O
retained	O
or	O
improved	O
activity	O
against	O
both	O
the	O
L1210	O
:	O
R7A	O
and	O
L1210	O
:	O
1565	O
cell	O
lines	O
.	O

N	O
-	O
Methylacetazolamide	O
was	O
shown	O
to	O
be	O
active	O
topically	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
to	O
a	O
small	O
but	O
statistically	O
significant	O
level	O
in	O
the	O
normotensive	O
rabbit	O
eye	O
.	O

In	O
vivo	O
experiments	O
with	O
N	B
-	I
methylacetazolamide	I
suggest	O
that	O
ocular	O
metabolism	O
to	O
acetazolamide	B
was	O
responsible	O
for	O
the	O
observed	O
topical	O
activity	O
.	O

Examination	O
of	O
initial	O
rate	O
kinetics	O
of	O
carbonic	O
anhydrase	O
catalyzed	O
p	B
-	I
nitrophenyl	I
acetate	I
hydrolysis	O
showed	O
that	O
N	B
-	I
methylacetazolamide	I
was	O
a	O
competitive	O
inhibitor	O
,	O
in	O
contrast	O
to	O
noncompetitive	O
inhibition	O
seen	O
with	O
acetazolamide	B
and	O
other	O
primary	O
sulfonamide	B
inhibitors	O
.	O

N	B
-	I
Substituted	I
and	O
unsubstituted	B
4	I
-	I
chlorobenzene	I
-	I
and	O
4	B
-	I
nitrobenzenesulfonamides	I
were	O
also	O
synthesized	O
,	O
and	O
their	O
biochemical	O
characteristics	O
and	O
in	O
vivo	O
ability	O
to	O
lower	O
IOP	O
when	O
applied	O
topically	O
were	O
determined	O
.	O

The	O
primary	O
sulfonamides	B
were	O
reversible	O
noncompetitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
with	O
no	O
effect	O
on	O
IOP	O
after	O
topical	O
administration	O
.	O

4	B
-	I
Nitrobenzene	I
-	I
and	O
4	B
-	I
chlorobenzenesulfonamides	I
containing	O
both	O
N	B
-	I
hydroxy	I
and	O
N	B
-	I
methyl	I
substituents	B
were	O
model	O
irreversible	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
and	O
exhibited	O
a	O
trend	O
toward	O
topical	O
activity	O
in	O
reducing	O
IOP	O
in	O
normotensive	O
rabbit	O
eyes	O
.	O

Therefore	O
,	O
this	O
paper	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
two	O
types	O
of	O
carbonic	O
anhydrase	O
inhibitors	O
;	O
the	O
N	B
-	I
methyl	I
-	I
substituted	I
sulfonamides	I
are	O
reversible	O
competitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
while	O
the	O
N	B
-	I
hydroxy	I
-	I
N	I
-	I
methyl	I
-	I
substituted	I
sulfonamides	I
are	O
irreversible	O
inhibitors	O
.	O

This	O
study	O
emphasizes	O
the	O
importance	O
of	O
the	O
metabolic	O
conversion	O
of	O
the	O
enantiomers	O
of	O
3	B
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
-	I
N	I
-	I
n	I
-	I
propylpiperidine	I
(	O
3	B
-	I
PPP	I
)	O
into	O
their	O
catechol	B
analogues	B
,	O
the	O
enantiomers	O
of	O
3	B
-	I
(	I
3,4	I
-	I
dihydroxyphenyl	I
)	I
-	I
N	I
-	I
n	I
-	I
propylpiperidine	I
.	O

These	O
isomers	O
are	O
both	O
shown	O
to	O
be	O
excellent	O
substrates	O
for	O
COMT	O
,	O
with	O
a	O
slight	O
preference	O
for	O
the	O
S	O
-	O
(	O
-	O
)	O
enantiomer	O
.	O

Assessment	O
of	O
the	O
dopaminergic	O
activity	O
of	O
these	O
catechols	O
and	O
the	O
results	O
from	O
the	O
determination	O
of	O
brain	O
levels	O
of	O
the	O
enantiomers	O
of	O
3	B
-	I
PPP	I
and	O
their	O
metabolites	O
indicate	O
that	O
the	O
metabolites	O
probably	O
do	O
not	O
alter	O
the	O
pharmacological	O
profiles	O
established	O
for	O
(	B
R	I
)	I
-	I
(	I
+	I
)	I
-	I
and	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
.	O

The	O
conversion	O
of	O
the	O
monophenols	B
into	O
catecholic	O
metabolites	O
is	O
only	O
1	O
-	O
5	O
%	O
,	O
and	O
the	O
further	O
conversion	O
of	O
these	O
catecholic	O
metabolites	O
into	O
methoxylated	O
analogues	O
is	O
very	O
rapid	O
.	O

However	O
,	O
the	O
very	O
interesting	O
observation	O
was	O
made	O
that	O
,	O
when	O
inhibiting	O
COMT	O
by	O
means	O
of	O
tropolone	B
and	O
subsequently	O
treating	O
the	O
rats	O
with	O
high	O
doses	O
of	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
(	O
ip	O
)	O
,	O
postsynaptic	O
dopaminergic	O
activity	O
was	O
elicited	O
.	O

This	O
has	O
never	O
been	O
seen	O
for	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
without	O
tropolone	B
pretreatment	O
and	O
might	O
indicate	O
that	O
,	O
in	O
this	O
special	O
case	O
,	O
the	O
catecholic	O
metabolite	O
affects	O
the	O
in	O
vivo	O
pharmacological	O
profile	O
of	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
.	O

The	O
syntheses	O
and	O
anthelmintic	O
activities	O
of	O
31	O
3	B
-	I
and	O
5	B
-	I
(	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazoles	I
are	O
reported	O
.	O

In	O
the	O
primary	O
anthelmintic	O
screen	O
,	O
3	B
-	I
(	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
39	O
)	O
showed	O
nematocidal	O
activity	O
and	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
63	O
)	O
,	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
2	I
-	I
chloro	I
-	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
64	O
)	O
,	O
and	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
4	I
-	I
chloro	I
-	I
3	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
66	O
)	O
showed	O
taeniacidal	O
activity	O
when	O
administered	O
orally	O
to	O
mice	O
.	O

The	O
two	O
most	O
active	O
members	O
of	O
this	O
series	O
,	O
39	O
and	O
63	O
,	O
were	O
active	O
against	O
the	O
gastrointestinal	O
nematodes	O
of	O
sheep	O
at	O
mg	O
/	O
kg	O
.	O

In	O
addition	O
,	O
39	O
was	O
also	O
found	O
to	O
be	O
active	O
against	O
hookworms	O
in	O
dogs	O
at	O
a	O
single	O
,	O
oral	O
dose	O
of	O
mg	O
/	O
kg	O
.	O

